



Print selected from 10-501,344.trn

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10-501,344a.str

10/501344



chain nodes :

1 2 3 4 5 6 7 14 24 25

ring nodes :

8 9 10 11 12 13 15 16 17 18 19 20

chain bonds :

1-2 1-5 1-6 2-3 2-4 6-7 6-14 7-8 7-24 7-25 14-15

ring bonds :

8-9 8-13 9-10 10-11 11-12 12-13 15-16 15-20 16-17 17-18 18-19 19-20

exact/norm bonds :

1-2 1-5 1-6 2-3 2-4 6-7 6-14 7-24 7-25

exact bonds :

7-8 14-15

normalized bonds :

8-9 8-13 9-10 10-11 11-12 12-13 15-16 15-20 16-17 17-18 18-19 19-20

G1:H,Ak

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:Atom 9:Atom
10:Atom

11:Atom 12:Atom 13:Atom 14:CLASS 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
20:Atom 24:CLASS

Print selected from 10-501,344.trn


25:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 H,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 14:02:49 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 1114 TO ITERATE

100.0% PROCESSED 1114 ITERATIONS

35 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 20278 TO 24282

PROJECTED ANSWERS: 346 TO 1054

L2 35 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 14:03:16 FILE 'REGISTRY'

Print selected from 10-501,344.trn

FULL SCREEN SEARCH COMPLETED - 22320 TO ITERATE

100.0% PROCESSED 22320 ITERATIONS
SEARCH TIME: 00.00.01

608 ANSWERS

L3 608 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.82

179.03

FILE 'CAPLUS' ENTERED AT 14:03:22 ON 03 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Jan 2008 VOL 148 ISS 1

FILE LAST UPDATED: 2 Jan 2008 (20080102/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 45 L3

=> s l3 and (py<2004 or ay<2004 or pry<2005)

45 L3

23975133 PY<2004

4754629 AY<2004

4563659 PRY<2005

L5 37 L3 AND (PY<2004 OR AY<2004 OR PRY<2005)

=> d ibib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 37 ANSWERS - CONTINUE? Y/(N):y

L5 ANSWER 1 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:984019 CAPLUS <<LOGINID::20080103>>

DOCUMENT NUMBER: 143:279395

TITLE: Methylene amide derivatives for cardiovascular disorders


INVENTOR(S): Hooft van Huijsduijnen, Rob; Richard, Vincent

PATENT ASSIGNEE(S): Applied Research Systems Ars Holding N. V., Neth. Antilles

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082347	A1	20050909	WO 2005-EP50823	20050225 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005216649	A1	20050909	AU 2005-216649	20050225 <--
CA 2554919	A1	20050909	CA 2005-2554919	20050225 <--
EP 1732534	A1	20061220	EP 2005-716814	20050225 <--
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 1933827	A	20070321	CN 2005-80008722	20050225 <--
BR 2005008080	A	20070717	BR 2005-8080	20050225 <--
JP 2007524701	T	20070830	JP 2007-500226	20050225 <--
MX 2006PA09777	A	20061030	MX 2006-PA9777	20060828 <--
NO 2006004295	A	20060922	NO 2006-4295	20060922 <--
US 2007185118	A1	20070809	US 2007-590808	20070112 <--
PRIORITY APPLN. INFO.:			EP 2004-100778	A 20040227 <--
			WO 2005-EP50823	W 20050225
OTHER SOURCE(S):		MARPAT 143:279395		
GI				



I

AB The present invention is related to the use of substituted methylene amide derivs. for the treatment and/or prevention of cardiovascular disorders such as coronary obstruction and heart failure and/or prevention of endothelial dysfunction in heart failure.. A methylene amide derivative I was able to acutely restore endothelial function in mice with chronic heart failure.


IT 578024-89-2

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(methylene amide derivs. for cardiovascular disorders)

RN 578024-89-2 CAPLUS

CN Acetic acid, 2-[[[4-[2-(4-hexylphenyl)ethynyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)



IT 578021-80-4 578021-81-5 578021-82-6
578021-83-7 578021-84-8 578021-85-9
578021-87-1 578021-88-2 578021-90-6,
Oxo[[4-(tridecanoylamino)benzyl][4-(trifluoromethyl)benzyl]amino]acetic
acid 578021-91-7 578021-92-8, Oxo[[4-(trifluoromethyl)benzyl][4-(10-undecenoylamino)benzyl]amino]acetic acid
578021-93-9, Oxo[[4-((9E)-9-tetradecenoylamino)benzyl][4-(trifluoromethyl)benzyl]amino]acetic acid 578021-94-0,
[Benzyl[4-(tridecanoylamino)benzyl]amino](oxo)acetic acid;
578021-95-1, [[4-[(2-Hydroxydodecyl)amino]benzyl][4-(trifluoromethyl)benzyl]amino]-(oxo)acetic acid 578021-96-2,
Oxo[[4-(trifluoromethyl)benzyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578021-99-5, [[4-[(Dodecylamino)carbonyl]benzyl][2-carboxy-1-phenylethyl]amino](oxo)acetic
acid; 578022-01-2 578022-02-3 578022-03-4,
[[2-(3-Chlorophenyl)ethyl][4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid; 578022-04-5, [[4-[(Dodecylamino)carbonyl]benzyl][2-(3-methoxyphenyl)ethyl]amino](oxo)acetic acid; 578022-10-3,
[[4-[(Dodecylamino)carbonyl]benzyl][2-(4-phenoxyphenyl)ethyl]amino](oxo)acetic acid; 578022-11-4, [[4-[(Dodecylamino)carbonyl]benzyl][2-(2-phenoxyphenyl)ethyl]amino](oxo)acetic acid 578022-12-5
578022-13-6 578022-14-7 578022-15-8,
[[4-(Benzoylamino)benzyl][4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid; 578022-16-9, [[4-[(Dodecylamino)carbonyl]benzyl][4-(1,2,3-thiadiazol-4-yl)benzyl]amino]-(oxo)acetic acid 578022-17-0
, [[4-[(Dodecylamino)carbonyl]benzyl][4-pentylbenzyl]amino](oxo)acetic acid; 578022-18-1, [[4-[(Dodecylamino)carbonyl]benzyl][1-phenylethyl]amino](oxo)acetic acid; 578022-19-2,
[[4-[(Dodecylamino)carbonyl]benzyl][1-(1-naphthyl)ethyl]amino](oxo)acetic acid 578022-20-5, [Benzyl[3-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578022-21-6, [[3-[(Dodecylamino)carbonyl]benzyl][4-(methylsulfonyl)benzyl]amino](oxo)acetic acid; 578022-22-7,
(3-Cyanobenzyl)[3-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578022-23-8, [[3-[(Dodecylamino)carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid; 578022-24-9,
[[4-Chlorobenzyl][3-[(4-pentylbenzyl)amino]carbonyl]benzyl]amino](oxo)acetic acid 578022-25-0, Oxo[[4-[[2-(2-thienyl)ethyl]amino]carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino]acetic acid; 578022-26-1 578022-27-2 578022-28-3
578022-29-4 578022-30-7 578022-31-8, Oxo[[[3-[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl](1,1'-biphenyl)-4-yl]methyl][4-(trifluoromethyl)benzyl]amino]acetic acid 578022-32-9

578022-33-0 578022-34-1 578022-35-2
 578022-36-3 578022-37-4 578022-38-5
 578022-39-6 578022-40-9 578022-41-0
 578022-42-1, Oxo[[[3'-[[[4-pentylbenzyl)amino]carbonyl](1,1
 '-biphenyl)-4-yl)methyl][4-(trifluoromethyl)benzyl]amino]acetic acid
 578022-43-2, Oxo[[[3'-[[[4-phenylbutyl)amino]carbonyl](1,1
 '-biphenyl)-4-yl)methyl][4-(trifluoromethyl)benzyl]amino]acetic acid
 578022-44-3 578022-45-4 578022-46-5
 578022-47-6 578022-48-7, [[4-
 [(Dodecylamino)carbonyl]benzyl][4-(methoxybenzyl)amino](oxo)acetic acid
 578022-49-8, [[4-[(Dodecylamino)carbonyl]benzyl][4-
 (methylsulfonyl)benzyl]amino](oxo)acetic acid; 578022-50-1,
 [[3-[(Dodecylamino)carbonyl]benzyl][4-(methoxybenzyl)amino](oxo)acetic acid
 578022-51-2, [[3-[(Dodecylamino)carbonyl]benzyl][3-
 (trifluoromethyl)benzyl]amino](oxo)acetic acid; 578022-53-4,
 4-[[[(Carboxycarbonyl)[3-[(dodecylamino)carbonyl]benzyl]amino]methyl]benzoi
 c acid; 578022-54-5 578022-55-6, [[3-
 [(Dodecylamino)carbonyl]benzyl][2-fluorobenzyl]amino](oxo)acetic acid
 578022-58-9, [[3-[(Dodecylamino)carbonyl]benzyl][4-
 hydroxybenzyl]amino](oxo)acetic acid 578022-59-0,
 [[3-[(Dodecylamino)carbonyl]benzyl][4-phenoxybenzyl]amino](oxo)acetic acid
 578022-61-4, 3-[[[(Carboxycarbonyl)[3-[(dodecylamino)carbonyl]benzy
 l]amino]methyl]benzoic acid 578022-63-6 578022-64-7,
 [(1,3-Benzodioxol-5-yl)methyl][4-[(dodecylamino)carbonyl]benzyl]amino]-
 (oxo)acetic acid 578022-65-8, [[4-[(Dodecylamino)carbonyl]benzyl
][2-fluorobenzyl]amino](oxo)acetic acid 578022-66-9
 578022-67-0, 4-[[[(Carboxycarbonyl)[4-[(dodecylamino)carbonyl]benzy
 l]amino]methyl]benzoic acid 578022-71-6, [(3,5-Dichlorobenzyl)[4-
 [(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578022-72-7
 , [(3,5-Dichlorobenzyl)[4-[[[(3,3-diphenylpropyl)amino]carbonyl]benzyl]amin
 o]-(oxo)acetic acid; 578022-73-8 578022-74-9
 578022-78-3, [4-(Dimethylamino)benzyl][4-
 [(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid; 578022-80-7
 , [(4-Cyanobenzyl)[4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid
 578022-85-2, [[3-[(Dodecylamino)carbonyl]benzyl][3-
 hydroxybenzyl]amino](oxo)acetic acid 578022-86-3,
 [(4-Cyanobenzyl)[3-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid
 578022-89-6, [(1,3-Benzodioxol-5-yl)methyl][3-
 [(dodecylamino)carbonyl]benzyl]amino]-(oxo)acetic acid;
 578022-93-2, [[4-[(Dodecylamino)carbonyl]benzyl][4-
 hydroxybenzyl]amino](oxo)acetic acid 578022-94-3,
 3-[[[(Carboxycarbonyl)[4-[(dodecylamino)carbonyl]benzyl]amino]methyl]benzoi
 c acid; 578023-20-8, [[4-[(Dodecylamino)carbonyl]phenyl][2-
 (methoxycarbonyl)benzyl]amino](oxo)acetic acid 578023-21-9
 578023-22-0, [[2-Bromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl](
 4-iodobenzyl)amino]-(oxo)acetic acid 578023-23-1,
 [[2-Bromo-4-[(dodecylamino)carbonyl]benzyl][4-iodobenzyl]amino](oxo)acetic
 acid 578023-24-2, [[2,6-Dibromo-4-[[[(4-
 pentylbenzyl)amino]carbonyl]benzyl][4-iodobenzyl]amino]-(oxo)acetic acid
 578023-25-3 578023-26-4 578023-27-5
 578023-28-6 578023-29-7 578023-30-0
 578023-31-1 578023-32-2 578023-33-3
 578023-34-4 578023-35-5, (2-Bromo-4-[[[(4-
 pentylbenzyl)amino]carbonyl]benzyl][2-(trifluoromethoxy)benzyl]amino](oxo)
 acetic acid 578023-36-6, [[2,6-Dibromo-4-[[[(4-
 pentylbenzyl)amino]carbonyl]benzyl][2-(trifluoromethoxy)benzyl]amino](oxo)
 acetic acid 578023-37-7, Oxo[[[4'-[[[2-(4-
 phenoxyphenyl)ethyl]amino]carbonyl]-1,1 '-biphenyl-4-yl)methyl][2-
 (trifluoromethoxy)benzyl]amino]acetic acid 578023-38-8

578023-39-9, [[2-Bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl](3-phenoxybenzyl)amino](oxo)acetic acid 578023-40-2
578023-41-3, [[2-Bromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl](3-phenoxybenzyl)amino](oxo)acetic acid; 578023-42-4,
[[2,6-Dibromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl](3-phenoxybenzyl)amino](oxo)acetic acid 578023-43-5
578023-44-6, [[2,6-Dibromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl](3-phenoxybenzyl)amino](oxo)acetic acid 578023-45-7,
[[2,6-Dibromo-4-[[[dodecylamino]carbonyl]benzyl](3-phenoxybenzyl)amino](oxo)acetic acid 578023-46-8,
Oxo[[3-phenoxybenzyl][4'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]-1,1'-biphenyl-4-yl]methyl]amino]acetic acid 578023-47-9,
Oxo[[[4'-[[[4-pentylbenzyl]amino]carbonyl]-1,1'-biphenyl-4-yl]methyl](3-phenoxybenzyl)amino]acetic acid 578023-48-0 578023-49-1
, [[2-Bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl](2-iodobenzyl)amino](oxo)acetic acid 578023-50-4
578023-51-5, [[2-Bromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl](2-iodobenzyl)amino]-(oxo)acetic acid 578023-52-6,
[[2-Bromo-4-[[[dodecylamino]carbonyl]benzyl](2-iodobenzyl)amino](oxo)acetic acid 578023-53-7 578023-54-8 578023-55-9
578023-56-0 578023-57-1 578023-58-2
578023-59-3 578023-60-6 578023-61-7
578023-62-8 578023-63-9 578023-64-0
578023-65-1 578023-66-2 578023-67-3
578023-68-4, [[2-Bromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl][4-(trifluoromethoxy)benzyl]amino](oxo)acetic acid 578023-69-5,
[[2-Bromo-4-[[[dodecylamino]carbonyl]benzyl][4-(trifluoromethoxy)benzyl]amino](oxo)acetic acid 578023-70-8, [[2,6-Dibromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl][4-(trifluoromethoxy)benzyl]amino](oxo)acetic acid 578023-71-9, [[2-Bromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl][3-(trifluoromethoxy)benzyl]amino](oxo)acetic acid; 578023-72-0, [[2-Bromo-4-[[[dodecylamino]carbonyl]benzyl][3-(trifluoromethoxy)benzyl]amino](oxo)acetic acid 578023-73-1, (2,6-Dibromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl)[3-(trifluoromethoxy)benzyl]amino](oxo)acetic acid 578023-74-2, [[2,6-Dibromo-4-[[[dodecylamino]carbonyl]benzyl][3-(trifluoromethoxy)benzyl]amino](oxo)acetic acid 578023-75-3 578023-76-4, [[2-Bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl][4-phenoxybenzyl]amino](oxo)acetic acid 578023-77-5 578023-78-6, [[2-Bromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl][4-phenoxybenzyl]amino](oxo)acetic acid 578023-79-7, [[2-Bromo-4-[[[dodecylamino]carbonyl]benzyl][4-phenoxybenzyl]amino](oxo)acetic acid 578023-80-0
578023-81-1, [[2,6-Dibromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl][4-phenoxybenzyl]amino](oxo)acetic acid 578023-82-2
578023-83-3, [[2-Bromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578023-84-4,
[[2-Bromo-4-[[[dodecylamino]carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578023-85-5,
[[2,6-Dibromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578023-86-6,
[[2,6-Dibromo-4-[[[dodecylamino]carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid; 578023-87-7,
Oxo[[[4'-[[[4-pentylbenzyl]amino]carbonyl]-1,1'-biphenyl-4-yl]methyl][4-(trifluoromethyl)benzyl]amino]acetic acid 578023-88-8,
[2-Bromo-4-[[[dodecylamino]carbonyl]benzyl][3-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578023-89-9, [[2,6-Dibromo-4-[[[dodecylamino]carbonyl]benzyl][3-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578023-90-2, Oxo[[[4'-[[[4-pentylbenzyl]amino]carbonyl]-


1,1'-biphenyl-4-yl)methyl][3-(trifluoromethyl)benzyl]amino]acetic acid
578023-91-3, [(4-Dibenzo[b,d]furan-4-ylbenzyl)[4-
(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578023-92-4,
[(4-Dibenzo[b,d]furan-4-ylbenzyl)[4-(trifluoromethyl)benzyl]amino] (oxo)ace
tic acid N-methyl-D-glucamine salt 578023-93-5,
[[4-[(Dodecylamino)carbonyl]benzyl][1-[4-(trifluoromethyl)phenyl]ethyl]ami
no]-(oxo)acetic acid 578023-94-6, [[4-
[(Dodecylamino)carbonyl]benzyl][1-[4-(trifluoromethyl)phenyl]ethyl]amino] (o
xo)acetic acid, N-methyl-D-glucamine salt 578023-95-7
578023-96-8, Oxo[[4-tetradec-1-ynylbenzyl)[4-
(trifluoromethyl)benzyl]amino]acetic acid 578023-97-9,
[(4-Dodec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid
578023-98-0, [[4-[(Dodecylamino)carbonyl]benzyl][4-
(trifluoromethyl)phenyl]amino] (oxo)acetic acid; 578023-99-1,
[[4-[(Dodecylamino)carbonyl]benzyl][2-methoxyphenyl]amino] (oxo)acetic acid
578024-00-7, [(1,2-Diphenylethyl)[4-[(dodecylamino)carbonyl]benzyl
]amino] (oxo)acetic acid 578024-02-9, [[4-
[(Dodecylamino)carbonyl]benzyl][3-phenoxyphenyl]amino] (oxo)acetic acid
578024-03-0, [[4-[(Dodecylamino)carbonyl]benzyl][2-
isopropoxyphenyl]amino] (oxo)acetic acid 578024-04-1,
[[4-[(Dodecylamino)carbonyl]benzyl][4-iodophenyl]amino] (oxo)acetic acid
578024-05-2, [[4-[(Dodecylamino)carbonyl]benzyl][3-fluoro-4-
(trifluoromethyl)benzyl]amino] (oxo)acetic acid; 578024-06-3,
[[3-Chloro-2-methylphenyl][4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)ace
tic acid 578024-07-4, 4'-[(Carboxycarbonyl)[4-
[(dodecylamino)carbonyl]benzyl]amino]-1,1'-biphenyl-2-carboxylic acid
578024-08-5, [(2,4-Dichlorobenzyl)[4-[(dodecylamino)carbonyl]benzy
l]amino] (oxo)acetic acid 578024-09-6, [4-
[(Dodecylamino)carbonyl]benzyl][1-phenylpropyl]amino] (oxo)acetic acid
578024-10-9, [[2-(4-Chlorophenyl)propyl][4-
[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid; 578024-11-0
, [[4-[(Dodecylamino)carbonyl]benzyl][4-isopropoxyphenyl]amino] (oxo)acetic
acid; 578024-12-1, [[4-(Benzyloxy)phenyl][4-
[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578024-13-2
, [[4-[(Dodecylamino)carbonyl]benzyl][2-(trifluoromethyl)benzyl]amino] (oxo)
)acetic acid 578024-14-3, [[4-[(Dodecylamino)carbonyl]benzyl][2-
methoxybenzyl]amino] (oxo)acetic acid 578024-15-4,
[[[(1R)-1-(4-Chlorophenyl)ethyl][4-[(dodecylamino)carbonyl]benzyl]amino] -
(oxo)acetic acid 578024-16-5, [(3,4-Dichlorobenzyl)[4-
[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578024-18-7
, [[2-(2,6-Dichlorophenyl)ethyl][4-[(dodecylamino)carbonyl]benzyl]amino] (o
xo)acetic acid; 578024-19-8, [[4-[(Dodecylamino)carbonyl]benzyl]
[2-[3-(trifluoromethyl)phenyl]ethyl]amino] (oxo)acetic acid;
578024-20-1, [4-[(Dodecylamino)carbonyl]benzyl][2-(3-
fluorophenyl)ethyl]amino] (oxo)acetic acid; 578024-21-2
578024-22-3 578024-23-4 578024-24-5,
N-(Carboxycarbonyl)-N-[4-[(dodecylamino)carbonyl]benzyl]-D-phenylalanine
578024-25-6, [[4-[(Dodecylamino)carbonyl]phenyl][4-
(trifluoromethyl)benzyl]amino] (oxo)acetic acid; 578024-26-7,
[[4-[(Dodecylamino)carbonyl]phenyl][4-(trifluoromethyl)benzyl]amino] (oxo)a
cetic acid, N-methyl-D-glucamine salt 578024-27-8,
Oxo[[1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-
yl)benzyl]amino]acetic acid 578024-28-9, Oxo[[1-[4-
(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-
yl)benzyl]amino]acetic acid, N-methyl-D-glucamine salt 578024-30-3
, [[1-[4-[(Dodecylamino)carbonyl]phenyl]ethyl][4-
(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-31-4,
[[1-[4-[(Dodecylamino)carbonyl]phenyl]ethyl][4-
(trifluoromethyl)benzyl]amino]-(oxo)acetic acid, N-methyl-D-glucamine salt

578024-32-5, [[4-[[4-(Octylphenyl)amino]carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578024-33-6, [(3-Chlorobenzyl)[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino](oxo)acetic acid 578024-34-7, [(3-Chlorobenzyl)[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino](oxo)acetic acid,N-methyl-D-glucamine salt 578024-35-8, [[Cyclopentyl[4-(trifluoromethyl)phenyl]methyl][4-(tridecanoylamino)benzyl]amino](oxo)acetic acid 578024-36-9, Oxo[[4-(trifluoromethyl)benzyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)-1-naphthyl]methyl]amino]acetic acid 578024-37-0 578024-38-1 578024-39-2 578024-40-5 578024-41-6 578024-42-7, [[4-(Octyloxy)benzyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578024-43-8, [[4-(Octyloxy)benzyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid,N-methyl-D-glucamine salt 578024-44-9, [[2-(3-Chlorophenyl)ethyl][4-(dec-1-ynylbenzyl)amino](oxo)acetic acid 578024-45-0, [[2-(3-Chlorophenyl)ethyl][4-(1Z)-dec-1-enyl]benzyl]amino](oxo)acetic acid 578024-46-1, [[2-(3-Chlorophenyl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino](oxo)acetic acid 578024-47-2, [[2-(3-Chlorophenyl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino](oxo)acetic acid,N-methyl-D-glucamine salt 578024-48-3, Oxo[[[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578024-49-4, Oxo[[[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid,N-methyl-D-glucamine salt 578024-50-7, Oxo[[4-(trifluoromethyl)phenyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid; 578024-51-8, Oxo[[4-(trifluoromethyl)phenyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid,N-methyl-D-glucamine salt 578024-52-9. 578024-53-0 578024-54-1, [(3-Chlorobenzyl)(4-dec-1-ynylbenzyl)amino](oxo)acetic acid 578024-55-2, [(3-Chlorobenzyl)(4-dec-1-ynylbenzyl)amino](oxo)acetic acid,N-methyl-D-glucamine salt 578024-56-3, [[2-(3-Chlorophenyl)ethyl][4-(oct-1-ynylbenzyl)amino](oxo)acetic acid 578024-57-4, [2-(3-Chlorophenyl)ethyl][4-(oct-1-ynylbenzyl)amino](oxo)acetic acid,N-methyl-D-glucamine salt 578024-58-5, [(4-Dec-1-ynylbenzyl)[4-(trifluoromethyl)phenyl]amino](oxo)acetic acid 578024-59-6, [(4-Dec-1-ynylbenzyl)[1-[4-(trifluoromethyl)phenyl]ethyl]amino](oxo)acetic acid 578024-60-9, [(4-Dec-1-ynylbenzyl)[1-[4-(trifluoromethyl)phenyl]ethyl]amino](oxo)acetic acid,N-methyl-D-glucamine salt 578024-61-0, [[1-Methyl-1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino](oxo)acetic acid 578024-62-1, [[1-Methyl-1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino](oxo)acetic acid,N-methyl-D-glucamine salt 578024-63-2, [[2-(3-Chlorophenyl)ethyl][4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino](oxo)acetic acid 578024-64-3, [[2-(3-Chlorophenyl)ethyl][4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino](oxo)acetic acid,N-methyl-D-glucamine salt 578024-65-4, [[4-(3-Octyl-1,2,4-oxadiazol-5-yl)benzyl][4-(trifluoromethyl)benzyl]amino]-(oxo)acetic acid; 578024-66-5, [4-(3-Octyl-1,2,4-oxadiazol-5-yl)benzyl][4-(trifluoromethyl)benzyl]amino]-(oxo)acetic acid,N-methyl-D-glucamine salt 578024-67-6, [[4-(Dodecyloxy)-1-naphthyl]methyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid; 578024-68-7, [[4-(Dodecyloxy)-1-naphthyl]methyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid,N-methyl-D-glucamine salt 578024-69-8, [(4-Bromobenzyl)(4-oct-1-ynylbenzyl)amino](oxo)acetic acid 578024-70-1, [[4-[(Dodecylamino)carbonyl]benzyl](2-hydroxy-

1-phenylethyl)amino] (oxo)acetic acid; 578024-71-2,
 [(4-Dec-1-ynylbenzyl)[1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl]amino] (o
 xo)acetic acid; 578024-72-3, [(4-Dec-1-ynylbenzyl)[1-methyl-1-[4-
 (trifluoromethyl)phenyl]ethyl]amino] (oxo)acetic acid, N-methyl-D-glucamine
 salt 578024-73-4, Oxo[[4-((9Z)-tetradec-9-enoylamino)benzyl][4-
 (trifluoromethyl)benzyl]amino]acetic acid; 578024-74-5,
 [(4-Dec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid
 578024-75-6, Oxo[[4-(trifluoromethyl)benzyl][3-(3-undecyl-1,2,4-
 oxadiazol-5-yl)benzyl]amino]acetic acid
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methylene amide derivs. for cardiovascular disorders)


RN 578021-80-4 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] (phenylmethyl)amin
 o]oxo- (9CI) (CA INDEX NAME)




RN 578021-81-5 CAPLUS

CN Acetic acid, oxo[[[4-[(pentadecylamino)carbonyl]phenyl]methyl] [[4-
 (trifluoromethyl)phenyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 578021-82-6 CAPLUS

CN Acetic acid, 2-oxo-2-[[[4-[(pentadecylamino)carbonyl]phenyl]methyl] (phenyl
 methyl)amino] - (CA INDEX NAME)




RN 578021-83-7 CAPLUS

CN Acetic acid, oxo[(phenylmethyl)[[4-[(tridecylamino)carbonyl]phenyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 578021-84-8 CAPLUS

CN Acetic acid, [[[4-[(dodecylmethylamino)carbonyl]phenyl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578021-85-9 CAPLUS

CN Acetic acid, [[[4-[(dodecylmethylamino)carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578021-87-1 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578021-88-2 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][[3-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578021-90-6 CAPLUS

CN Acetic acid, oxo[[[4-[(1-oxotridecyl)amino]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578021-91-7 CAPLUS

CN Acetic acid, [[4-[[4-(hexyloxy)benzoyl]amino]phenyl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 578021-92-8 CAPLUS

CN Acetic acid, oxo[[[4-[(1-oxo-10-undecenyl)amino]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




Print selected from 10-501,344.trn

RN 578021-93-9 CAPLUS


CN Acetic acid, 2-oxo-2-[[[4-[[[(9E)-1-oxo-9-tetradecen-1-yl]amino]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.




RN 578021-94-0 CAPLUS

CN Acetic acid, oxo[[[4-[(1-oxotridecyl)amino]phenyl]methyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 578021-95-1 CAPLUS

CN Acetic acid, [[4-[(2-hydroxydodecyl)amino]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578021-96-2 CAPLUS


CN Acetic acid, 2-oxo-2-[[[4-(trifluoromethyl)phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 578021-99-5 CAPLUS
 CN Benzenepropanoic acid, β -[(carboxycarbonyl)[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]- (CA INDEX NAME)



RN 578022-01-2 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl]phenylamino]oxo- (9CI) (CA INDEX NAME)




RN 578022-02-3 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl]phenylamino]oxo- (9CI) (CA INDEX NAME)




RN 578022-03-4 CAPLUS
 CN Acetic acid, [[2-(3-chlorophenyl)ethyl][[4-[(dodecylamino)carbonyl]phenyl]

methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-04-5 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][2-(3-methoxyphenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-10-3 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][2-(4-phenoxyphenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-11-4 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][2-(2-phenoxyphenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-12-5 CAPLUS


CN Acetic acid, [(2-[1,1'-biphenyl]-4-ylethyl)[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-13-6 CAPLUS
 CN Acetic acid, [[[4-[1,1'-biphenyl]-3-ylmethyl]] [4-
 [(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-14-7 CAPLUS
 CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl] [3-
 (phenylmethoxy)phenyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-15-8 CAPLUS
 CN Acetic acid, [[[4-(benzoylamino)phenyl]methyl] [4-
 [(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-16-9 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-17-0 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][(4-pentylphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-18-1 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][1-(phenylethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-19-2 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][1-(1-naphthalenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-20-5 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-21-6 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl] [4-(methylsulfonyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-22-7 CAPLUS

CN Acetic acid, [[[3-cyanophenyl]methyl] [3-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-23-8 CAPLUS

CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-24-9 CAPLUS

CN Acetic acid, [[(4-chlorophenyl)methyl][[3-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-25-0 CAPLUS

CN Acetic acid, oxo[[[4-[[[2-(2-thienyl)ethyl]amino]carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578022-26-1 CAPLUS

CN Acetic acid, [[[3'-[[[(2,2-diphenylethyl)amino]carbonyl][1,1'-biphenyl]-4-yl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-27-2 CAPLUS

CN Acetic acid, [[[3-cyanophenyl)methyl][[3'-[[[(2,2-diphenylethyl)amino]carbonyl][1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-28-3 CAPLUS

CN Acetic acid, [[[4-chlorophenyl)methyl][[3'-[[[(2,2-diphenylethyl)amino]carbonyl][1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-29-4 CAPLUS

CN Acetic acid, [[[3'-[[[(2,2-diphenylethyl)amino]carbonyl][1,1'-biphenyl]-4-yl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-30-7 CAPLUS
 CN Acetic acid, [[(3-cyanophenyl)methyl] [[3'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl] [1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— CN

RN 578022-31-8 CAPLUS
 CN Acetic acid, oxo[[[3'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl] [1,1'-biphenyl]-4-yl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino] - (9CI) (CA INDEX NAME)


PAGE 1-A



—CF₃


RN 578022-32-9 CAPLUS

CN Acetic acid, [[[3-cyanophenyl)methyl][[3'-[(octylamino)carbonyl][1,1'-biphenyl]-4-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-33-0 CAPLUS

CN Acetic acid, [[[4-chlorophenyl)methyl][[3'-[(octylamino)carbonyl][1,1'-biphenyl]-4-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-34-1 CAPLUS

CN Acetic acid, [[[3'-[(octylamino)carbonyl][1,1'-biphenyl]-4-yl)methyl][[4-(trifluoromethyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-35-2 CAPLUS

CN Acetic acid, [[[3-cyanophenyl)methyl] [[3'-[[[(3-phenylpropyl)amino]carbonyl] [1,1'-biphenyl]-4-yl)methyl]amino]oxo- (9CI)
(CA INDEX NAME)




RN 578022-36-3 CAPLUS

CN Acetic acid, [[[3-cyanophenyl)methyl] [[3'-[[[(dodecylamino)carbonyl] [1,1'-biphenyl]-4-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-37-4 CAPLUS

CN Acetic acid, [[[4-chlorophenyl)methyl] [[3'-[[[(dodecylamino)carbonyl] [1,1'-biphenyl]-4-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-38-5 CAPLUS

CN Acetic acid, [[[3'-[[[(dodecylamino)carbonyl] [1,1'-biphenyl]-4-yl)methyl] [[4-(trifluoromethyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-39-6 CAPLUS


CN Acetic acid, oxo[[[3'-[[[(4-pentylphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 578022-40-9 CAPLUS

CN Acetic acid, [[(3-cyanophenyl)methyl][[3'-[[[(4-pentylphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B


-CN

RN 578022-41-0 CAPLUS

CN Acetic acid, [[(4-chlorophenyl)methyl][[3'-[[[(4-pentylphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl]amino]oxo-

(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

Cl

RN 578022-42-1 CAPLUS

CN Acetic acid, oxo[[[3'-[[[(4-pentylphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino] - (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B


CF₃

RN 578022-43-2 CAPLUS


CN Acetic acid, oxo[[[3'-[[[(4-phenylbutyl)amino]carbonyl][1,1'-biphenyl]-4-yl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino] - (9CI) (CA INDEX NAME)



RN 578022-44-3 CAPLUS
 CN Acetic acid, [[(3-cyanophenyl)methyl] [[3'-[[[2-(2,4,6-trimethylphenyl)ethyl]amino] carbonyl] [1,1'-biphenyl] -4-yl]methyl]amino] oxo- (9CI) (CA INDEX NAME)




RN 578022-45-4 CAPLUS
 CN Acetic acid, [[(4-chlorophenyl)methyl] [[3'-[[[2-(2,4,6-trimethylphenyl)ethyl]amino] carbonyl] [1,1'-biphenyl] -4-yl]methyl]amino] oxo- (9CI) (CA INDEX NAME)



RN 578022-46-5 CAPLUS
 CN Acetic acid, oxo[[[4-(trifluoromethyl)phenyl]methyl] [[3'-[[[2-(2,4,6-trimethylphenyl)ethyl]amino] carbonyl] [1,1'-biphenyl] -4-yl]methyl]amino] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— CF₃

RN 578022-47-6 CAPLUS
 CN Acetic acid, [[[4-chlorophenyl)methyl] [[3'-[[[2-(4-methoxyphenyl)ethyl]amino]carbonyl] [1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B

— Cl

RN 578022-48-7 CAPLUS
 CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl] [[4-methoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-49-8 CAPLUS
 CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl] [[4-(methylsulfonyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-50-1 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl][(4-methoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-51-2 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl][(3-(trifluoromethyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-53-4 CAPLUS

CN Benzoic acid, 4-[[[(carboxycarbonyl)[[3-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (CA INDEX NAME)




RN 578022-54-5 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl][(4-nitrophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-55-6 CAPLUS

CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl][(2-fluorophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-58-9 CAPLUS

CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl][(4-hydroxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-59-0 CAPLUS

CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl]methyl][(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-61-4 CAPLUS

CN Benzoic acid, 3-[[[(carboxycarbonyl)[[3-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (CA INDEX NAME)




RN 578022-63-6 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][[4-nitrophenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-64-7 CAPLUS

CN Acetic acid, [(1,3-benzodioxol-5-ylmethyl)[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-65-8 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][[2-fluorophenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-66-9 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-67-0 CAPLUS

CN Benzoic acid, 4-[[[(carboxycarbonyl)[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (CA INDEX NAME)




RN 578022-71-6 CAPLUS

CN Acetic acid, [[(3,5-dichlorophenyl)methyl] [(4-[(dodecylamino)carbonyl]phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-72-7 CAPLUS

CN Acetic acid, [[(3,5-dichlorophenyl)methyl] [(4-[(3,3-diphenylpropyl)amino]carbonyl]phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-73-8 CAPLUS

CN Acetic acid, [[[4-[[[2-[1,1'-biphenyl]-4-ylethyl)amino]carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-74-9 CAPLUS

CN Acetic acid, [(1,3-benzodioxol-5-ylmethyl)[[4-[[[2-[1,1'-biphenyl]-4-ylethyl)amino]carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-78-3 CAPLUS

CN Acetic acid, [[[4-(dimethylamino)phenyl]methyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-80-7 CAPLUS


CN Acetic acid, [[[4-cyanophenyl]methyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-85-2 CAPLUS


CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl][[3-

hydroxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-86-3 CAPLUS

CN Acetic acid, [[(4-cyanophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-89-6 CAPLUS

CN Acetic acid, [(1,3-benzodioxol-5-ylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-93-2 CAPLUS

CN Acetic acid, [[[(4-hydroxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-94-3 CAPLUS

CN Benzoic acid, 3-[[[(carboxycarbonyl)[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (CA INDEX NAME)




RN 578023-20-8 CAPLUS

CN Benzoic acid, 2-[[[(carboxycarbonyl)[4-[(dodecylamino)carbonyl]phenyl]amino]methyl]-, 1-methyl ester (CA INDEX NAME)




RN 578023-21-9 CAPLUS

CN Acetic acid, [[[4-[[[(2-[1,1'-biphenyl]-4-ylethyl)amino]carbonyl]-2-bromophenyl]methyl][[(4-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-22-0 CAPLUS

CN Acetic acid, [[[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][[(4-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-23-1 CAPLUS

CN Acetic acid, [[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][(4-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-24-2 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][(4-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-25-3 CAPLUS


CN Acetic acid, [[(4-iodophenyl)methyl][(4'-[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-4-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-26-4 CAPLUS


CN Acetic acid, [[2-bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl][(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)

INDEX NAME)




RN 578023-27-5 CAPLUS

CN Acetic acid, [[4-[[2-(1,1'-biphenyl)-4-ylethyl]amino]carbonyl]-2-bromophenyl]methyl] [(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]amino]oxo- (9CI)
(CA INDEX NAME)



RN 578023-28-6 CAPLUS

CN Acetic acid, [[[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl] [(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

— Me


RN 578023-29-7 CAPLUS

CN Acetic acid, [[[2,6-dibromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl] [(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-30-0 CAPLUS

CN Acetic acid, [[4-[(2-[1,1'-biphenyl]-4-ylethyl)amino]carbonyl]-2,6-dibromophenyl]methyl][(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-31-1 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



PAGE 1-A


(CH₂)₄—

PAGE 1-B

— Me

RN 578023-32-2 CAPLUS


CN Acetic acid, [[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl][(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-33-3 CAPLUS

CN Acetic acid, [[(4'-fluoro[1,1'-biphenyl]-3-yl)methyl] [[4'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl] [1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B




RN 578023-34-4 CAPLUS

CN Acetic acid, [[(4'-fluoro[1,1'-biphenyl]-3-yl)methyl] [[4'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl] [1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-35-5 CAPLUS

CN Acetic acid, [[(2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl)methyl] [[2-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-36-6 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][2-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-37-7 CAPLUS

CN Acetic acid, oxo[[[4'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl][2-(trifluoromethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578023-38-8 CAPLUS

CN Acetic acid, [[4'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl][2-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-39-9 CAPLUS

CN Acetic acid, [[[2-bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-40-2 CAPLUS

CN Acetic acid, [[[4-[[[2-[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-2-bromophenyl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-41-3 CAPLUS

CN Acetic acid, [[[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-42-4 CAPLUS


CN Acetic acid, [[[2,6-dibromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-43-5 CAPLUS
 CN Acetic acid, [[4-[[2-[[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-2,6-dibromophenyl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-44-6 CAPLUS
 CN Acetic acid, [[[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-45-7 CAPLUS
 CN Acetic acid, [[[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-46-8 CAPLUS

CN Acetic acid, oxo[[[4'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl][(3-phenoxyphenyl)methyl]amino] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OPh

RN 578023-47-9 CAPLUS

CN Acetic acid, oxo[[[4'-[[[(4-pentylphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl][(3-phenoxyphenyl)methyl]amino] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OPh


RN 578023-48-0 CAPLUS

CN Acetic acid, [[[4'-[(dodecylamino)carbonyl][1,1'-biphenyl]-4-yl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-49-1 CAPLUS

CN Acetic acid, [[[2-bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl][(2-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-50-4 CAPLUS

CN Acetic acid, [[[4-[[[2-[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-2-bromophenyl]methyl][(2-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-51-5 CAPLUS

CN Acetic acid, [[[2-bromo-4-[[[4-(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][(2-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-52-6 CAPLUS

CN Acetic acid, [[[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][(2-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-53-7 CAPLUS

CN Acetic acid, [[2-bromo-4-[[[2-(4-iodophenyl)ethyl]amino]carbonyl]phenyl]methyl][[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-54-8 CAPLUS

CN Acetic acid, [[4-[[[2-(1,1'-biphenyl)-4-ylethyl]amino]carbonyl]-2-bromophenyl]methyl][[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-55-9 CAPLUS


CN Acetic acid, [[2-bromo-4-[[[4-pentylphenyl]methyl]amino]carbonyl]phenyl]methyl][[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-56-0 CAPLUS


CN Acetic acid, [[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

(trifluoromethyl) [1,1'-biphenyl] -4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-57-1 CAPLUS

CN Acetic acid, [[4-[[2-[(2,6-dibromophenyl)methyl]amino]carbonyl]-2,6-dibromophenyl]methyl] [[2'-(trifluoromethyl) [1,1'-biphenyl] -4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-58-2 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl] [[2'-(trifluoromethyl) [1,1'-biphenyl] -4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-59-3 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[(dodecylamino)carbonyl]phenyl]methyl] [[2'-(trifluoromethyl) [1,1'-biphenyl] -4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-60-6 CAPLUS

CN Acetic acid, [[4'-[(dodecylamino)carbonyl][1,1'-biphenyl]-4-yl]methyl][[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-61-7 CAPLUS

CN Acetic acid, [[4-[[2-[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-2-bromophenyl]methyl]([1,1'-biphenyl]-2-ylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-62-8 CAPLUS


CN Acetic acid, [[([1,1'-biphenyl]-2-ylmethyl)[[2-bromo-4-[[[4-pentylphenyl]methyl]amino]carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-63-9 CAPLUS
CN Acetic acid, [[(1,1'-biphenyl)-2-ylmethyl][(2-bromo-4-[(dodecylamino)carbonyl]phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-64-0 CAPLUS
CN Acetic acid, [[(1,1'-biphenyl)-2-ylmethyl][(2,6-dibromo-4-[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-65-1 CAPLUS
CN Acetic acid, [[(4-[[2-(1,1'-biphenyl)-4-ylethyl]amino]carbonyl]-2,6-dibromophenyl)methyl][(1,1'-biphenyl)-2-ylmethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-66-2 CAPLUS

CN Acetic acid, [[([1,1'-biphenyl]-2-ylmethyl)[[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-67-3 CAPLUS

CN Acetic acid, [[([1,1'-biphenyl]-2-ylmethyl)[[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-68-4 CAPLUS

CN Acetic acid, [[([2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl)[[4-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-69-5 CAPLUS

CN Acetic acid, [[([2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl)[[4-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-70-8 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][[4-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-71-9 CAPLUS

CN Acetic acid, [[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][[3-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-72-0 CAPLUS

CN Acetic acid, [[2-bromo-4-[[[(dodecylamino)carbonyl]phenyl]methyl][[3-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-73-1 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][[3-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-74-2 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl][[3-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-75-3 CAPLUS

CN Acetic acid, [[4'-[(dodecylamino)carbonyl][1,1'-biphenyl]-4-yl]methyl][[3-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-76-4 CAPLUS


CN Acetic acid, [[2-bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl][[4-phenoxyphenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-77-5 CAPLUS
CN Acetic acid, [[4-[[2-[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-2-bromophenyl]methyl] [(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-78-6 CAPLUS
CN Acetic acid, [[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl] [(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-79-7 CAPLUS
CN Acetic acid, [[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl] [(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-80-0 CAPLUS
CN Acetic acid, [[4-[[2-[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-2,6-

dibromophenyl)methyl] [(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-81-1 CAPLUS

CN Acetic acid, [[[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl)methyl] [(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-82-2 CAPLUS

CN Acetic acid, [[[4-[[[(2-[1,1'-biphenyl]-4-ylethyl)amino]carbonyl]-2-bromophenyl)methyl] [[4-(trifluoromethyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-83-3 CAPLUS

CN Acetic acid, [[[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl)methyl] [[4-(trifluoromethyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-84-4 CAPLUS

CN Acetic acid, [[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-85-5 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-86-6 CAPLUS


CN Acetic acid, [[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-87-7 CAPLUS

CN Acetic acid, oxo[[[4'-[[[(4-pentylphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CF₃


RN 578023-88-8 CAPLUS

CN Acetic acid, [[[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][[3-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-89-9 CAPLUS

CN Acetic acid, [[[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl][[3-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-90-2 CAPLUS

Print selected from 10-501,344.trn

CN Acetic acid, oxo[[[4'-[[[(4-pentylphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl][[3-(trifluoromethyl)phenyl]methyl]amino] - (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— (CH₂)₄—Me

RN 578023-91-3 CAPLUS

CN Acetic acid, [[[4-(4-dibenzofuranyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-92-4 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-(1-dibenzofuranyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino] oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

Print selected from 10-501,344.trn


CRN 578023-91-3
CMF C29 H20 F3 N O4




CM 2

CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.




RN 578023-93-5 CAPLUS
CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][1-[4-(trifluoromethyl)phenyl]ethyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-94-6 CAPLUS
 CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][1-[4-(trifluoromethyl)phenyl]ethyl]amino]oxoacetate (salt) (9CI)
 (CA INDEX NAME)

CM 1


CRN 578023-93-5
 CMF C31 H41 F3 N2 O4




CM 2

CRN 6284-40-8
 CMF C7 H17 N O5


Absolute stereochemistry.




RN 578023-95-7 CAPLUS
 CN Acetic acid, [[[4'-[(octylamino)carbonyl][1,1'-biphenyl]-4-yl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-96-8 CAPLUS
 CN Acetic acid, 2-oxo-2-[[[4-(1-tetradecyn-1-yl)phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 578023-97-9 CAPLUS
 CN Acetic acid, 2-[[[4-(1-dodecyn-1-yl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578023-98-0 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][4-(trifluoromethyl)phenyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-99-1 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][2-methoxyphenyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-00-7 CAPLUS
 CN Acetic acid, [(1,2-diphenylethyl)[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-02-9 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] (3-phenoxyphenyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-03-0 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [2-(1-methylethoxy)phenyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-04-1 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] (4-iodophenyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-05-2 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [[3-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-06-3 CAPLUS

CN Acetic acid, [(3-chloro-2-methylphenyl)[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-07-4 CAPLUS

CN [1,1'-Biphenyl]-2-carboxylic acid, 4'--[(carboxycarbonyl)[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino] - (CA INDEX NAME)




RN 578024-08-5 CAPLUS

CN Acetic acid, [[(2,4-dichlorophenyl)methyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-09-6 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl] (1-phenylpropyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-10-9 CAPLUS

CN Acetic acid, [[2-(4-chlorophenyl)propyl] [[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-11-0 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl] [4-(1-methylethoxy)phenyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-12-1 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl] [4-(phenylmethoxy)phenyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-13-2 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl] [(2-(trifluoromethyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-14-3 CAPLUS


CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl] [(2-methoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-15-4 CAPLUS


CN Acetic acid, [[[1R]-1-(4-chlorophenyl)ethyl] [(4-[(dodecylamino)carbonyl]phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 578024-16-5 CAPLUS

CN Acetic acid, [[[3,4-dichlorophenyl)methyl] [(4-[(dodecylamino)carbonyl]phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-18-7 CAPLUS

CN Acetic acid, [[2-(2,6-dichlorophenyl)ethyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-19-8 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][2-[3-(trifluoromethyl)phenyl]ethyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-20-1 CAPLUS


CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][2-(3-fluorophenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-21-2 CAPLUS


CN Acetic acid, [[[1S]-1-(4-chlorophenyl)ethyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 578024-22-3 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [(1S)-1-phenylethyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 578024-23-4 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [(1R)-1-phenylethyl]amino]oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 578024-24-5 CAPLUS
CN D-Phenylalanine, N-(carboxycarbonyl)-N-[[4-[(dodecylamino)carbonyl]phenyl]methyl]- (CA INDEX NAME)


Print selected from 10-501,344.trn

Absolute stereochemistry.



RN 578024-25-6 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-26-7 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[4-[(dodecylamino)carbonyl]phenyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-25-6

CMF C29 H37 F3 N2 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-27-8 CAPLUS

CN Acetic acid, 2-oxo-2-[[1-[4-(trifluoromethyl)phenyl]ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 578024-28-9 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[1-[4-(trifluoromethyl)phenyl]ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-27-8

CMF C31 H38 F3 N3 O4



CM 2


CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.


RN 578024-32-5 CAPLUS

CN Acetic acid, 2-[[[4-[[[4-octylphenyl]amino]carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)



RN 578024-33-6 CAPLUS

CN Acetic acid, [[[(3-chlorophenyl)methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-34-7 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[(3-chlorophenyl)methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-33-6

CMF C29 H36 Cl N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-35-8 CAPLUS

CN Acetic acid, 2-[[cyclopentyl[4-(trifluoromethyl)phenyl]methyl][[4-[(1-oxotridecyl)amino]phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)



RN 578024-36-9 CAPLUS

CN Acetic acid, 2-oxo-2-[[[4-(trifluoromethyl)phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)-1-naphthalenyl]methyl]amino]- (CA INDEX NAME)




RN 578024-37-0 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[[4-(trifluoromethyl)phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)-1-naphthalenyl]methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-36-9

CMF C34 H38 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-38-1 CAPLUS

CN Acetic acid, 2-[[cyclopentyl[4-(trifluoromethyl)phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)



Print selected from 10-501,344.trn


RN 578024-39-2 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[cyclopentyl[4-(trifluoromethyl)phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-38-1

CMF C35 H44 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-40-5 CAPLUS

CN Acetic acid, [[4-(4-dibenzofuranyl)phenyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-41-6 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[4-(4-dibenzofuranyl)phenyl][4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-40-5

CMF C28 H18 F3 N O4




CM 2

CRN 6284-40-8

Print selected from 10-501,344.trn


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-42-7 CAPLUS

CN Acetic acid, [[4-(octyloxy)phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-43-8 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[4-(octyloxy)phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-42-7

CMF C25 H30 F3 N O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-44-9 CAPLUS


CN Acetic acid, [[2-(3-chlorophenyl)ethyl][[4-(1-decynyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-45-0 CAPLUS


CN Acetic acid, 2-[[[2-(3-chlorophenyl)ethyl][[4-(1Z)-1-decen-1-yl]phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)

Double bond geometry as shown.



RN 578024-46-1 CAPLUS

CN Acetic acid, 2-[[[2-(3-chlorophenyl)ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)



RN 578024-47-2 CAPLUS


CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[2-(3-chlorophenyl)ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-46-1

Print selected from 10-501,344.trn

CMF C30 H38 Cl N3 O4




CM 2

CRN 6284-40-8

CMF C7 H17 N O5


Absolute stereochemistry.



RN 578024-48-3 CAPLUS

CN Acetic acid, 2-oxo-2-[[[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl] [[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 578024-49-4 CAPLUS


CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl] [[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-48-3

CMF C31 H38 F3 N3 O4

Absolute stereochemistry.




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-50-7 CAPLUS

CN Acetic acid, 2-oxo-2-[[4-(trifluoromethyl)phenyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (CA INDEX NAME)



Print selected from 10-501,344.trn


RN 578024-51-8 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[4-(trifluoromethyl)phenyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]acetate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 578024-50-7

CMF C29 H34 F3 N3 O4




CM 2

CRN 6284-40-8

CMF C7 H17 N O5


Absolute stereochemistry.



RN 578024-52-9 CAPLUS

CN Acetic acid, 2-oxo-2-[[[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 578024-53-0 CAPLUS
CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl] [[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-52-9
CMF C31 H38 F3 N3 O4


Absolute stereochemistry.



CM 2


CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-54-1 CAPLUS

CN Acetic acid, [[[3-chlorophenyl)methyl][[4-(1-decynyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-55-2 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[3-chlorophenyl)methyl][[4-(1-decynyl)phenyl)methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-54-1

CMF C26 H30 Cl N O3




CM 2

CRN 6284-40-8

CMF C7 H17 N O5


Absolute stereochemistry.



Print selected from 10-501,344.trn

RN 578024-56-3 CAPLUS

CN Acetic acid, [[2-(3-chlorophenyl)ethyl][[4-(1-octynyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-57-4 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[2-(3-chlorophenyl)ethyl][[4-(1-octynyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-56-3

CMF C25 H28 Cl N O3




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-58-5 CAPLUS

CN Acetic acid, [[[4-(1-decynyl)phenyl]methyl][4-(trifluoromethyl)phenyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-59-6 CAPLUS

CN Acetic acid, 2-[[[4-(1-decyn-1-yl)phenyl]methyl][1-[4-(trifluoromethyl)phenyl]ethyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-60-9 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[4-(1-decynyl)phenyl]methyl][1-[4-(trifluoromethyl)phenyl]ethyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-59-6

CMF C28 H32 F3 N O3




CM 2

CRN 6284-40-8

CMF C7 H17 N O5


Absolute stereochemistry.



RN 578024-61-0 CAPLUS

CN Acetic acid, 2-[[[1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-

undecyl-1,2,4-oxadiazol-5-yl]phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-62-1 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-61-0

CMF C32 H40 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-63-2 CAPLUS

CN Acetic acid, [[2-(3-chlorophenyl)ethyl][[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-64-3 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[2-(3-chlorophenyl)ethyl][[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]oxoacetate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 578024-63-2

CMF C27 H32 Cl N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-65-4 CAPLUS

CN Acetic acid, [[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl)methyl][[4-(trifluoromethyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-66-5 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-65-4

CMF C27 H30 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-67-6 CAPLUS

CN Acetic acid, 2-[[[4-(dodecyloxy)-1-naphthalenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-68-7 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-(dodecyloxy)-1-naphthalenyl]methyl] [4-(trifluoromethyl)phenyl]methyl] amino] oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-67-6

CMF C33 H40 F3 N O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-69-8 CAPLUS

CN Acetic acid, [[(4-bromophenyl)methyl] [[4-(1-octynyl)phenyl]methyl] amino] oxo- (9CI) (CA INDEX NAME)




RN 578024-70-1 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] (2-hydroxy-1-phenylethyl)amino] oxo- (9CI) (CA INDEX NAME)



RN 578024-71-2 CAPLUS

CN Acetic acid, 2-[[[4-(1-decyn-1-yl)phenyl]methyl] [1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl] amino] -2-oxo- (CA INDEX NAME)



RN 578024-72-3 CAPLUS


Print selected from 10-501,344.trn

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-(1-decynyl)phenyl]methyl][1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl]amino]oxoacetate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 578024-71-2

CMF C29 H34 F3 N O3




CM 2

CRN 6284-40-8

CMF C7 H17 N O5


Absolute stereochemistry.



RN 578024-73-4 CAPLUS


CN Acetic acid, oxo[[[4-[(9Z)-1-oxo-9-tetradecenyl]amino]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 578024-74-5 CAPLUS

CN Acetic acid, 2-[[[4-(1-decyn-1-yl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)



RN 578024-75-6 CAPLUS

CN Acetic acid, 2-oxo-2-[[4-(trifluoromethyl)phenyl]methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino] - (CA INDEX NAME)



IT 578024-76-7, Oxo[[4-(trifluoromethyl)benzyl] [3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid, N-methyl-D-glucamine salt 578024-77-8, [(4-Dodecylbenzyl) [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-78-9, [(4-Dodecylbenzyl) [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid, N-methyl-D-glucamine salt 578024-79-0 578024-80-3, (4-[[4-(Benzyloxy)benzoyl]amino]benzyl) [4-(trifluoromethyl)benzyl]amino] - (oxo)acetic acid; 578024-81-4, [(3,5-Dichlorobenzyl) [4-(tridecanoylamino)benzyl]amino] (oxo)acetic acid 578024-82-5, [(3,5-Dichlorobenzyl) [4-(tridecanoylamino)benzyl]amino] (oxo)acetic acid, N-methyl-D-glucamine salt 578024-83-6, [[4-[(4-Octylphenyl)ethynyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-84-7, Oxo[[4-(trifluoromethyl)benzyl] [4-(5-undecyl-1,2,4-oxadiazol-3-yl)benzyl]amino]acetic acid 578024-85-8, Oxo[[4-(trifluoromethyl)benzyl] [4-(5-undecyl-1,2,4-oxadiazol-3-yl)benzyl]amino]acetic acid, N-methyl-D-glucamine salt 578024-86-9, [[4-[2-(4-Octylphenyl)ethyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-87-0, (4-[[4-(Heptyloxy)phenyl]ethynyl]benzyl) [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-88-1, [4-[(4-Butylphenyl)ethynyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-90-5, [[4-[(4-Hexylphenyl)ethynyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid, N-methyl-D-glucamine salt 578024-91-6, Oxo[[4-[[4-(pentyloxy)phenyl]ethynyl]benzyl] [4-(trifluoromethyl)benzyl]amino]acetic acid 578024-92-7, Oxo[[4-[(4-propylphenyl)ethynyl]benzyl] [4-(trifluoromethyl)benzyl]amino]acetic acid; 578024-93-8, [2-(3-Chlorophenyl)ethyl] (4-dodec-1-ynylbenzyl)amino] (oxo)acetic acid; 578024-94-9, [[2-(3-Chlorophenyl)ethyl] (4-dodec-1-ynylbenzyl)amino] (oxo)acetic acid, N-methyl-D-glucamine salt 578024-95-0, [(4-Oct-1-ynylbenzyl) [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-96-1, [4-(11-Hydroxyundec-1-ynyl)benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid; 578024-97-2, [4-(11-Methoxy-11-oxoundec-1-ynyl)benzyl] [4-(trifluoromethyl)benzyl]amino]

(oxo)acetic acid; 578024-98-3, 11-[4-[[[(Carboxycarbonyl) 4-(trifluoromethyl)benzyl]amino]methyl]phenyl]undec-10-ynoic acid; 578024-99-4, [[4-[[4-(Benzyloxy)phenyl]ethynyl]benzyl] 4-(trifluoromethyl)benzyl]amino]-(oxo)acetic acid; 578025-00-0, [[4-[2-[4-(Heptyloxy)phenyl]ethyl]benzyl] 4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid; 578025-01-1, [[4-[2-(4-Butylphenyl)ethyl]benzyl] 4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid; 578025-02-2, [4-[2-(4-Hexylphenyl)ethyl]benzyl] 4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid; 578025-03-3, [[4-[2-(4-Hexylphenyl)ethyl]benzyl] 4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid, N-methyl-D-glucamine salt 578025-04-4, Oxo[[4-[2-[4-(pentyloxy)phenyl]ethyl]benzyl] 4-(trifluoromethyl)benzyl]amino]acetic acid 578025-05-5, Oxo[[4-[2-(4-propylphenyl)ethyl]benzyl] 4-(trifluoromethyl)benzyl]amino]acetic acid; 578025-06-6, 11-[4-[[[(Carboxycarbonyl) 4-(trifluoromethyl)benzyl]amino]methyl]phenyl]undecanoic acid 578025-07-7, [[4-(11-Hydroxyundecyl)benzyl] 4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-08-8, (4-Dodec-1-ynylbenzyl) 4-(trifluoromethyl)phenyl]amino] (oxo)acetic acid 578025-09-9, (4-Dodec-1-ynylbenzyl) 4-(trifluoromethyl)phenyl]amino] (oxo)acetic acid, N-methyl-D-glucamine salt 578025-10-2, Oxo[[4-(trifluoromethyl)benzyl] 4-[2-(3-undecyl-1,2,4-oxadiazol-5-yl)ethyl]benzyl]amino]acetic acid 578025-11-3, Oxo[[4-(trifluoromethyl)benzyl] 4-[2-(3-undecyl-1,2,4-oxadiazol-5-yl)ethyl]benzyl]amino]acetic acid, N-methyl-D-glucamine salt 578025-12-4, [[4-[2-(3-Octyl-1,2,4-oxadiazol-5-yl)ethyl]benzyl] 4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid; 578025-13-5, [[4-[2-(3-Octyl-1,2,4-oxadiazol-5-yl)ethyl]benzyl] 4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid, N-methyl-D-glucamine salt 578025-14-6, [[4-[[4-Octylbenzoyl]amino]benzyl] 4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid; 578025-15-7, [[4-[[4-Octylbenzoyl]amino]benzyl] 4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid, N-methyl-D-glucamine salt 578025-19-1, [(3-Dec-1-ynyl-1-benzofuran-5-yl)methyl] 4-(trifluoromethyl)benzyl]amino]-(oxo)acetic acid 578025-20-4, [(3-Dodec-1-ynyl-1-benzofuran-5-yl)methyl] 4-(trifluoromethyl)benzyl]amino]-(oxo)acetic acid 578025-21-5, Oxo[[[3-[[4-propylphenyl]ethynyl]-1-benzofuran-5-yl)methyl] 4-(trifluoromethyl)benzyl]amino]acetic acid 578025-22-6, [[4-Dodec-1-ynylbenzyl] (4-fluorobenzyl)amino] (oxo)acetic acid; 578025-23-7, [Bis(4-oct-1-ynylbenzyl)amino] (oxo)acetic acid 578025-25-9, [(3-Dodec-1-ynylbenzyl) 4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid; 578025-26-0, [2-(2-Fluorophenyl)ethyl] 4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]-(oxo)acetic acid 578025-27-1, [[2-(2-Fluorophenyl)ethyl] 3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]-(oxo)acetic acid 578025-28-2, [2-(2-Fluorophenyl)ethyl] 4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid; 578025-29-3, [[2-(3,4-Dichlorophenyl)ethyl] 4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-30-6, [[2-(3,4-Dichlorophenyl)ethyl] 3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-31-7, [[2-(3,4-Dichlorophenyl)ethyl] 4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-32-8 578025-33-9 578025-34-0 578025-35-1, Oxo[5,6,7,8-tetrahydronaphthalen-1-yl] 4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578025-36-2, Oxo[5,6,7,8-tetrahydronaphthalen-1-yl] 3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578025-37-3, [[4-(3-Octyl-1,2,4-oxadiazol-5-yl)benzyl] (5,6,7,8-tetrahydronaphthalen-1-yl)amino] (oxo)acetic

acid; 578025-38-4 578025-39-5 578025-40-8
 578025-44-2, Oxo[[2-(trifluoromethyl)benzyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid; 578025-45-3,
 Oxo[[2-(trifluoromethyl)benzyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578025-46-4, [[4-(3-Octyl-1,2,4-oxadiazol-5-yl)benzyl][2-(trifluoromethyl)benzyl]amino](oxo)acetic acid
 578025-47-5, Oxo[[3-(trifluoromethyl)benzyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid; 578025-48-6,
 Oxo[[3-(trifluoromethyl)benzyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578025-49-7, [4-(3-Octyl-1,2,4-oxadiazol-5-yl)benzyl][3-(trifluoromethyl)benzyl]amino]-(oxo)acetic acid;
 578025-50-0, [(2-Methoxybenzyl)[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino](oxo)acetic acid 578025-51-1,
 [(2-Methoxybenzyl)[3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino](oxo)acetic acid; 578025-52-2,
 [(2-Methoxybenzyl)[4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino](oxo)acetic acid; 578025-53-3,
 Oxo[[4-[(trifluoromethyl)sulfonyl]benzyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)-benzyl]amino]acetic acid; 578025-54-4, Oxo[[4-[(trifluoromethyl)sulfonyl]benzyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)-benzyl]amino]acetic acid 578025-55-5, [[4-(3-Octyl-1,2,4-oxadiazol-5-yl)benzyl][4-[(trifluoromethyl)sulfonyl]benzyl]amino](oxo)acetic acid; 578025-56-6, 1,3-Benzodioxol-5-yl[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino](oxo)acetic acid; 578025-57-7,
 [1,3-Benzodioxol-5-yl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino](oxo)acetic acid 578025-58-8,
 [1,3-Benzodioxol-5-yl][4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino](oxo)acetic acid 578025-59-9,
 [[(4-Dodec-1-ynyl-1-naphthyl)methyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578025-60-2, [[(4-Dec-1-ynyl-1-naphthyl)methyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578025-61-3,
 Oxo[[4-(trifluoromethyl)benzyl][4-(4-undecyl-1,3-thiazol-2-yl)benzyl]amino]acetic acid; 578025-62-4, [(4-Dec-1-ynylbenzyl)[2-(2-fluorophenyl)ethyl]amino](oxo)acetic acid;
 578025-63-5, [(4-Dodec-1-ynylbenzyl)[2-(2-fluorophenyl)ethyl]amino](oxo)acetic acid 578025-64-6,
 [[(4-(Dodecyloxy)-1-naphthyl)methyl][2-(2-fluorophenyl)ethyl]amino](oxo)acetic acid 578025-65-7, [[2-(2-Fluorophenyl)ethyl][4-(octyloxy)benzyl]amino](oxo)acetic acid 578025-66-8,
 [(4-Dec-1-ynylbenzyl)[2-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578025-67-9, [(4-Dodec-1-ynylbenzyl)[2-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578025-68-0,
 [[(4-(Dodecyloxy)-1-naphthyl)methyl][2-(trifluoromethyl)benzyl]amino](oxo)acetic acid; 578025-69-1, [[4-(Octyloxy)benzyl][2-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578025-70-4,
 [(4-Dec-1-ynylbenzyl)[2-(3,4-dichlorophenyl)ethyl]amino](oxo)acetic acid 578025-71-5, [[2-(3,4-Dichlorophenyl)ethyl][4-dodec-1-ynylbenzyl]amino](oxo)acetic acid; 578025-72-6
 578025-73-7 578025-74-8 578025-75-9,
 [[4-(5-Cyclohexylpent-1-ynyl)benzyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578025-76-0, [[3-[(4-Hexylphenyl)ethynyl]benzyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid; 578025-77-1,
 [4-(4-Ethyl-3-hydroxyoct-1-ynyl)benzyl][4-(trifluoromethyl)benzyl]amino]-(oxo)-acetic acid 578025-78-2, [(2-Dec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578025-79-3,
 (4-Dec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino](oxo)acetic acid, L-lysine salt; 578025-80-6, [(4-Dec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino](oxo)acetic acid tromethamine salt
 578025-81-7, [(4-Dec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino]

] (oxo)acetic acid, L-Arginine salt 578025-82-8,
Sodium[(4-dec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino] (oxo)acetate
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(methylene amide derivs. for cardiovascular disorders)


RN 578024-76-7 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[[4-(trifluoromethyl)phenyl]methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-75-6

CMF C30 H36 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-77-8 CAPLUS

CN Acetic acid, 2-[[[4-(dodecylphenyl)methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)



RN 578024-78-9 CAPLUS


CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[(4-dodecylphenyl)methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

NAME)

CM 1

CRN 578024-77-8

CMF C29 H38 F3 N O3




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-79-0 CAPLUS

CN Acetic acid, [[4-[[[(2-butyl-3-benzofuranyl)methyl]amino]carbonyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-80-3 CAPLUS

CN Acetic acid, oxo[[[4-[[4-(phenylmethoxy)benzoyl]amino]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 578024-81-4 CAPLUS

CN Acetic acid, 2-[[[(3,5-dichlorophenyl)methyl][[4-[(1-oxotridecyl)amino]phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-82-5 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[(3,5-dichlorophenyl)methyl][[4-[(1-oxotridecyl)amino]phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-81-4

CMF C29 H38 Cl2 N2 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-83-6 CAPLUS

CN Acetic acid, 2-[[[4-[2-(4-octylphenyl)ethynyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)



RN 578024-84-7 CAPLUS

CN Acetic acid, 2-oxo-2-[[[4-(trifluoromethyl)phenyl]methyl][[4-(5-undecyl-1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 578024-85-8 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[[4-(trifluoromethyl)phenyl]methyl][[4-(5-undecyl-1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-84-7

CMF C30 H36 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-86-9 CAPLUS

CN Acetic acid, 2-[[[4-[2-(4-octylphenyl)ethyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-87-0 CAPLUS

CN Acetic acid, 2-[[[4-[2-[4-(heptyloxy)phenyl]ethynyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)



RN 578024-88-1 CAPLUS

CN Acetic acid, 2-[[[4-[2-(4-butylphenyl)ethynyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-90-5 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-[(4-hexylphenyl)ethynyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-89-2

CMF C31 H30 F3 N O3




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-91-6 CAPLUS

CN Acetic acid, oxo[[[4-[(4-(pentyloxy)phenyl)ethynyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578024-92-7 CAPLUS

CN Acetic acid, oxo[[[4-[(4-propylphenyl)ethynyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 578024-93-8 CAPLUS

CN Acetic acid, 2-[[[2-(3-chlorophenyl)ethyl][[4-(1-dodecyn-1-yl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-94-9 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[2-(3-chlorophenyl)ethyl][[4-(1-dodecynyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-93-8

CMF C29 H36 Cl N O3




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-95-0 CAPLUS

CN Acetic acid, [[[4-(1-octynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-96-1 CAPLUS

CN Acetic acid, [[[4-(11-hydroxy-1-undecynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-97-2 CAPLUS


CN 10-Undecynoic acid, 11-[4-[[[(carboxycarbonyl)[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]phenyl]-, 1-methyl ester (CA INDEX NAME)



RN 578024-98-3 CAPLUS


CN 10-Undecynoic acid, 11-[4-[[[(carboxycarbonyl)[[4-

(trifluoromethyl)phenyl)methyl]amino)methyl]phenyl] - (CA INDEX NAME)




RN 578024-99-4 CAPLUS

CN Acetic acid, 2-oxo-2-[[[4-[2-[4-(phenylmethoxy)phenyl]ethynyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino] - (CA INDEX NAME)




RN 578025-00-0 CAPLUS

CN Acetic acid, [[4-[2-[4-(heptyloxy)phenyl]ethyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-01-1 CAPLUS

CN Acetic acid, [[4-[2-(4-butylphenyl)ethyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-02-2 CAPLUS

CN Acetic acid, 2-[[[4-[2-(4-hexylphenyl)ethyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-03-3 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[4-[2-(4-hexylphenyl)ethyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578025-02-2

CMF C31 H34 F3 N O3




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578025-04-4 CAPLUS

CN Acetic acid, oxo[[[4-[2-[4-(pentyloxy)phenyl]ethyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578025-05-5 CAPLUS

CN Acetic acid, oxo[[[4-[2-(4-propylphenyl)ethyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578025-06-6 CAPLUS

CN Benzeneundecanoic acid, 4-[[[(carboxycarbonyl)[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]- (CA INDEX NAME)




RN 578025-07-7 CAPLUS

CN Acetic acid, [[4-(11-hydroxyundecyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-08-8 CAPLUS

CN Acetic acid, 2-[[[4-(1-dodecyn-1-yl)phenyl]methyl][4-(trifluoromethyl)phenyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-09-9 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-(1-dodecynyl)phenyl]methyl][4-(trifluoromethyl)phenyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578025-08-8

CMF C28 H32 F3 N O3




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578025-10-2 CAPLUS

CN Acetic acid, oxo[[[4-(trifluoromethyl)phenyl]methyl][[4-[2-(3-undecyl-1,2,4-oxadiazol-5-yl)ethyl]phenyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 578025-11-3 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[[4-(trifluoromethyl)phenyl]methyl][[4-[2-(3-undecyl-1,2,4-oxadiazol-5-yl)ethyl]phenyl]methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578025-10-2

CMF C32 H40 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578025-12-4 CAPLUS

CN Acetic acid, [[4-[2-(3-octyl-1,2,4-oxadiazol-5-yl)ethyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-13-5 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[4-[2-(3-octyl-1,2,4-oxadiazol-5-yl)ethyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578025-12-4

CMF C29 H34 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578025-14-6 CAPLUS

CN Acetic acid, 2-[[[4-[(4-octylbenzoyl)amino]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-15-7 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[4-[(4-octylbenzoyl)amino]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino] oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578025-14-6

CMF C32 H35 F3 N2 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578025-19-1 CAPLUS

CN Acetic acid, 2-[[[3-(1-decyn-1-yl)-5-benzofuranyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-20-4 CAPLUS

CN Acetic acid, 2-[[[3-(1-dodecyn-1-yl)-5-benzofuranyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-21-5 CAPLUS

CN Acetic acid, 2-oxo-2-[[[3-[2-(4-propylphenyl)ethynyl]-5-benzofuranyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino] - (CA INDEX NAME)




RN 578025-22-6 CAPLUS

CN Acetic acid, 2-[[[4-(1-dodecyn-1-yl)phenyl]methyl][[4-fluorophenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-23-7 CAPLUS

CN Acetic acid, 2-[bis[[4-(1-octyn-1-yl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-25-9 CAPLUS

CN Acetic acid, [[3-(1-dodecynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-26-0 CAPLUS

CN Acetic acid, [[2-(2-fluorophenyl)ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-27-1 CAPLUS

CN Acetic acid, [[2-(2-fluorophenyl)ethyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-28-2 CAPLUS

CN Acetic acid, [[2-(2-fluorophenyl)ethyl][[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-29-3 CAPLUS

CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-30-6 CAPLUS

CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-31-7 CAPLUS

CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-32-8 CAPLUS

CN Acetic acid, [[2-(1,1'-biphenyl)-4-ylethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-33-9 CAPLUS

CN Acetic acid, [(2-[1,1'-biphenyl]-4-ylethyl)[[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-34-0 CAPLUS

CN Acetic acid, [(2-[1,1'-biphenyl]-4-ylethyl)[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-35-1 CAPLUS


CN Acetic acid, oxo[(5,6,7,8-tetrahydro-1-naphthalenyl)[[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]- (9CI) (CA INDEX NAME)



Print selected from 10-501,344.trn


RN 578025-36-2 CAPLUS

CN Acetic acid, oxo[(5,6,7,8-tetrahydro-1-naphthalenyl)[[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578025-37-3 CAPLUS

CN Acetic acid, [[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl](5,6,7,8-tetrahydro-1-naphthalenyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-38-4 CAPLUS

CN Acetic acid, [[([1,1'-biphenyl]-3-ylmethyl)[[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-39-5 CAPLUS

CN Acetic acid, [[([1,1'-biphenyl]-3-ylmethyl)[[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-40-8 CAPLUS

CN Acetic acid, [[([1,1'-biphenyl]-3-ylmethyl)[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-44-2 CAPLUS

CN Acetic acid, oxo[[[2-(trifluoromethyl)phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578025-45-3 CAPLUS

CN Acetic acid, oxo[[[2-(trifluoromethyl)phenyl]methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578025-46-4 CAPLUS

CN Acetic acid, [[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl][[2-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-47-5 CAPLUS

CN Acetic acid, oxo[[[3-(trifluoromethyl)phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578025-48-6 CAPLUS

CN Acetic acid, oxo[[[3-(trifluoromethyl)phenyl]methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578025-49-7 CAPLUS

CN Acetic acid, [[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl] [[3-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-50-0 CAPLUS

CN Acetic acid, [[[2-methoxyphenyl]methyl] [[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-51-1 CAPLUS

CN Acetic acid, [[[2-methoxyphenyl]methyl] [[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-52-2 CAPLUS


CN Acetic acid, [[[2-methoxyphenyl]methyl] [[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-53-3 CAPLUS
 CN Acetic acid, oxo[[[4-[(trifluoromethyl)sulfonyl]phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino] - (9CI) (CA INDEX NAME)



RN 578025-54-4 CAPLUS
 CN Acetic acid, oxo[[[4-[(trifluoromethyl)sulfonyl]phenyl]methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 578025-55-5 CAPLUS
 CN Acetic acid, [[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl][[4-[(trifluoromethyl)sulfonyl]phenyl]methyl]amino] oxo- (9CI) (CA INDEX NAME)




RN 578025-56-6 CAPLUS

CN Acetic acid, [1,3-benzodioxol-5-yl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-57-7 CAPLUS

CN Acetic acid, [1,3-benzodioxol-5-yl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-58-8 CAPLUS

CN Acetic acid, [1,3-benzodioxol-5-yl][4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-59-9 CAPLUS

CN Acetic acid, 2-[[[4-(1-dodecyn-1-yl)-1-naphthalenyl)methyl][4-(trifluoromethyl)phenyl)methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-60-2 CAPLUS

CN Acetic acid, [[4-(1-decynyl)-1-naphthalenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-61-3 CAPLUS


CN Acetic acid, 2-oxo-2-[[[4-(trifluoromethyl)phenyl]methyl][[4-(4-undecyl-2-thiazolyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 578025-62-4 CAPLUS
 CN Acetic acid, [[[4-(1-decynyl)phenyl]methyl][2-(2-fluorophenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-63-5 CAPLUS
 CN Acetic acid, [[[4-(1-dodecynyl)phenyl]methyl][2-(2-fluorophenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-64-6 CAPLUS
 CN Acetic acid, [[[4-(dodecyloxy)-1-naphthalenyl]methyl][2-(2-fluorophenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-65-7 CAPLUS

CN Acetic acid, [[2-(2-fluorophenyl)ethyl][[4-(octyloxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-66-8 CAPLUS

CN Acetic acid, [[[4-(1-decynyl)phenyl]methyl][[2-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-67-9 CAPLUS

CN Acetic acid, [[[4-(1-dodecynyl)phenyl]methyl][[2-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-68-0 CAPLUS


CN Acetic acid, [[[4-(dodecyloxy)-1-naphthalenyl]methyl][[2-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



Me-(CH₂)₁₁-O


RN 578025-69-1 CAPLUS

CN Acetic acid, [[[4-(octyloxy)phenyl]methyl][[2-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-70-4 CAPLUS

CN Acetic acid, [[[4-(1-decynyl)phenyl]methyl][2-(3,4-dichlorophenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-71-5 CAPLUS


CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(1-dodecynyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-72-6 CAPLUS
 CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(dodecyloxy)-1-naphthalenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-73-7 CAPLUS
 CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(octyloxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-74-8 CAPLUS
 CN Acetic acid, 2-[[[4-[2-(4-hexylphenyl)ethynyl]phenyl]methyl][1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-75-9 CAPLUS

CN Acetic acid, 2-[[[4-(5-cyclohexyl-1-pentyn-1-yl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-76-0 CAPLUS

CN Acetic acid, 2-[[[3-[2-(4-hexylphenyl)ethynyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-77-1 CAPLUS

CN Acetic acid, [[4-(4-ethyl-3-hydroxy-1-octynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-78-2 CAPLUS

CN Acetic acid, [[2-(1-decynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-79-3 CAPLUS

CN L-Lysine, mono[[[4-(1-decynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate] (9CI) (CA INDEX NAME)

CM 1

CRN 578024-74-5

CMF C27 H30 F3 N O3




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.



RN 578025-80-6 CAPLUS


CN Acetic acid, [[4-(1-decynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-74-5

CMF C27 H30 F3 N O3


Print selected from 10-501,344.trn



CM 2

CRN 77-86-1

CMF C4 H11 N O3




RN 578025-81-7 CAPLUS

CN L-Arginine, mono[[[4-(1-decynyl)phenyl)methyl][4-(trifluoromethyl)phenyl)methyl]amino]oxoacetate] (9CI) (CA INDEX NAME)

CM 1

CRN 578024-74-5

CMF C27 H30 F3 N O3




CM 2

CRN 74-79-3


CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 578025-82-8 CAPLUS

CN Acetic acid, [[[4-(1-decynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, sodium salt (9CI) (CA INDEX NAME)



● Na

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:610410 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 139:179889
 TITLE: Methylene amides, particularly
 [(arylmethyl)amino](oxo)acetic acids, useful as
 modulators, and especially inhibitors, of protein
 tyrosine phosphatases (PTPs), and their preparation,
 uses, e.g., as antidiabetics, and pharmaceutical
 compositions.
 INVENTOR(S): Swinnen, Dominique; Bombrun, Agnes; Gonzalez, Jerome;
 Gerber, Patrick; Pittet, Pierre-Andre
 PATENT ASSIGNEE(S): Applied Research Systems ARS Holding N.V., Neth.
 Antilles
 SOURCE: PCT Int. Appl., 346 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064376	A1	20030807	WO 2003-EP808	20030127 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2472021	A1	20030807	CA 2003-2472021	20030127 <--
EP 1470102	A1	20041027	EP 2003-734697	20030127 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003007394	A	20041109	BR 2003-7394	20030127 <--

Print selected from 10-501,344.trn

JP 2005516061	T	20050602	JP 2003-564000	20030127 <--
CN 1633410	A	20050629	CN 2003-807036	20030127 <--
ZA 2004005179	A	20050629	ZA 2004-5179	20040629 <--
IN 2004DN01884	A	20070406	IN 2004-DN1884	20040701 <--
MX 2004PA07253	A	20041029	MX 2004-PA7253	20040727 <--
NO 2004003520	A	20041005	NO 2004-3520	20040824 <--
US 2005124656	A1	20050609	US 2005-501344	20050126 <--
PRIORITY APPLN. INFO.:			EP 2002-100078	A 20020129 <--
			EP 2002-100410	A 20020425 <--
			WO 2003-EP808	W 20030127 <--

OTHER SOURCE(S): MARPAT 139:179889

GI




AB Title compds. I [wherein R1 = alkyl, alkenyl, alkynyl, aryl, heteroaryl, (3-8-membered)-cycloalkyl, heterocycloalkyl, (alkyl)aryl, (alkyl)heteroaryl, (alkenyl)aryl, heteroaryl, (alkynyl)aryl, heteroaryl; R2, R3 = independently H or alkyl; Cy = aryl, heteroaryl, cycloalkyl, heterocyclyl; with the proviso that four compds. are excluded; their geometrical isomers, optically active forms as enantiomers, diastereomers and racemates, and pharmaceutically acceptable salts and active derivs.] were prepared as inhibitors of protein tyrosine phosphatases (PTPs), in particular PTP1B. Examples include over 400 invention compds., five pharmaceutical formulations, and two biol. assays. For example, II was prepared in 4 steps by amidation of 4-formylbenzoic acid with dodecylamine in THF in the presence of 4-methylmorpholine and iso-Bu chloroformate for 3 h at room temperature, reductive amination with 4-trifluoromethylbenzylamine in DCE in the presence of NaBH(OAc)₃, TEA-acylation with chlorooxoacetic acid Et ester in THF, and base-catalyzed hydrolysis of the ester. II exhibited an IC₅₀ value of 2.224 μ M for inhibition of PTP1B, 1.40 μ M for GLEPP-1, 2.40 μ M for SHP-1, and 2.70 μ M for SHP-2 in an in vitro assay. In an in vivo postprandial glycemia model in db/db mice, II, at

20-200 mg/kg orally, decreased blood glucose level by 17% at 20 mg/kg, by 42% at 100 mg/kg, and by 48% at 200 mg/kg, with decreases in serum insulin levels of -2%, 66%, and 89%, resp. Thus, I and their formulations are useful for the treatment and/or prevention of metabolic disorders mediated by insulin resistance or hyperglycemia, comprising diabetes type I and/or II, inadequate glucose tolerance, insulin resistance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, polycystic ovary syndrome (PCOS).

IT 578024-74-5P, [(4-Dec-1-ynylbenzyl) [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-83-6P, [[4-[(4-Octylphenyl)ethynyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-87-0P, [[4-[[4-(Heptyloxy)phenyl]ethynyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-88-1P, [[4-[(4-Butylphenyl)ethynyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-91-6P, Oxo[[4-[[4-(pentyloxy)phenyl]ethynyl]benzyl] [4-(trifluoromethyl)benzyl]amino]acetic acid 578024-92-7P, Oxo[[4-[[4-(propylphenyl)ethynyl]benzyl] [4-(trifluoromethyl)benzyl]amino]acetic acid 578024-96-1P, [[4-(11-Hydroxyundec-1-ynyl)benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-98-3P, 11-[4-[[Carboxycarbonyl] [4-(trifluoromethyl)benzyl]amino]methyl]phenyl]undec-10-ynoic acid
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of [(arylmethyl)amino] (oxo)acetic acids as PTP inhibitors for antidiabetics)


RN 578024-74-5 CAPLUS

CN Acetic acid, 2-[[[4-(1-decyn-1-yl)phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-83-6 CAPLUS

CN Acetic acid, 2-[[[4-[2-(4-octylphenyl)ethynyl]phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-87-0 CAPLUS

CN Acetic acid, 2-[[[4-[2-[4-(heptyloxy)phenyl]ethynyl]phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-88-1 CAPLUS

CN Acetic acid, 2-[[[4-[2-(4-butylphenyl)ethynyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-91-6 CAPLUS

CN Acetic acid, oxo[[[4-[4-(pentyloxy)phenyl]ethynyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578024-92-7 CAPLUS

CN Acetic acid, oxo[[[4-[4-(propylphenyl)ethynyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578024-96-1 CAPLUS

CN Acetic acid, [[4-(11-hydroxy-1-undecynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-98-3 CAPLUS

CN 10-Undecynoic acid, 11-[4-[[[(carboxycarbonyl)[4-(trifluoromethyl)phenyl]methyl]amino]methyl]phenyl]- (CA INDEX NAME)



IT 578021-80-4P, [Benzyl[4-[(dodecylamino)carbonyl]benzyl]amino] (oxo) acetic acid 578021-81-5P, Oxo[[4-[(pentadecylamino)carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino]acetic acid 578021-82-6P, [Benzyl[4-[(pentadecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-83-7P, [Benzyl[4-[(tridecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578021-84-8P, [Benzyl[4-[[dodecyl(methyl)amino]carbonyl]benzyl]amino] (oxo)acetic acid 578021-85-9P, [[4-[[Dodecyl(methyl)amino]carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578021-87-1P, [[4-[(Dodecylamino)carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578021-88-2P, [[4-[(Dodecylamino)carbonyl]benzyl][3-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578021-90-6P, Oxo[[4-(tridecanoylamino)benzyl][4-(trifluoromethyl)benzyl]amino]acetic acid 578021-91-7P, [Benzyl[4-[[4-(hexyloxy)benzoyl]amino]benzyl]amino] (oxo)acetic acid 578021-92-8P, Oxo[[4-(trifluoromethyl)benzyl][4-(10-undecenoylamino)benzyl]amino]acetic acid 578021-93-9P, Oxo[[4-[(9E)-9-tetradecenoylamino]benzyl][4-(trifluoromethyl)benzyl]amino]acetic acid 578021-94-0P, [Benzyl[4-(tridecanoylamino)benzyl]amino] (oxo)acetic acid 578021-95-1P, [[4-[(2-Hydroxydodecyl)amino]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578021-96-2P, Oxo[[4-(trifluoromethyl)benzyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578021-99-5P, [[4-[(Dodecylamino)carbonyl]benzyl][2-carboxy-1-phenylethyl]amino] (oxo)acetic acid 578022-01-2P, [4-Bromo-N-[4-[(dodecylamino)carbonyl]benzyl]anilino] (oxo)acetic acid 578022-02-3P, [N-[4-[(Dodecylamino)carbonyl]benzyl]anilino] (oxo)acetic acid 578022-03-4P, [[2-(3-Chlorophenyl)ethyl][4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-04-5P, [[4-[(Dodecylamino)carbonyl]benzyl][2-(3-methoxyphenyl)ethyl]amino] (oxo)acetic acid 578022-07-8P, [N-[4-[(Dodecylamino)carbonyl]benzyl]-4-phenoxyanilino] (oxo)acetic acid 578022-10-3P, [[4-[(Dodecylamino)carbonyl]benzyl][2-(4-phenoxyphenyl)ethyl]amino] (oxo)acetic acid 578022-11-4P, [[4-[(Dodecylamino)carbonyl]benzyl][2-(2-phenoxyphenyl)ethyl]amino] (oxo)acetic acid 578022-12-5P, [[2-[1,1'-Biphenyl]-4-ylethyl][4-[(dodecylamino)carbonyl]benzyl]amino]glyoxylic acid 578022-13-6P, [[1,1'-Biphenyl]-3-ylmethyl][4-

[(dodecylamino)carbonyl]benzyl]amino]glyoxylic acid 578022-14-7P
 , [3-(Benzyloxy)-N-[4-[(dodecylamino)carbonyl]benzyl]anilino] (oxo)acetic
 acid 578022-15-8P, [[4-(Benzoylamino)benzyl] [4-
 [(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-16-9P
 , [[4-[(Dodecylamino)carbonyl]benzyl] [4-(1,2,3-thiadiazol-4-
 yl)benzyl]amino] (oxo)acetic acid 578022-17-0P,
 [[4-[(Dodecylamino)carbonyl]benzyl] (4-pentylbenzyl)amino] (oxo)acetic acid
 578022-18-1P, [[4-[(Dodecylamino)carbonyl]benzyl] (1-
 phenylethyl)amino] (oxo)acetic acid 578022-19-2P,
 [[4-[(Dodecylamino)carbonyl]benzyl] [1-(1-naphthyl)ethyl]amino] (oxo)acetic
 acid 578022-20-5P, [Benzyl [3-[(dodecylamino)carbonyl]benzyl]amin
 o] (oxo)acetic acid 578022-21-6P, [[3-
 [(Dodecylamino)carbonyl]benzyl] [4-(methylsulfonyl)benzyl]amino] (oxo)acetic
 acid 578022-22-7P, [(3-Cyanobenzyl) [3-
 [(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid 578022-23-8P
 , [[3-[(Dodecylamino)carbonyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)
 acetic acid 578022-24-9P, [[4-Chlorobenzyl] [3-[[4-
 pentylbenzyl]amino]carbonyl]benzyl]amino] (oxo)acetic acid
 578022-25-0P, Oxo[[4-[[[2-(2-thienyl)ethyl]amino]carbonyl]benzyl] [4-
 (trifluoromethyl)benzyl]amino]acetic acid 578022-26-1P,
 [Benzyl [[3'-[[[2,2-diphenylethyl]amino]carbonyl] [1,1'-biphenyl]-4-
 yl]methyl]amino]glyoxylic acid 578022-27-2P,
 [(3-Cyanobenzyl) [[3'-[[[2,2-diphenylethyl]amino]carbonyl] [1,1'-biphenyl]-4-
 yl]methyl]amino]glyoxylic acid 578022-28-3P,
 [[4-Chlorobenzyl] [[3'-[[[2,2-diphenylethyl]amino]carbonyl] [1,1'-biphenyl]-
 4-yl]methyl]amino]glyoxylic acid 578022-29-4P,
 [[[[3'-[[[2,2-Diphenylethyl]amino]carbonyl] [1,1'-biphenyl]-4-yl]methyl] [4-
 (trifluoromethyl)benzyl]amino]glyoxylic acid 578022-30-7P,
 [(3-Cyanobenzyl) [[3'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl] [1,1'-
 biphenyl]-4-yl]methyl]amino]glyoxylic acid 578022-31-8P,
 Oxo[[[3'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl] [1,1'-biphenyl]-4-
 yl]methyl] [4-(trifluoromethyl)benzyl]amino]acetic acid
 578022-32-9P, [(3-Cyanobenzyl) [[3'-[(octylamino)carbonyl] [1,1'-
 biphenyl]-4-yl]methyl]amino]glyoxylic acid 578022-33-0P,
 [[4-Chlorobenzyl] [[3'-[(octylamino)carbonyl] [1,1'-biphenyl]-4-
 yl]methyl]amino]glyoxylic acid 578022-34-1P,
 [[[[3'-[(Octylamino)carbonyl] [1,1'-biphenyl]-4-yl]methyl] [4-
 (trifluoromethyl)benzyl]amino]glyoxylic acid 578022-35-2P,
 [(3-Cyanobenzyl) [[3'-[[[3-phenylpropyl]amino]carbonyl] [1,1'-biphenyl]-4-
 yl]methyl]amino]glyoxylic acid 578022-36-3P,
 [(3-Cyanobenzyl) [[3'-[(dodecylamino)carbonyl] [1,1'-biphenyl]-4-
 yl]methyl]amino]glyoxylic acid 578022-37-4P,
 [[4-Chlorobenzyl] [[3'-[(dodecylamino)carbonyl] [1,1'-biphenyl]-4-
 yl]methyl]amino]glyoxylic acid 578022-38-5P,
 [[[[3'-[(Dodecylamino)carbonyl] [1,1'-biphenyl]-4-yl]methyl] [4-
 (trifluoromethyl)benzyl]amino]glyoxylic acid 578022-39-6P,
 [Benzyl [[3'-[[[4-pentylbenzyl]amino]carbonyl] [1,1'-biphenyl]-4-
 yl]methyl]amino]glyoxylic acid 578022-40-9P,
 [(3-Cyanobenzyl) [[3'-[[[4-pentylbenzyl]amino]carbonyl] [1,1'-biphenyl]-4-
 yl]methyl]amino]glyoxylic acid 578022-41-0P,
 [[4-Chlorobenzyl] [[3'-[[[4-pentylbenzyl]amino]carbonyl] [1,1'-biphenyl]-4-
 yl]methyl]amino]glyoxylic acid 578022-42-1P,
 Oxo[[[3'-[[[4-pentylbenzyl]amino]carbonyl] [1,1'-biphenyl]-4-yl]methyl] [4-
 (trifluoromethyl)benzyl]amino]acetic acid 578022-43-2P,
 Oxo[[[3'-[[[4-phenylbutyl]amino]carbonyl] [1,1'-biphenyl]-4-yl]methyl] [4-
 (trifluoromethyl)benzyl]amino]acetic acid 578022-44-3P,
 [(3-Cyanobenzyl) [[3'-[[[2-mesitylethyl]amino]carbonyl] [1,1'-biphenyl]-4-
 yl]methyl]amino]glyoxylic acid 578022-45-4P,
 [[4-Chlorobenzyl] [[3'-[[[2-mesitylethyl]amino]carbonyl] [1,1'-biphenyl]-4-

yl)methyl]amino]glyoxylic acid 578022-46-5P,
 [[3'-[[[2-Mesitylethyl]amino]carbonyl][1,1'-biphenyl]-4-yl)methyl][4-(trifluoromethyl)benzyl]amino]glyoxylic acid 578022-47-6P,
 [[4-Chlorobenzyl][3'-[[[2-(4-methoxyphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-4-yl)methyl]amino]glyoxylic acid 578022-48-7P,
 [[4-[(Dodecylamino)carbonyl]benzyl](4-methoxybenzyl)amino](oxo)acetic acid 578022-49-8P, [[4-[(Dodecylamino)carbonyl]benzyl][4-(methylsulfonyl)benzyl]amino](oxo)acetic acid 578022-50-1P,
 [[3-[(Dodecylamino)carbonyl]benzyl](4-methoxybenzyl)amino](oxo)acetic acid 578022-51-2P, [[3-[(Dodecylamino)carbonyl]benzyl][3-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578022-53-4P,
 4-[[[(Carboxycarbonyl)[3-[(dodecylamino)carbonyl]benzyl]amino]methyl]benzoic acid 578022-54-5P, [[3-[(Dodecylamino)carbonyl]benzyl][4-nitrobenzyl]amino](oxo)acetic acid 578022-55-6P,
 [[3-[(Dodecylamino)carbonyl]benzyl](2-fluorobenzyl)amino](oxo)acetic acid 578022-58-9P, [[3-[(Dodecylamino)carbonyl]benzyl](4-hydroxybenzyl)amino](oxo)acetic acid 578022-59-0P,
 [[3-[(Dodecylamino)carbonyl]benzyl](4-phenoxybenzyl)amino](oxo)acetic acid 578022-61-4P, 3-[[[(Carboxycarbonyl)[3-[(dodecylamino)carbonyl]benzyl]amino]methyl]benzoic acid 578022-63-6P, [[4-[(Dodecylamino)carbonyl]benzyl][4-nitrobenzyl]amino](oxo)acetic acid 578022-64-7P,
 [[1,3-Benzodioxol-5-ylmethyl][4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578022-65-8P, [[4-[(Dodecylamino)carbonyl]benzyl](2-fluorobenzyl)amino](oxo)acetic acid 578022-66-9P,
 [[4-[(Dodecylamino)carbonyl]benzyl](4-phenoxybenzyl)amino](oxo)acetic acid 578022-67-0P, 4-[[[(Carboxycarbonyl)[4-[(dodecylamino)carbonyl]benzyl]amino]methyl]benzoic acid 578022-71-6P, [(3,5-Dichlorobenzyl)[4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578022-72-7P,
 , [(3,5-Dichlorobenzyl)[4-[[[(3,3-diphenylpropyl)amino]carbonyl]benzyl]amino](oxo)acetic acid 578022-73-8P, [[4-[[[2-[1,1'-Biphenyl]-4-ylethyl]amino]carbonyl]benzyl](3,5-dichlorobenzyl)amino]glyoxylic acid 578022-74-9P, [(1,3-Benzodioxol-5-ylmethyl)[4-[[[2-[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]benzyl]amino]glyoxylic acid 578022-78-3P,
 , [[4-(Dimethylamino)benzyl][4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578022-80-7P, [(4-Cyanobenzyl)[4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578022-85-2P,
 , [[3-[(Dodecylamino)carbonyl]benzyl][3-hydroxybenzyl]amino](oxo)acetic acid 578022-86-3P, [(4-Cyanobenzyl)[3-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578022-89-6P,
 , [(1,3-Benzodioxol-5-ylmethyl)[3-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578022-93-2P, [[4-[(Dodecylamino)carbonyl]benzyl](4-hydroxybenzyl)amino](oxo)acetic acid 578022-94-3P,
 3-[[[(Carboxycarbonyl)[4-[(dodecylamino)carbonyl]benzyl]amino]methyl]benzoic acid 578023-20-8P, [[4-[(Dodecylamino)carbonyl]phenyl][2-(methoxycarbonyl)benzyl]amino](oxo)acetic acid 578023-21-9P,
 [[4-[[[2-(1,1'-Biphenyl-4-yl)ethyl]amino]carbonyl]-2-bromobenzyl](4-iodobenzyl)amino]glyoxylic acid 578023-22-0P,
 [[2-Bromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl](4-iodobenzyl)amino](oxo)acetic acid 578023-23-1P,
 [[2-Bromo-4-[(dodecylamino)carbonyl]benzyl](4-iodobenzyl)amino](oxo)acetic acid 578023-24-2P, [[2,6-Dibromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl](4-iodobenzyl)amino](oxo)acetic acid 578023-25-3P, [(4-Iodobenzyl)[4'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]-1,1'-biphenyl-4-yl)methyl]amino]glyoxylic acid 578023-26-4P,
 [[2-Bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl][(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino]glyoxylic acid 578023-27-5P,

[[4-[[[2-(1,1'-Biphenyl-4-yl)ethyl]amino]carbonyl]-2-bromobenzyl][(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino]glyoxylic acid 578023-28-6P,
, [[2-Bromo-4-[[[4-(pentybenzyl)amino]carbonyl]benzyl][(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino]glyoxylic acid 578023-29-7P,
[[2,6-Dibromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl][(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino]glyoxylic acid 578023-30-0P,
, [[4-[[[2-(1,1'-Biphenyl-4-yl)ethyl]amino]carbonyl]-2,6-dibromobenzyl][(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino]glyoxylic acid 578023-31-1P,
[[2,6-Dibromo-4-[[[4-(pentybenzyl)amino]carbonyl]benzyl][(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino]glyoxylic acid 578023-32-2P,
[[2,6-Dibromo-4-[(dodecylamino)carbonyl]benzyl][(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino]glyoxylic acid 578023-33-3P,
, [[(4'-Fluoro-1,1'-biphenyl-3-yl)methyl][(4'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]-1,1'-biphenyl-4-yl)methyl]amino]glyoxylic acid 578023-34-4P,
[[[4'-[(Dodecylamino)carbonyl]-1,1'-biphenyl-4-yl)methyl][(4'-fluoro-1,1'-biphenyl-3-yl)methyl]amino]glyoxylic acid 578023-35-5P,
[[2-Bromo-4-[[[4-(pentybenzyl)amino]carbonyl]benzyl][2-(trifluoromethoxy)benzyl]amino](oxo)acetic acid 578023-36-6P,
[[2,6-Dibromo-4-[[[4-(pentybenzyl)amino]carbonyl]benzyl][2-(trifluoromethoxy)benzyl]amino](oxo)acetic acid 578023-37-7P,
Oxo[[[4'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]-1,1'-biphenyl-4-yl)methyl][2-(trifluoromethoxy)benzyl]amino]acetic acid 578023-38-8P,
[[[4'-[(Dodecylamino)carbonyl]-1,1'-biphenyl-4-yl)methyl][2-(trifluoromethoxy)benzyl]amino]glyoxylic acid 578023-39-9P,
[[2-Bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl][(3-phenoxybenzyl)amino](oxo)acetic acid 578023-40-2P,
[[4-[[[2-(1,1'-Biphenyl-4-yl)ethyl]amino]carbonyl]-2-bromobenzyl][(3-phenoxybenzyl)amino]glyoxylic acid 578023-41-3P,
[[2-Bromo-4-[[[4-(pentybenzyl)amino]carbonyl]benzyl][(3-phenoxybenzyl)amino](oxo)acetic acid 578023-42-4P,
[[2,6-Dibromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl][(3-phenoxybenzyl)amino](oxo)acetic acid 578023-43-5P,
[[4-[[[2-(1,1'-Biphenyl-4-yl)ethyl]amino]carbonyl]-2,6-dibromobenzyl][(3-phenoxybenzyl)amino]glyoxylic acid 578023-44-6P,
[[2,6-Dibromo-4-[[[4-(pentybenzyl)amino]carbonyl]benzyl][(3-phenoxybenzyl)amino](oxo)acetic acid 578023-45-7P,
[[2,6-Dibromo-4-[(dodecylamino)carbonyl]benzyl][(3-phenoxybenzyl)amino](oxo)acetic acid 578023-46-8P,
Oxo[[3-phenoxybenzyl][(4'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]-1,1'-biphenyl-4-yl)methyl]amino]acetic acid 578023-47-9P,
Oxo[[[4'-[[[4-(pentybenzyl)amino]carbonyl]-1,1'-biphenyl-4-yl)methyl][(3-phenoxybenzyl)amino]acetic acid 578023-48-0P,
[[[4'-[(Dodecylamino)carbonyl]-1,1'-biphenyl-4-yl)methyl][(3-phenoxybenzyl)amino]glyoxylic acid 578023-49-1P,
[[2-Bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl][(2-iodobenzyl)amino](oxo)acetic acid 578023-50-4P,
[[4-[[[2-(1,1'-Biphenyl-4-yl)ethyl]amino]carbonyl]-2-bromobenzyl][(2-iodobenzyl)amino]glyoxylic acid 578023-51-5P,
[[2-Bromo-4-[[[4-(pentybenzyl)amino]carbonyl]benzyl][(2-iodobenzyl)amino](oxo)acetic acid 578023-52-6P,
[[2-Bromo-4-[(dodecylamino)carbonyl]benzyl][(2-iodobenzyl)amino](oxo)acetic acid 578023-53-7P,
[[2-Bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl][(2'-(trifluoromethyl)-1,1'-biphenyl-4-yl)methyl]amino]glyoxylic acid 578023-54-8P,
[[4-[[[2-(1,1'-Biphenyl-4-yl)ethyl]amino]carbonyl]-2-bromobenzyl][(2'-(trifluoromethyl)-1,1'-biphenyl-4-yl)methyl]amino]glyoxylic acid 578023-55-9P,
[[2-Bromo-4-[[[4-(pentybenzyl)amino]carbonyl]benzyl][(2'-(trifluoromethyl)-1,1'-biphenyl-4-yl)methyl]amino]glyoxylic acid

578023-56-0P, [[2-Bromo-4-[(dodecylamino)carbonyl]benzyl][[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl]amino]glyoxylic acid
578023-57-1P, [[4-[[[2-(1,1'-Biphenyl-4-yl)ethyl]amino]carbonyl]-2,6-dibromobenzyl][[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl]amino]glyoxylic acid 578023-58-2P,
[[2,6-Dibromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl][[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl]amino]glyoxylic acid
578023-59-3P, [[2,6-Dibromo-4-[(dodecylamino)carbonyl]benzyl][[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl]amino]glyoxylic acid
578023-60-6P, [[4'-[(Dodecylamino)carbonyl]-1,1'-biphenyl-4-yl]methyl][[2'-(trifluoromethyl)-1,1'-biphenyl-4-yl]methyl]amino]glyoxylic acid 578023-61-7P, [[4-[[[2-(1,1'-Biphenyl-4-yl)ethyl]amino]carbonyl]-2-bromobenzyl](1,1'-biphenyl-2-ylmethyl)amino]glyoxylic acid 578023-62-8P, [[(1,1'-Biphenyl-2-ylmethyl)[2-bromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl]amino]glyoxylic acid 578023-63-9P, [(1,1'-Biphenyl-2-ylmethyl)[2-bromo-4-[(dodecylamino)carbonyl]benzyl]amino]glyoxylic acid 578023-64-0P,
[(1,1'-Biphenyl-2-ylmethyl)[2,6-dibromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl]amino]glyoxylic acid
578023-65-1P, [[4-[[[2-(1,1'-Biphenyl-4-yl)ethyl]amino]carbonyl]-2,6-dibromobenzyl](1,1'-biphenyl-2-ylmethyl)amino]glyoxylic acid
578023-66-2P, [(1,1'-Biphenyl-2-ylmethyl)[2,6-dibromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl]amino]glyoxylic acid
578023-67-3P, [(1,1'-Biphenyl-2-ylmethyl)[2,6-dibromo-4-[(dodecylamino)carbonyl]benzyl]amino]glyoxylic acid 578023-68-4P,
[[2-Bromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl][4-(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-69-5P,
[[2-Bromo-4-[(dodecylamino)carbonyl]benzyl][4-(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-70-8P,
[[2,6-Dibromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl][4-(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-71-9P,
[[2-Bromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl][3-(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-72-0P,
[[2-Bromo-4-[(dodecylamino)carbonyl]benzyl][3-(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-73-1P,
[[2,6-Dibromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl][3-(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-74-2P,
[[2,6-Dibromo-4-[(dodecylamino)carbonyl]benzyl][3-(trifluoromethoxy)benzyl]amino] (oxo)acetic acid 578023-75-3P,
[[[4'-[(Dodecylamino)carbonyl]-1,1'-biphenyl-4-yl]methyl][3-(trifluoromethoxy)benzyl]amino]glyoxylic acid 578023-76-4P,
[[2-Bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]benzyl](4-phenoxybenzyl)amino] (oxo)acetic acid 578023-77-5P,
[[4-[[[2-(1,1'-Biphenyl-4-yl)ethyl]amino]carbonyl]-2-bromobenzyl](4-phenoxybenzyl)amino]glyoxylic acid 578023-78-6P,
[[2-Bromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl](4-phenoxybenzyl)amino] (oxo)acetic acid 578023-79-7P,
[[2-Bromo-4-[(dodecylamino)carbonyl]benzyl](4-phenoxybenzyl)amino] (oxo)acetic acid 578023-80-0P,
[[4-[[[2-(1,1'-Biphenyl-4-yl)ethyl]amino]carbonyl]-2,6-dibromobenzyl](4-phenoxybenzyl)amino]glyoxylic acid 578023-81-1P,
[[2,6-Dibromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl](4-phenoxybenzyl)amino] (oxo)acetic acid 578023-82-2P,
[[4-[[[2-(1,1'-Biphenyl-4-yl)ethyl]amino]carbonyl]-2-bromobenzyl][4-(trifluoromethyl)benzyl]amino]glyoxylic acid 578023-83-3P,
[[2-Bromo-4-[[[4-pentylbenzyl]amino]carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578023-84-4P,
[[2-Bromo-4-[(dodecylamino)carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578023-85-5P,

[[2,6-Dibromo-4-[[[(4-pentylbenzyl)amino]carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578023-86-6P,
[[2,6-Dibromo-4-[(dodecylamino)carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578023-87-7P,
Oxo[[[4'-[[[(4-pentylbenzyl)amino]carbonyl]-1,1'-biphenyl-4-yl]methyl][4-(trifluoromethyl)benzyl]amino]acetic acid 578023-88-8P,
[[2-Bromo-4-[(dodecylamino)carbonyl]benzyl][3-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578023-89-9P,
[[2,6-Dibromo-4-[(dodecylamino)carbonyl]benzyl][3-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578023-90-2P,
Oxo[[[4'-[[[(4-pentylbenzyl)amino]carbonyl]-1,1'-biphenyl-4-yl]methyl][3-(trifluoromethyl)benzyl]amino]acetic acid 578023-91-3P,
[[4-(Dibenzo[b,d]furan-4-yl)benzyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578023-92-4P, [[4-(Dibenzo[b,d]furan-4-yl)benzyl][4-(trifluoromethyl)benzyl]amino](oxo)acetic acid N-methyl-D-glucamine salt 578023-93-5P, [[4-[(Dodecylamino)carbonyl]benzyl][1-[4-(trifluoromethyl)phenyl]ethyl]amino](oxo)acetic acid 578023-94-6P,
, [[4-[(Dodecylamino)carbonyl]benzyl][1-[4-(trifluoromethyl)phenyl]ethyl]amino](oxo)acetic acid N-methyl-D-glucamine salt 578023-95-7P,
[[[4'-[(Octylamino)carbonyl]-1,1'-biphenyl-4-yl]methyl][4-(trifluoromethyl)benzyl]amino]glyoxylic acid 578023-96-8P,
Oxo[(4-tetradec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino]acetic acid 578023-97-9P, [(4-Dodec-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578023-98-0P,
[[4-[(Dodecylamino)carbonyl]benzyl][4-(trifluoromethyl)phenyl]amino](oxo)acetic acid 578023-99-1P, [[4-[(Dodecylamino)carbonyl]benzyl][2-methoxyphenyl]amino](oxo)acetic acid 578024-00-7P
, [(1,2-Diphenylethyl)[4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578024-01-8P, N-(Carboxycarbonyl)-N-[4-[(dodecylamino)carbonyl]benzyl]-L-phenylalanine 578024-02-9P,
[[4-[(Dodecylamino)carbonyl]benzyl][3-phenoxyphenyl]amino](oxo)acetic acid 578024-03-0P, [[4-[(Dodecylamino)carbonyl]benzyl][2-isopropoxyphenyl]amino](oxo)acetic acid 578024-04-1P,
[[4-[(Dodecylamino)carbonyl]benzyl][4-iodophenyl]amino](oxo)acetic acid 578024-05-2P, [[4-[(Dodecylamino)carbonyl]benzyl][3-fluoro-4-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578024-06-3P,
[(3-Chloro-2-methylphenyl)[4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578024-07-4P, 4'-[(Carboxycarbonyl)[4-[(dodecylamino)carbonyl]benzyl]amino]-1,1'-biphenyl-2-carboxylic acid 578024-08-5P, [(2,4-Dichlorobenzyl)[4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578024-09-6P,
, [[4-[(Dodecylamino)carbonyl]benzyl][1-phenylpropyl]amino](oxo)acetic acid 578024-10-9P, [[2-(4-Chlorophenyl)propyl][4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578024-11-0P,
, [[4-[(Dodecylamino)carbonyl]benzyl][4-isopropoxyphenyl]amino](oxo)acetic acid 578024-12-1P, [[4-(Benzyloxy)phenyl][4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578024-13-2P,
, [[4-[(Dodecylamino)carbonyl]benzyl][2-(trifluoromethyl)benzyl]amino](oxo)acetic acid 578024-14-3P, [[4-[(Dodecylamino)carbonyl]benzyl][2-methoxybenzyl]amino](oxo)acetic acid 578024-15-4P,
[[[(1R)-1-(4-Chlorophenyl)ethyl][4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578024-16-5P, [(3,4-Dichlorobenzyl)[4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578024-18-7P,
, [[2-(2,6-Dichlorophenyl)ethyl][4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578024-19-8P, [[4-[(Dodecylamino)carbonyl]benzyl][2-[3-(trifluoromethyl)phenyl]ethyl]amino](oxo)acetic acid 578024-20-1P, [[4-[(Dodecylamino)carbonyl]benzyl][2-(3-fluorophenyl)ethyl]amino](oxo)acetic acid 578024-21-2P,
[[[(1S)-1-(4-Chlorophenyl)ethyl][4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid 578024-22-3P,

o)acetic acid 578024-22-3P, [[4-[(Dodecylamino)carbonyl]benzyl] (1S)-1-phenylethyl]amino] (oxo)acetic acid 578024-23-4P, [[4-[(Dodecylamino)carbonyl]benzyl] (1R)-1-phenylethyl]amino] (oxo)acetic acid 578024-24-5P, N-(Carboxycarbonyl)-N-[4-[(dodecylamino)carbonyl]benzyl]-D-phenylalanine 578024-25-6P, [[4-[(Dodecylamino)carbonyl]phenyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-26-7P, [[4-[(Dodecylamino)carbonyl]phenyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-27-8P, Oxo[[1-[4-(trifluoromethyl)phenyl]ethyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578024-28-9P, Oxo[[1-[4-(trifluoromethyl)phenyl]ethyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid N-methyl-D-glucamine salt 578024-30-3P, [[1-[4-[(Dodecylamino)carbonyl]phenyl]ethyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-31-4P, [[1-[4-[(Dodecylamino)carbonyl]phenyl]ethyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-32-5P, [[4-[[4-(Octylphenyl)amino]carbonyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-33-6P, [(3-Chlorobenzyl) [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578024-34-7P, [(3-Chlorobenzyl) [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-35-8P, [[Cyclopentyl [4-(trifluoromethyl)phenyl]methyl] [4-(tridecanoylamino)benzyl]amino] (oxo)acetic acid 578024-36-9P, Oxo[[4-(trifluoromethyl)benzyl] [[4-(3-undecyl-1,2,4-oxadiazol-5-yl)-1-naphthyl]methyl]amino]acetic acid 578024-37-0P, Oxo[[4-(trifluoromethyl)benzyl] [[4-(3-undecyl-1,2,4-oxadiazol-5-yl)-1-naphthyl]methyl]amino]acetic acid N-methyl-D-glucamine salt 578024-38-1P, [[Cyclopentyl [4-(trifluoromethyl)phenyl]methyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]glyoxylic acid 578024-39-2P, [[Cyclopentyl [4-(trifluoromethyl)phenyl]methyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-40-5P, [[4-(Dibenzo[b,d]furan-4-yl)phenyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-41-6P, [[4-(Dibenzo[b,d]furan-4-yl)phenyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-42-7P, [[4-(Octyloxy)benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-43-8P, [[4-(Octyloxy)benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-44-9P, [[2-(3-Chlorophenyl)ethyl] [4-dec-1-ynylbenzyl]amino] (oxo)acetic acid 578024-45-0P, [[2-(3-Chlorophenyl)ethyl] [4-((1Z)-dec-1-enyl)benzyl]amino] (oxo)acetic acid 578024-46-1P, [[2-(3-Chlorophenyl)ethyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578024-47-2P, [[2-(3-Chlorophenyl)ethyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-48-3P, Oxo[[1-(1R)-1-[4-(trifluoromethyl)phenyl]ethyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578024-49-4P, Oxo[[1-(1R)-1-[4-(trifluoromethyl)phenyl]ethyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid N-methyl-D-glucamine salt 578024-50-7P, Oxo[[4-(trifluoromethyl)phenyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578024-51-8P, Oxo[[4-(trifluoromethyl)phenyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid N-methyl-D-glucamine salt 578024-52-9P, Oxo[[1-(1S)-1-[4-(trifluoromethyl)phenyl]ethyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578024-53-0P, Oxo[[1-(1S)-1-[4-(trifluoromethyl)phenyl]ethyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid N-methyl-D-glucamine salt


578024-54-1P, [(3-Chlorobenzyl)(4-dec-1-ynylbenzyl)amino](oxo)acetic acid 578024-55-2P, [(3-Chlorobenzyl)(4-dec-1-ynylbenzyl)amino](oxo)acetic acid N-methyl-D-glucamine salt 578024-56-3P, [[2-(3-Chlorophenyl)ethyl](4-oct-1-ynylbenzyl)amino](oxo)acetic acid 578024-57-4P, [[2-(3-Chlorophenyl)ethyl](4-oct-1-ynylbenzyl)amino](oxo)acetic acid N-methyl-D-glucamine salt 578024-58-5P, [(4-Dec-1-ynylbenzyl)[4-(trifluoromethyl)phenyl]amino](oxo)acetic acid 578024-59-6P, [(4-Dec-1-ynylbenzyl)[1-[4-(trifluoromethyl)phenyl]ethyl]amino](oxo)acetic acid 578024-60-9P, [(4-Dec-1-ynylbenzyl)[1-[4-(trifluoromethyl)phenyl]ethyl]amino](oxo)acetic acid N-methyl-D-glucamine salt

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of [(arylmethyl)amino](oxo)acetic acids as PTP inhibitors for antidiabetics)


RN 578021-80-4 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578021-81-5 CAPLUS

CN Acetic acid, oxo[[[4-[(pentadecylamino)carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578021-82-6 CAPLUS

CN Acetic acid, 2-oxo-2-[[[4-[(pentadecylamino)carbonyl]phenyl]methyl](phenylmethyl)amino]- (CA INDEX NAME)




RN 578021-83-7 CAPLUS

CN Acetic acid, oxo[(phenylmethyl)[[4-[(tridecylamino)carbonyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578021-84-8 CAPLUS

CN Acetic acid, [[[4-[(dodecylmethylamino)carbonyl]phenyl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578021-85-9 CAPLUS

CN Acetic acid, [[[4-[(dodecylmethylamino)carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578021-87-1 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578021-88-2 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][[3-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578021-90-6 CAPLUS

CN Acetic acid, oxo[[[4-[(1-oxotridecyl)amino]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 578021-91-7 CAPLUS


CN Acetic acid, [[[4-[[4-(hexyloxy)benzoyl]amino]phenyl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 578021-92-8 CAPLUS

Print selected from 10-501,344.trn


CN Acetic acid, oxo[[[4-[(1-oxo-10-undecenyl)amino]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 578021-93-9 CAPLUS


CN Acetic acid, 2-oxo-2-[[[4-[(9E)-1-oxo-9-tetradecen-1-yl]amino]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)

Double bond geometry as shown.




RN 578021-94-0 CAPLUS

CN Acetic acid, oxo[[[4-[(1-oxotridecyl)amino]phenyl]methyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)




RN 578021-95-1 CAPLUS

CN Acetic acid, [[4-[(2-hydroxydodecyl)amino]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578021-96-2 CAPLUS

CN Acetic acid, 2-oxo-2-[[[4-(trifluoromethyl)phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino] - (CA INDEX NAME)




RN 578021-99-5 CAPLUS

CN Benzenepropanoic acid, β-[(carboxycarbonyl)[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino] - (CA INDEX NAME)




RN 578022-01-2 CAPLUS

CN Acetic acid, [(4-bromophenyl)[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-02-3 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl]phenylamino]oxo- (9CI) (CA INDEX NAME)




RN 578022-03-4 CAPLUS

CN Acetic acid, [[2-(3-chlorophenyl)ethyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-04-5 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][2-(3-methoxyphenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-07-8 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][4-phenoxyphenyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-10-3 CAPLUS


CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][2-(4-phenoxyphenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-11-4 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][2-(2-phenoxyphenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-12-5 CAPLUS
 CN Acetic acid, [(2-[1,1'-biphenyl]-4-ylethyl)[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-13-6 CAPLUS
 CN Acetic acid, [[(1,1'-biphenyl)-3-ylmethyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-14-7 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][3-

(phenylmethoxy)phenyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-15-8 CAPLUS

CN Acetic acid, [[4-(benzoylamino)phenyl]methyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-16-9 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-17-0 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(1,2,3-thiadiazol-4-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-18-1 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl] (1-phenylethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-19-2 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl] [1-(1-naphthalenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-20-5 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-21-6 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl] [[4-(methylsulfonyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-22-7 CAPLUS

CN Acetic acid, [[(3-(4-(methylsulfonyl)phenyl)methyl)amino]oxy]phenylmethylmethylamino- (9CI) (CA INDEX NAME)




RN 578022-23-8 CAPLUS

CN Acetic acid, [[(3-[(4-(trifluoromethyl)phenyl)methyl]amino]oxy]phenyl)methyl]methylamino- (9CI) (CA INDEX NAME)




RN 578022-24-9 CAPLUS

CN Acetic acid, [[(4-(4-(4-(4-(methylundecylamino)carbonyl)phenyl)methyl)amino]oxy]phenyl)methyl]methylamino- (9CI) (CA INDEX NAME)




RN 578022-25-0 CAPLUS

CN Acetic acid, oxo[[[4-[[[2-(2-thienyl)ethyl]amino]carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578022-26-1 CAPLUS

CN Acetic acid, [[[3'-[[[2,2-diphenylethyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-27-2 CAPLUS

CN Acetic acid, [[[3-cyanophenyl]methyl][[3'-[[[2,2-diphenylethyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-28-3 CAPLUS

CN Acetic acid, [[[4-chlorophenyl]methyl][[3'-[[[2,2-diphenylethyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-29-4 CAPLUS
CN Acetic acid, [[3'-[[[(2,2-diphenylethyl)amino]carbonyl][1,1'-biphenyl]-4-yl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-30-7 CAPLUS
CN Acetic acid, [[(3-cyanophenyl)methyl][3'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— CN

RN 578022-31-8 CAPLUS
CN Acetic acid, oxo[[[3'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl][1,1'-

biphenyl]-4-yl)methyl] [[4-(trifluoromethyl)phenyl)methyl]amino]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CF₃


RN 578022-32-9 CAPLUS

CN Acetic acid, [[[3-(3-cyanophenyl)methyl] [[3'-[(octylamino)carbonyl] [1,1'-biphenyl]-4-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-33-0 CAPLUS

CN Acetic acid, [[[4-(4-chlorophenyl)methyl] [[3'-[(octylamino)carbonyl] [1,1'-biphenyl]-4-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-34-1 CAPLUS

CN Acetic acid, [[[3'-[(octylamino)carbonyl] [1,1'-biphenyl]-4-yl)methyl] [[4-(trifluoromethyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-35-2 CAPLUS

Acetic acid, [[(3-cyanophenyl)methyl] [(3'-[[[(3-phenylpropyl)amino]carbonyl] [1,1'-biphenyl]-4-yl]methyl)amino] oxo- (9CI)
(CA INDEX NAME)




RN 578022-36-3 CAPLUS

CN Acetic acid, [[(3-cyanophenyl)methyl] [3'-[(dodecylamino)carbonyl] [1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-37-4 CAPLUS

CN Acetic acid, [[(4-chlorophenyl)methyl] [3'-[(dodecylamino)carbonyl] [1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-38-5 CAPLUS

CN Acetic acid, [[3'-[(dodecylamino)carbonyl][1,1'-biphenyl]-4-yl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-39-6 CAPLUS


CN Acetic acid, oxo[[[3'-[[[(4-pentylphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl](phenylmethyl)amino]- (9CI) (CA INDEX NAME)



RN 578022-40-9 CAPLUS

CN Acetic acid, [[(3-cyanophenyl)methyl][[3'-[[[(4-pentylphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— CN

RN 578022-41-0 CAPLUS
CN Acetic acid, [[(4-chlorophenyl)methyl] [3'-[[[(4-pentylphenyl)methyl]amino]carbonyl] [1,1'-biphenyl]-4-yl]methyl]amino]oxo-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— Cl

RN 578022-42-1 CAPLUS
CN Acetic acid, oxo[[[3'-[[[(4-pentylphenyl)methyl]amino]carbonyl] [1,1'-biphenyl]-4-yl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— CF₃


RN 578022-43-2 CAPLUS

CN Acetic acid, oxo[[[3'-[[[4-phenylbutyl)amino]carbonyl][1,1'-biphenyl]-4-yl)methyl][[4-(trifluoromethyl)phenyl)methyl]amino]-(9CI) (CA INDEX NAME)




RN 578022-44-3 CAPLUS

CN Acetic acid, [[(3-cyanophenyl)methyl][[3'-[[[2-(2,4,6-trimethylphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-4-yl)methyl]amino]oxo-(9CI) (CA INDEX NAME)



RN 578022-45-4 CAPLUS


CN Acetic acid, [[(4-chlorophenyl)methyl][[3'-[[[2-(2,4,6-trimethylphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-4-yl)methyl]amino]oxo-(9CI) (CA INDEX NAME)



RN 578022-46-5 CAPLUS

CN Acetic acid, oxo[[[4-(trifluoromethyl)phenyl)methyl][[3'-[[[2-(2,4,6-trimethylphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-4-yl)methyl]amino]-(9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CF₃

RN 578022-47-6 CAPLUS
 CN Acetic acid, [[[4-(chlorophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 1-B


—Cl

RN 578022-48-7 CAPLUS
 CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-49-8 CAPLUS
 CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

(methylsulfonyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-50-1 CAPLUS

CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl)methyl][(4-methoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-51-2 CAPLUS

CN Acetic acid, [[3-[(dodecylamino)carbonyl]phenyl)methyl][(3-(trifluoromethyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-53-4 CAPLUS

CN Benzoic acid, 4-[[[(carboxycarbonyl)[3-[(dodecylamino)carbonyl]phenyl)methyl]amino]methyl]- (CA INDEX NAME)




RN 578022-54-5 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl][(4-nitrophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-55-6 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl][(2-fluorophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-58-9 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl][(4-hydroxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-59-0 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl][(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-61-4 CAPLUS

CN Benzoic acid, 3-[[[(carboxycarbonyl)[[3-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (CA INDEX NAME)




RN 578022-63-6 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][[4-nitrophenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-64-7 CAPLUS

CN Acetic acid, [(1,3-benzodioxol-5-ylmethyl)[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-65-8 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][[2-fluorophenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-66-9 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-67-0 CAPLUS

CN Benzoic acid, 4-[[[(carboxycarbonyl)[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (CA INDEX NAME)




RN 578022-71-6 CAPLUS

CN Acetic acid, [[(3,5-dichlorophenyl)methyl][4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-72-7 CAPLUS


CN Acetic acid, [[(3,5-dichlorophenyl)methyl][4-[[[(3,3-diphenylpropyl)amino]carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-73-8 CAPLUS
 CN Acetic acid, [[4-[[2-[[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-74-9 CAPLUS
 CN Acetic acid, [(1,3-benzodioxol-5-ylmethyl)[[4-[[2-[[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578022-78-3 CAPLUS
 CN Acetic acid, [[4-(dimethylamino)phenyl]methyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-80-7 CAPLUS
 CN Acetic acid, [[4-cyanophenyl]methyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-85-2 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl][(3-hydroxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-86-3 CAPLUS

CN Acetic acid, [[[4-cyanophenyl]methyl][(3-[(dodecylamino)carbonyl]phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-89-6 CAPLUS

CN Acetic acid, [(1,3-benzodioxol-5-ylmethyl)[(3-[(dodecylamino)carbonyl]phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-93-2 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][(4-hydroxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-94-3 CAPLUS

CN Benzoic acid, 3-[[[(carboxycarbonyl)[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]methyl]- (CA INDEX NAME)




RN 578023-20-8 CAPLUS

CN Benzoic acid, 2-[[[(carboxycarbonyl)[4-[(dodecylamino)carbonyl]phenyl]amino]methyl]-, 1-methyl ester (CA INDEX NAME)




RN 578023-21-9 CAPLUS

CN Acetic acid, [[4-[[[(2-[1,1'-biphenyl]-4-ylethyl)amino]carbonyl]-2-bromophenyl]methyl][(4-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-22-0 CAPLUS

CN Acetic acid, [[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][(4-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-23-1 CAPLUS

CN Acetic acid, [[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][(4-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-24-2 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][(4-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-25-3 CAPLUS

CN Acetic acid, [[[(4-iodophenyl)methyl][(4'-[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-26-4 CAPLUS

CN Acetic acid, [[[2-bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl][(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-27-5 CAPLUS

CN Acetic acid, [[[4-[[[2-(1,1'-biphenyl)-4-ylethyl]amino]carbonyl]-2-bromophenyl]methyl][(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-28-6 CAPLUS

CN Acetic acid, [[[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B


— Me

RN 578023-29-7 CAPLUS


CN Acetic acid, [[[2,6-dibromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl][(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-30-0 CAPLUS
 CN Acetic acid, [[4-[[2-[[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-2,6-dibromophenyl]methyl][(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-31-1 CAPLUS
 CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




PAGE 1-A

(CH₂)₄

PAGE 1-B


— Me

RN 578023-32-2 CAPLUS
 CN Acetic acid, [[2,6-dibromo-4-[[[(dodecylamino)carbonyl]phenyl]methyl][(4'-fluoro[1,1'-biphenyl]-3-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-33-3 CAPLUS
 CN Acetic acid, [[(4'-fluoro[1,1'-biphenyl]-3-yl)methyl] [[4'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl] [1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 1-B



RN 578023-34-4 CAPLUS
 CN Acetic acid, [[(4'-fluoro[1,1'-biphenyl]-3-yl)methyl] [[4'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl] [1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-35-5 CAPLUS
 CN Acetic acid, [[(2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl)methyl] [[2-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-36-6 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[4-pentylphenyl)methyl]amino]carbonyl]phenyl)methyl][2-(trifluoromethoxy)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-37-7 CAPLUS

CN Acetic acid, oxo[[[4'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-4-yl)methyl][2-(trifluoromethoxy)phenyl)methyl]amino] - (9CI) (CA INDEX NAME)




RN 578023-38-8 CAPLUS

CN Acetic acid, [[4'-[(dodecylamino)carbonyl][1,1'-biphenyl]-4-yl)methyl][2-(trifluoromethoxy)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-39-9 CAPLUS

CN Acetic acid, [[2-bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl][[3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-40-2 CAPLUS

CN Acetic acid, [[4-[[[2-[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-2-bromophenyl]methyl][[3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-41-3 CAPLUS

CN Acetic acid, [[2-bromo-4-[[[4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][[3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-42-4 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl][[3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-43-5 CAPLUS

CN Acetic acid, [[4-[[2-[[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-2,6-dibromophenyl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-44-6 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-45-7 CAPLUS


CN Acetic acid, [[2,6-dibromo-4-[[[(dodecylamino)carbonyl]phenyl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-46-8 CAPLUS

CN Acetic acid, oxo[[[4'-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl][(3-phenoxyphenyl)methyl]amino] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OPh

RN 578023-47-9 CAPLUS

CN Acetic acid, oxo[[[4'-[[[(4-pentylphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl][(3-phenoxyphenyl)methyl]amino] - (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— OPh


RN 578023-48-0 CAPLUS

CN Acetic acid, [[[4'-[(dodecylamino)carbonyl][1,1'-biphenyl]-4-yl]methyl][(3-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-49-1 CAPLUS

CN Acetic acid, [[[2-bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl][(2-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-50-4 CAPLUS

CN Acetic acid, [[[4-[[[2-(1,1'-biphenyl)-4-ylethyl]amino]carbonyl]-2-bromophenyl]methyl][(2-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-51-5 CAPLUS

CN Acetic acid, [[[2-bromo-4-[[[4-(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][(2-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-52-6 CAPLUS

CN Acetic acid, [[[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][(2-iodophenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-53-7 CAPLUS

CN Acetic acid, [[2-bromo-4-[[[2-(4-iodophenyl)ethyl]amino]carbonyl]phenyl]methyl][[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-54-8 CAPLUS

CN Acetic acid, [[4-[[[2-(1,1'-biphenyl)-4-ylethyl]amino]carbonyl]-2-bromophenyl]methyl][[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-55-9 CAPLUS


CN Acetic acid, [[2-bromo-4-[[[4-pentylphenyl]methyl]amino]carbonyl]phenyl]methyl][[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-56-0 CAPLUS


CN Acetic acid, [[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

(trifluoromethyl) [1,1'-biphenyl] -4-yl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-57-1 CAPLUS

CN Acetic acid, [[[4-[[2-(2,6-dibromophenyl)methyl]amino]carbonyl]-2,6-dibromophenyl]methyl] [[2'-(trifluoromethyl) [1,1'-biphenyl] -4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-58-2 CAPLUS

CN Acetic acid, [[[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl] [[2'-(trifluoromethyl) [1,1'-biphenyl] -4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-59-3 CAPLUS

CN Acetic acid, [[[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl] [[2'-(trifluoromethyl) [1,1'-biphenyl] -4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-60-6 CAPLUS

CN Acetic acid, [[[4'-[(dodecylamino)carbonyl][1,1'-biphenyl]-4-yl]methyl][[2'-(trifluoromethyl)[1,1'-biphenyl]-4-yl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-61-7 CAPLUS

CN Acetic acid, [[[4'-[(2-[1,1'-biphenyl]-4-ylethyl)amino]carbonyl]-2-bromophenyl]methyl]([1,1'-biphenyl]-2-ylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-62-8 CAPLUS

CN Acetic acid, [[[4'-[(2-[1,1'-biphenyl]-4-ylethyl)amino]carbonyl]-2-bromophenyl]methyl]([1,1'-biphenyl]-2-ylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-63-9 CAPLUS

CN Acetic acid, [(1,1'-biphenyl)-2-ylmethyl] [[2-bromo-4-
[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-64-0 CAPLUS

CN	Acetic acid, [[([1,1'-biphenyl]-2-ylmethyl) [[2,6-dibromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl]amino]oxo-	(9CI)	(CA)
	INDEX NAME)		




RN 578023-65-1 CAPLUS

CN Acetic acid, [[[4-[[[2-[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-2,6-dibromophenyl]methyl]([1,1'-biphenyl]-2-ylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-66-2 CAPLUS

CN Acetic acid, [[([1,1'-biphenyl]-2-ylmethyl) [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-67-3 CAPLUS

CN Acetic acid, [[([1,1'-biphenyl]-2-ylmethyl) [[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-68-4 CAPLUS

CN Acetic acid, [[([2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl) [[4-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-69-5 CAPLUS

CN Acetic acid, [[([2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl) [[4-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-70-8 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][[4-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-71-9 CAPLUS

CN Acetic acid, [[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][[3-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-72-0 CAPLUS

CN Acetic acid, [[2-bromo-4-[[[(dodecylamino)carbonyl]phenyl]methyl][[3-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-73-1 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][[3-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-74-2 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl][[3-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-75-3 CAPLUS

CN Acetic acid, [[4'-[(dodecylamino)carbonyl][1,1'-biphenyl]-4-yl]methyl][[3-(trifluoromethoxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-76-4 CAPLUS


CN Acetic acid, [[2-bromo-4-[[[2-(4-phenoxyphenyl)ethyl]amino]carbonyl]phenyl]methyl][[4-phenoxyphenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-77-5 CAPLUS
 CN Acetic acid, [[4-[[[(2-[1,1'-biphenyl]-4-ylethyl)amino]carbonyl]-2-bromophenyl]methyl][(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-78-6 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-79-7 CAPLUS
 CN Acetic acid, [[2-bromo-4-[[[(dodecylamino)carbonyl]phenyl]methyl]methyl][(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-80-0 CAPLUS
 CN Acetic acid, [[4-[[[(2-[1,1'-biphenyl]-4-ylethyl)amino]carbonyl]-2,6-dibromophenyl]methyl][(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)

dibromophenyl]methyl] [(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-81-1 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl] [(4-phenoxyphenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-82-2 CAPLUS

CN Acetic acid, [[4-[[2-[[1,1'-biphenyl]-4-ylethyl]amino]carbonyl]-2-bromophenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-83-3 CAPLUS

CN Acetic acid, [[2-bromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-84-4 CAPLUS

CN Acetic acid, [[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-85-5 CAPLUS

CN Acetic acid, [[2,6-dibromo-4-[[[(4-pentylphenyl)methyl]amino]carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-86-6 CAPLUS


CN Acetic acid, [[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-87-7 CAPLUS

CN Acetic acid, oxo[[[4'-[[[(4-pentylphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino] - (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—CF₃


RN 578023-88-8 CAPLUS

CN Acetic acid, [[[2-bromo-4-[(dodecylamino)carbonyl]phenyl]methyl][[3-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-89-9 CAPLUS


CN Acetic acid, [[[2,6-dibromo-4-[(dodecylamino)carbonyl]phenyl]methyl][[3-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578023-90-2 CAPLUS

CN Acetic acid, oxo[[[4'-[[[(4-pentylphenyl)methyl]amino]carbonyl][1,1'-biphenyl]-4-yl]methyl][[3-(trifluoromethyl)phenyl]methyl]amino]- (9CI)
(CA INDEX NAME)

PAGE 1-A




PAGE 1-B

— (CH₂)₄—Me

RN 578023-91-3 CAPLUS

CN Acetic acid, [[[4-(4-dibenzofuranyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-92-4 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-(1-dibenzofuranyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxoa
cetate (salt) (9CI) (CA INDEX NAME)

CM 1

Print selected from 10-501,344.trn


CRN 578023-91-3
CMF C29 H20 F3 N O4




CM 2

CRN 6284-40-8
CMF C7 H17 N O5

Absolute stereochemistry.



RN 578023-93-5 CAPLUS
CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] [1-[4-(trifluoromethyl)phenyl]ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-94-6 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][1-[4-(trifluoromethyl)phenyl]ethyl]amino]oxoacetate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 578023-93-5

CMF C31 H41 F3 N2 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578023-95-7 CAPLUS

CN Acetic acid, [[[4'-[(octylamino)carbonyl][1,1'-biphenyl]-4-yl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-96-8 CAPLUS

CN Acetic acid, 2-oxo-2-[[[4-(1-tetradecyn-1-yl)phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 578023-97-9 CAPLUS

CN Acetic acid, 2-[[[4-(1-dodecyn-1-yl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578023-98-0 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][4-(trifluoromethyl)phenyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578023-99-1 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][2-methoxyphenyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-00-7 CAPLUS


CN Acetic acid, [(1,2-diphenylethyl)[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-01-8 CAPLUS


CN L-Phenylalanine, N-(carboxycarbonyl)-N-[[4-[(dodecylamino)carbonyl]phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 578024-02-9 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl](3-phenoxyphenyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-03-0 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][2-(1-methylethoxy)phenyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-04-1 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl] (4-iodophenyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-05-2 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl] [[3-fluoro-4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-06-3 CAPLUS


CN Acetic acid, [(3-chloro-2-methylphenyl) [[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-07-4 CAPLUS


CN [1,1'-Biphenyl]-2-carboxylic acid, 4'-[(carboxycarbonyl) [[4-[(dodecylamino)carbonyl]phenyl]methyl]amino] - (CA INDEX NAME)






RN 578024-08-5 CAPLUS

CN Acetic acid, [[(2,4-dichlorophenyl)methyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-09-6 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl](1-phenylpropyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-10-9 CAPLUS

CN Acetic acid, [[2-(4-chlorophenyl)propyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-11-0 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][4-(1-methylethoxy)phenyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-12-1 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][4-(phenylmethoxy)phenyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-13-2 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][[2-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-14-3 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][[2-methoxyphenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-15-4 CAPLUS

CN Acetic acid, [[[1-(4-chlorophenyl)ethyl][4-

Print selected from 10-501,344.trn


[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 578024-16-5 CAPLUS

CN Acetic acid, [[(3,4-dichlorophenyl)methyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-18-7 CAPLUS

CN Acetic acid, [[2-(2,6-dichlorophenyl)ethyl][[4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-19-8 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][2-[3-(trifluoromethyl)phenyl]ethyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-20-1 CAPLUS


CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][2-(3-fluorophenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-21-2 CAPLUS

CN Acetic acid, [[(1S)-1-(4-chlorophenyl)ethyl][4-[(dodecylamino)carbonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 578024-22-3 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][(1S)-1-phenylethyl]amino]oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Print selected from 10-501,344.trn



RN 578024-23-4 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][(1R)-1-phenylethyl]amino]oxo- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 578024-24-5 CAPLUS


CN D-Phenylalanine, N-(carboxycarbonyl)-N-[[4-[(dodecylamino)carbonyl]phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 578024-25-6 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][(4-(trifluoromethyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-26-7 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[4-[(dodecylamino)carbonyl]phenyl][4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-25-6

CMF C29 H37 F3 N2 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-27-8 CAPLUS

CN Acetic acid, 2-oxo-2-[[1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 578024-28-9 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-27-8

CMF C31 H38 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-30-3 CAPLUS

CN Acetic acid, [[1-[4-[(dodecylamino)carbonyl]phenyl]ethyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-31-4 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[1-[4-[(dodecylamino)carbonyl]phenyl]ethyl][4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-30-3

CMF C31 H41 F3 N2 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-32-5 CAPLUS

CN Acetic acid, 2-[[[4-[[[4-octylphenyl]amino]carbonyl]phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)



RN 578024-33-6 CAPLUS

CN Acetic acid, [[[3-chlorophenyl]methyl] [[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-34-7 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[3-chlorophenyl]methyl] [[4-(3-


Print selected from 10-501,344.trn

undecyl-1,2,4-oxadiazol-5-yl]phenyl]methyl]amino]oxoacetate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 578024-33-6

CMF C29 H36 Cl N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-35-8 CAPLUS

CN Acetic acid, 2-[[cyclopentyl[4-(trifluoromethyl)phenyl]methyl]amino][4-[(1-oxotridecyl)amino]phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-36-9 CAPLUS

CN Acetic acid, 2-oxo-2-[[[4-(trifluoromethyl)phenyl]methyl]amino][4-(3-undecyl-

Print selected from 10-501,344.trn

1,2,4-oxadiazol-5-yl)-1-naphthalenyl)methyl]amino]- (CA INDEX NAME)




RN 578024-37-0 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[[4-(trifluoromethyl)phenyl)methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)-1-naphthalenyl)methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-36-9

CMF C34 H38 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-38-1 CAPLUS

CN Acetic acid, 2-[[cyclopentyl[4-(trifluoromethyl)phenyl]methyl] [[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)



Print selected from 10-501,344.trn


RN 578024-39-2 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[cyclopentyl[4-(trifluoromethyl)phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-38-1

CMF C35 H44 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-40-5 CAPLUS

CN Acetic acid, [[4-(4-dibenzofuranyl)phenyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-41-6 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[4-(4-dibenzofuranyl)phenyl][[4-(trifluoromethyl)phenyl)methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-40-5

CMF C28 H18 F3 N O4




CM 2

CRN 6284-40-8

Print selected from 10-501,344.trn


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-42-7 CAPLUS

CN Acetic acid, [[[4-(octyloxy)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-43-8 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-(octyloxy)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-42-7

CMF C25 H30 F3 N O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-44-9 CAPLUS


CN Acetic acid, [[2-(3-chlorophenyl)ethyl][[4-(1-decynyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-45-0 CAPLUS


CN Acetic acid, 2-[[[2-(3-chlorophenyl)ethyl][[4-(1Z)-1-decen-1-yl]phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)

Double bond geometry as shown.



RN 578024-46-1 CAPLUS

CN Acetic acid, 2-[[[2-(3-chlorophenyl)ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-47-2 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[2-(3-chlorophenyl)ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-46-1

CMF C30 H38 Cl N3 O4




CM 2

CRN 6284-40-8

CMF C7 H17 N O5


Absolute stereochemistry.



RN 578024-48-3 CAPLUS

CN Acetic acid, 2-oxo-2-[[[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.



RN 578024-49-4 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)


Print selected from 10-501,344.trn

CM 1

CRN 578024-48-3

CMF C31 H38 F3 N3 O4

Absolute stereochemistry.




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-50-7 CAPLUS

CN Acetic acid, 2-oxo-2-[[4-(trifluoromethyl)phenyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino] - (CA INDEX NAME)



Print selected from 10-501,344.trn


RN 578024-51-8 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[4-(trifluoromethyl)phenyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]acetate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 578024-50-7

CMF C29 H34 F3 N3 O4




CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-52-9 CAPLUS

CN Acetic acid, 2-oxo-2-[[[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (CA INDEX NAME)

Absolute stereochemistry.


CM 1

Absolute stereochemistry.




CM 2

Absolute stereochemistry.



RN 578024-54-1 CAPLUS

CN Acetic acid, [[(3-chlorophenyl)methyl][[4-(1-decynyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-55-2 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[(3-chlorophenyl)methyl][[4-(1-decynyl)phenyl)methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-54-1

CMF C26 H30 Cl N O3




CM 2

CRN 6284-40-8

CMF C7 H17 N O5


Absolute stereochemistry.



Print selected from 10-501,344.trn

RN 578024-56-3 CAPLUS

CN Acetic acid, [[2-(3-chlorophenyl)ethyl][[4-(1-octynyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-57-4 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[2-(3-chlorophenyl)ethyl][[4-(1-octynyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-56-3

CMF C25 H28 Cl N O3




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-58-5 CAPLUS

CN Acetic acid, [[[4-(1-decynyl)phenyl]methyl][4-(trifluoromethyl)phenyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-59-6 CAPLUS

CN Acetic acid, 2-[[[4-(1-decyn-1-yl)phenyl]methyl][1-[4-(trifluoromethyl)phenyl]ethyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-60-9 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-(1-decynyl)phenyl]methyl][1-[4-(trifluoromethyl)phenyl]ethyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-59-6

CMF C28 H32 F3 N O3




CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.



IT 578024-61-0P, [[1-Methyl-1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid

578024-62-1P, [[1-Methyl-1-[4-(trifluoromethyl)phenyl]ethyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-63-2P, [[2-(3-Chlorophenyl)ethyl] [4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578024-64-3P, [[2-(3-Chlorophenyl)ethyl] [4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-65-4P, [[4-(3-Octyl-1,2,4-oxadiazol-5-yl)benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-66-5P, [[4-(3-Octyl-1,2,4-oxadiazol-5-yl)benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-67-6P, [[4-(Dodecyloxy)-1-naphthyl]methyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-68-7P, [[4-(Dodecyloxy)-1-naphthyl]methyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-69-8P, [(4-Bromobenzyl) (4-oct-1-ynylbenzyl)amino] (oxo)acetic acid 578024-70-1P, [[4-[(Dodecylamino)carbonyl]benzyl] (2-hydroxy-1-phenylethyl)amino] (oxo)acetic acid 578024-71-2P, [(4-Dec-1-ynylbenzyl) [1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl]amino] (oxo)acetic acid 578024-72-3P, [(4-Dec-1-ynylbenzyl) [1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-73-4P, Oxo[[4-((9Z)-tetradec-9-enoylamino)benzyl] [4-(trifluoromethyl)benzyl]amino]acetic acid 578024-75-6P, Oxo[[4-(trifluoromethyl)benzyl] [3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578024-76-7P, Oxo[[4-(trifluoromethyl)benzyl] [3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid N-methyl-D-glucamine salt 578024-77-8P, [(4-Dodecylbenzyl) [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-78-9P, [(4-Dodecylbenzyl) [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-79-0P, [[4-[[[(2-Butylbenzofuran-3-yl)methyl]amino]carbonyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-80-3P, [[4-[[4-(Benzyloxy)benzoyl]amino]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-81-4P, [(3,5-Dichlorobenzyl) [4-(tridecanoylamino)benzyl]amino] (oxo)acetic acid 578024-82-5P, [(3,5-Dichlorobenzyl) [4-(tridecanoylamino)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-84-7P, Oxo[[4-(trifluoromethyl)benzyl] [4-(5-undecyl-1,2,4-oxadiazol-3-yl)benzyl]amino]acetic acid 578024-85-8P, Oxo[[4-(trifluoromethyl)benzyl] [4-(5-undecyl-1,2,4-oxadiazol-3-yl)benzyl]amino]acetic acid N-methyl-D-glucamine salt 578024-86-9P, [[4-[2-(4-Octylphenyl)ethyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-89-2P, [[4-[[4-(Hexylphenyl)ethynyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-90-5P, [[4-[[4-(Hexylphenyl)ethynyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-93-8P, [[2-(3-Chlorophenyl)ethyl] (4-dodec-1-ynylbenzyl)amino] (oxo)acetic acid 578024-94-9P, [[2-(3-Chlorophenyl)ethyl] (4-dodec-1-ynylbenzyl)amino] (oxo)acetic acid N-methyl-D-glucamine salt 578024-95-0P, [(4-Oct-1-ynylbenzyl) [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-97-2P, [[4-(11-Methoxy-11-oxoundec-1-ynyl)benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578024-99-4P, [[4-[[4-(Benzyloxy)phenyl]ethynyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-00-0P, [[4-[2-[4-(Heptyloxy)phenyl]ethyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-01-1P, [[4-[2-(4-Butylphenyl)ethyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-02-2P, [[4-[2-(4-Hexylphenyl)ethyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-03-3P,

[[4-[2-(4-Hexylphenyl)ethyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578025-04-4P,
Oxo[[4-[2-[4-(pentyloxy)phenyl]ethyl]benzyl][4-(trifluoromethyl)benzyl]amino]acetic acid 578025-05-5P,
Oxo[[4-[2-(4-propylphenyl)ethyl]benzyl][4-(trifluoromethyl)benzyl]amino]acetic acid 578025-06-6P, 11-[4-[[[Carboxycarbonyl][4-(trifluoromethyl)benzyl]amino]methyl]phenyl]undecanoic acid 578025-07-7P, [[4-(11-Hydroxyundecyl)benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-08-8P,
[[4-Dodec-1-ynylbenzyl][4-(trifluoromethyl)phenyl]amino] (oxo)acetic acid 578025-09-9P, [[4-Dodec-1-ynylbenzyl][4-(trifluoromethyl)phenyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578025-10-2P, Oxo[[4-(trifluoromethyl)benzyl][4-[2-(3-undecyl-1,2,4-oxadiazol-5-yl)ethyl]benzyl]amino]acetic acid 578025-11-3P,
, Oxo[[4-(trifluoromethyl)benzyl][4-[2-(3-undecyl-1,2,4-oxadiazol-5-yl)ethyl]benzyl]amino]acetic acid N-methyl-D-glucamine salt 578025-12-4P, [[4-[2-(3-Octyl-1,2,4-oxadiazol-5-yl)ethyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-13-5P,
[[4-[2-(3-Octyl-1,2,4-oxadiazol-5-yl)ethyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578025-14-6P, [[4-[[4-Octylbenzoyl]amino]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-15-7P,
[[4-[[4-Octylbenzoyl]amino]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt 578025-19-1P,
[[3-Dec-1-ynyl-1-benzofuran-5-yl)methyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-20-4P, [[3-Dodec-1-ynyl-1-benzofuran-5-yl)methyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-21-5P, Oxo[[3-[[4-propylphenyl]ethynyl]-1-benzofuran-5-yl)methyl][4-(trifluoromethyl)benzyl]amino]acetic acid 578025-22-6P, [[4-Dodec-1-ynylbenzyl][4-fluorobenzyl]amino] (oxo)acetic acid 578025-23-7P,
[Bis(4-oct-1-ynylbenzyl)amino] (oxo)acetic acid 578025-25-9P,
[[3-Dodec-1-ynylbenzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-26-0P, [[2-(2-Fluorophenyl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-27-1P,
[[2-(2-Fluorophenyl)ethyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-28-2P,
[[2-(2-Fluorophenyl)ethyl][4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-29-3P,
[[2-(3,4-Dichlorophenyl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-30-6P,
[[2-(3,4-Dichlorophenyl)ethyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-31-7P,
[[2-(3,4-Dichlorophenyl)ethyl][4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-32-8P,
[[2-(1,1'-Biphenyl-4-yl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]glyoxylic acid 578025-33-9P,
[[2-(1,1'-Biphenyl-4-yl)ethyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]glyoxylic acid 578025-34-0P,
[[2-(1,1'-Biphenyl-4-yl)ethyl][4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino]glyoxylic acid 578025-35-1P,
Oxo[(5,6,7,8-tetrahydronaphthalen-1-yl)[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578025-36-2P, Oxo[(5,6,7,8-tetrahydronaphthalen-1-yl)[3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578025-37-3P, [[4-(3-Octyl-1,2,4-oxadiazol-5-yl)benzyl][5,6,7,8-tetrahydronaphthalen-1-yl]amino] (oxo)acetic acid 578025-38-4P, [(1,1'-Biphenyl-3-yl)methyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]glyoxylic acid 578025-39-5P,
[(1,1'-Biphenyl-3-yl)methyl][3-(3-undecyl-1,2,4-oxadiazol-5-

yl)benzyl]amino]glyoxylic acid 578025-40-8P,
 [(1,1'-Biphenyl-3-ylmethyl) [4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino]glyoxylic acid 578025-44-2P,
 Oxo[[2-(trifluoromethyl)benzyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578025-45-3P, Oxo[[2-(trifluoromethyl)benzyl] [3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578025-46-4P, [[4-(3-Octyl-1,2,4-oxadiazol-5-yl)benzyl] [2-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-47-5P, Oxo[[3-(trifluoromethyl)benzyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578025-48-6P, Oxo[[3-(trifluoromethyl)benzyl] [3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578025-49-7P, [[4-(3-Octyl-1,2,4-oxadiazol-5-yl)benzyl] [3-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-50-0P, [(2-Methoxybenzyl) [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-51-1P, [(2-Methoxybenzyl) [3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-52-2P, [(2-Methoxybenzyl) [4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-53-3P, Oxo[[4-[(trifluoromethyl)sulfonyl]benzyl] [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578025-54-4P, Oxo[[4-[(trifluoromethyl)sulfonyl]benzyl] [3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetic acid 578025-55-5P, [[4-(3-Octyl-1,2,4-oxadiazol-5-yl)benzyl] [4-[(trifluoromethyl)sulfonyl]benzyl]amino] (oxo)acetic acid 578025-56-6P, [(1,3-Benzodioxol-5-yl) [4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-57-7P, [(1,3-Benzodioxol-5-yl) [3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-58-8P, [(1,3-Benzodioxol-5-yl) [4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetic acid 578025-59-9P, [[(4-Dodec-1-ynyl-1-naphthyl)methyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-60-2P, [[(4-Dec-1-ynyl-1-naphthyl)methyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-61-3P, Oxo[[4-(trifluoromethyl)benzyl] [4-(4-undecyl-1,3-thiazol-2-yl)benzyl]amino]acetic acid 578025-62-4P, [(4-Dec-1-ynylbenzyl) [2-(2-fluorophenyl)ethyl]amino] (oxo)acetic acid 578025-63-5P, [(4-Dodec-1-ynylbenzyl) [2-(2-fluorophenyl)ethyl]amino] (oxo)acetic acid 578025-64-6P, [[(4-(Dodecyloxy)-1-naphthyl)methyl] [2-(2-fluorophenyl)ethyl]amino] (oxo)acetic acid 578025-65-7P, [[2-(2-Fluorophenyl)ethyl] [4-(octyloxy)benzyl]amino] (oxo)acetic acid 578025-66-8P, [(4-Dec-1-ynylbenzyl) [2-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-67-9P, [(4-Dodec-1-ynylbenzyl) [2-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-68-0P, [[(4-(Dodecyloxy)-1-naphthyl)methyl] [2-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-69-1P, [[4-(Octyloxy)benzyl] [2-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-70-4P, [(4-Dec-1-ynylbenzyl) [2-(3,4-dichlorophenyl)ethyl]amino] (oxo)acetic acid 578025-71-5P, [[2-(3,4-Dichlorophenyl)ethyl] [4-dodec-1-ynylbenzyl]amino] (oxo)acetic acid 578025-72-6P, [[2-(3,4-Dichlorophenyl)ethyl] [[4-(dodecyloxy)-1-naphthyl)methyl]amino]glyoxylic acid 578025-73-7P, [[2-(3,4-Dichlorophenyl)ethyl] [4-(octyloxy)benzyl]amino] (oxo)acetic acid 578025-74-8P, [[4-[(4-Hexylphenyl)ethynyl]benzyl] [1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl]amino] (oxo)acetic acid 578025-75-9P, [[4-(5-Cyclohexylpent-1-ynyl)benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-76-0P, [[3-[(4-Hexylphenyl)ethynyl]benzyl] [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-77-1P, [[4-(4-Ethyl-3-hydroxyoct-1-ynyl)benzyl] [4-


(trifluoromethyl)benzyl]amino] (oxo)acetic acid 578025-78-2P,
 [(2-Dec-1-ynylbenzyl) [4-(trifluoromethyl)benzyl]amino] (oxo)acetic acid
 578025-79-3P, [(4-Dec-1-ynylbenzyl) [4-
 (trifluoromethyl)benzyl]amino] (oxo)acetic acid L-lysine salt
 578025-80-6P, [(4-Dec-1-ynylbenzyl) [4-
 (trifluoromethyl)benzyl]amino] (oxo)acetic acid tromethamine salt
 578025-81-7P, [(4-Dec-1-ynylbenzyl) [4-
 (trifluoromethyl)benzyl]amino] (oxo)acetic acid L-arginine salt
 578025-82-8P, Sodium [(4-dec-1-ynylbenzyl) [4-
 (trifluoromethyl)benzyl]amino] (oxo)acetate 578025-86-2P,
 [Benzyl [4-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid
 tromethamine salt 578025-87-3P, [Benzyl [4-
 [(dodecylamino)carbonyl]benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine
 salt 578026-02-5P, [[4-[(Dodecylamino)carbonyl]benzyl] [4-
 (trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt
 578026-05-8P, [[4-[(Dodecylamino)carbonyl]benzyl] [3-
 (trifluoromethyl)benzyl]amino] (oxo)acetic acid N-methyl-D-glucamine salt
 578026-12-7P, Oxo[[4-(tridecanoylamino)benzyl] [4-
 (trifluoromethyl)benzyl]amino]acetic acid N-methyl-D-glucamine salt
 578026-20-7P, Oxo[[4-((9E)-9-tetradecenoylamino)benzyl] [4-
 (trifluoromethyl)benzyl]amino]acetic acid N-methyl-D-glucamine salt
 578029-15-9P, [[1-(3-Chlorophenyl)-1-methylethyl] [4-[(4-
 hexylphenyl)ethynyl]benzyl]amino] (oxo)acetic acid 578029-16-0P,
 [[1-(3-Chlorophenyl)-1-methylethyl] [4-[(4-hexylphenyl)ethynyl]benzyl]amino
] (oxo)acetic acid N-methyl-D-glucamine salt 578029-47-7P,
 [[4-[(Dodecylamino)carbonyl]benzyl] (carboxyphenylmethyl)amino] (oxo)acetic
 acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(drug candidate; preparation of [(arylmethyl)amino] (oxo)acetic acids as PTP
 inhibitors for antidiabetics)

RN 578024-61-0 CAPLUS

CN Acetic acid, 2-[[1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl] [[4-(3-
 undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-62-1 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[1-methyl-1-[4-
 (trifluoromethyl)phenyl]ethyl] [[4-(3-undecyl-1,2,4-oxadiazol-5-
 yl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-61-0

CMF C32 H40 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-63-2 CAPLUS

CN Acetic acid, [[2-(3-chlorophenyl)ethyl][[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-64-3 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[2-(3-chlorophenyl)ethyl][[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-63-2

CMF C27 H32 Cl N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-65-4 CAPLUS

CN Acetic acid, [[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-66-5 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-65-4

CMF C27 H30 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-67-6 CAPLUS

CN Acetic acid, 2-[[[4-(dodecyloxy)-1-naphthalenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-68-7 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-(dodecyloxy)-1-naphthalenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-67-6

CMF C33 H40 F3 N O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-69-8 CAPLUS

CN Acetic acid, [[[4-bromophenyl)methyl] [[4-(1-octynyl)phenyl)methyl] amino] ox
o- (9CI) (CA INDEX NAME)




RN 578024-70-1 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl] (2-hydroxy-1-phenylethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 578024-71-2 CAPLUS

CN Acetic acid, 2-[[[4-(1-decyn-1-yl)phenyl]methyl] [1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-72-3 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-(1-decynyl)phenyl]methyl] [1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-71-2

CMF C29 H34 F3 N O3




CM 2

CRN 6284-40-8

CMF C7 H17 N O5


Absolute stereochemistry.



RN 578024-73-4 CAPLUS


CN Acetic acid, oxo[[[4-[[[(9Z)-1-oxo-9-tetradecenyl]amino]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 578024-75-6 CAPLUS

CN Acetic acid, 2-oxo-2-[[[4-(trifluoromethyl)phenyl]methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 578024-76-7 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[[4-(trifluoromethyl)phenyl]methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-75-6

CMF C30 H36 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-77-8 CAPLUS

CN Acetic acid, 2-[[[4-dodecylphenyl)methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-78-9 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[(4-dodecylphenyl)methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-77-8

CMF C29 H38 F3 N O3




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-79-0 CAPLUS

CN Acetic acid, [[[4-[[[(2-butyl-3-benzofuranyl)methyl]amino]carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-80-3 CAPLUS

CN Acetic acid, oxo[[[4-[[(4-(phenylmethoxy)benzoyl]amino]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)



RN 578024-81-4 CAPLUS

CN Acetic acid, 2-[[[(3,5-dichlorophenyl)methyl][[4-[(1-oxotridecyl)amino]phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-82-5 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[(3,5-dichlorophenyl)methyl][[4-[(1-oxotridecyl)amino]phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-81-4

CMF C29 H38 Cl2 N2 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-84-7 CAPLUS

CN Acetic acid, 2-oxo-2-[[[4-(trifluoromethyl)phenyl]methyl][[4-(5-undecyl-1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 578024-85-8 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[[4-(trifluoromethyl)phenyl]methyl][[4-(5-undecyl-1,2,4-oxadiazol-3-yl)phenyl]methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-84-7

CMF C30 H36 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-86-9 CAPLUS

CN Acetic acid, 2-[[[4-[2-(4-octylphenyl)ethyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)



RN 578024-89-2 CAPLUS

CN Acetic acid, 2-[[[4-[2-(4-hexylphenyl)ethynyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-90-5 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-[(4-hexylphenyl)ethynyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-89-2

CMF C31 H30 F3 N O3




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578024-93-8 CAPLUS

CN Acetic acid, 2-[[2-(3-chlorophenyl)ethyl][[4-(1-dodecyn-1-yl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578024-94-9 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[2-(3-chlorophenyl)ethyl][[4-(1-dodecynyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-93-8

CMF C29 H36 Cl N O3




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578024-95-0 CAPLUS

CN Acetic acid, [[4-(1-octynyl)phenyl)methyl][4-(trifluoromethyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578024-97-2 CAPLUS

CN 10-Undecynoic acid, 11-[4-[[[(carboxycarbonyl)[4-(trifluoromethyl)phenyl)methyl]amino]methyl]phenyl]-, 1-methyl ester (CA INDEX NAME)




RN 578024-99-4 CAPLUS

CN Acetic acid, 2-oxo-2-[[[4-[2-[4-(phenylmethoxy)phenyl]ethynyl]phenyl)methyl][4-(trifluoromethyl)phenyl)methyl]amino]- (CA INDEX NAME)




RN 578025-00-0 CAPLUS

CN Acetic acid, [[4-[2-[4-(heptyloxy)phenyl]ethyl]phenyl)methyl][4-(trifluoromethyl)phenyl)methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-01-1 CAPLUS

CN Acetic acid, [[[4-[2-(4-butylphenyl)ethyl]phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-02-2 CAPLUS

CN Acetic acid, 2-[[[4-[2-(4-hexylphenyl)ethyl]phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-03-3 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[[4-[2-(4-hexylphenyl)ethyl]phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino] oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578025-02-2

CMF C31 H34 F3 N O3




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578025-04-4 CAPLUS

CN Acetic acid, oxo[[[4-[2-[4-(pentyloxy)phenyl]ethyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578025-05-5 CAPLUS

CN Acetic acid, oxo[[[4-[2-(4-propylphenyl)ethyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578025-06-6 CAPLUS

CN Benzeneundecanoic acid, 4-[[[(carboxycarbonyl)[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]- (CA INDEX NAME)




RN 578025-07-7 CAPLUS

CN Acetic acid, [[4-(11-hydroxyundecyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-08-8 CAPLUS

CN Acetic acid, 2-[[[4-(1-dodecyn-1-yl)phenyl]methyl][4-(trifluoromethyl)phenyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-09-9 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-(1-dodecynyl)phenyl]methyl][4-(trifluoromethyl)phenyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578025-08-8

CMF C28 H32 F3 N O3




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578025-10-2 CAPLUS

CN Acetic acid, oxo[[[4-(trifluoromethyl)phenyl]methyl][[4-[2-(3-undecyl-1,2,4-oxadiazol-5-yl)ethyl]phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578025-11-3 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[[4-(trifluoromethyl)phenyl]methyl][[4-[2-(3-undecyl-1,2,4-oxadiazol-5-yl)ethyl]phenyl]methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578025-10-2

CMF C32 H40 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578025-12-4 CAPLUS

CN Acetic acid, [[4-[2-(3-octyl-1,2,4-oxadiazol-5-yl)ethyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-13-5 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[4-[2-(3-octyl-1,2,4-oxadiazol-5-yl)ethyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578025-12-4

CMF C29 H34 F3 N3 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578025-14-6 CAPLUS

CN Acetic acid, 2-[[[4-[(4-octylbenzoyl)amino]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-15-7 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-[(4-octylbenzoyl)amino]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578025-14-6

CMF C32 H35 F3 N2 O4




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.




RN 578025-19-1 CAPLUS

CN Acetic acid, 2-[[[3-(1-decyn-1-yl)-5-benzofuranyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-20-4 CAPLUS

CN Acetic acid, 2-[[[3-(1-dodecyn-1-yl)-5-benzofuranyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-21-5 CAPLUS

CN Acetic acid, 2-oxo-2-[[[3-[2-(4-propylphenyl)ethynyl]-5-benzofuranyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]- (CA INDEX NAME)




RN 578025-22-6 CAPLUS

CN Acetic acid, 2-[[[4-(1-dodecyn-1-yl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-23-7 CAPLUS

CN Acetic acid, 2-[bis[[4-(1-octyn-1-yl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-25-9 CAPLUS

CN Acetic acid, [[[3-(1-dodecynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-26-0 CAPLUS

CN Acetic acid, [[2-(2-fluorophenyl)ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-27-1 CAPLUS

CN Acetic acid, [[2-(2-fluorophenyl)ethyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-28-2 CAPLUS

CN Acetic acid, [[2-(2-fluorophenyl)ethyl][[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-29-3 CAPLUS

CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-30-6 CAPLUS

CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-31-7 CAPLUS

CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-32-8 CAPLUS

CN Acetic acid, [(2-[1,1'-biphenyl]-4-ylethyl)[[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-33-9 CAPLUS

CN Acetic acid, [(2-[1,1'-biphenyl]-4-ylethyl)[[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-34-0 CAPLUS


CN Acetic acid, [(2-[1,1'-biphenyl]-4-ylethyl)[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



Print selected from 10-501,344.trn


RN 578025-35-1 CAPLUS

CN Acetic acid, oxo[(5,6,7,8-tetrahydro-1-naphthalenyl)[[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 578025-36-2 CAPLUS

CN Acetic acid, oxo[(5,6,7,8-tetrahydro-1-naphthalenyl)[[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 578025-37-3 CAPLUS

CN Acetic acid, [[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl](5,6,7,8-tetrahydro-1-naphthalenyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-38-4 CAPLUS

CN Acetic acid, [([1,1'-biphenyl]-3-ylmethyl)[[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-39-5 CAPLUS

CN Acetic acid, [([1,1'-biphenyl]-3-ylmethyl)[[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-40-8 CAPLUS

CN Acetic acid, [([1,1'-biphenyl]-3-ylmethyl)[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-44-2 CAPLUS

CN Acetic acid, oxo[[[2-(trifluoromethyl)phenyl]methyl] [[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 578025-45-3 CAPLUS

CN Acetic acid, oxo[[[2-(trifluoromethyl)phenyl]methyl] [[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 578025-46-4 CAPLUS

CN Acetic acid, [[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl] [[2-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-47-5 CAPLUS

CN Acetic acid, oxo[[[3-(trifluoromethyl)phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578025-48-6 CAPLUS

CN Acetic acid, oxo[[[3-(trifluoromethyl)phenyl]methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578025-49-7 CAPLUS

CN Acetic acid, [[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl][[3-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-50-0 CAPLUS

CN Acetic acid, [[(2-methoxyphenyl)methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-51-1 CAPLUS

CN Acetic acid, [[(2-methoxyphenyl)methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-52-2 CAPLUS

CN Acetic acid, [[(2-methoxyphenyl)methyl][[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-53-3 CAPLUS

CN Acetic acid, oxo[[[4-[(trifluoromethyl)sulfonyl]phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578025-54-4 CAPLUS

CN Acetic acid, oxo[[[4-[(trifluoromethyl)sulfonyl]phenyl]methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 578025-55-5 CAPLUS

CN Acetic acid, [[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl][[4-[(trifluoromethyl)sulfonyl]phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-56-6 CAPLUS

CN Acetic acid, [1,3-benzodioxol-5-yl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-57-7 CAPLUS

CN Acetic acid, [1,3-benzodioxol-5-yl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-58-8 CAPLUS

CN Acetic acid, [1,3-benzodioxol-5-yl][4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-59-9 CAPLUS

CN Acetic acid, 2-[[[4-(1-dodecyn-1-yl)-1-naphthalenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-60-2 CAPLUS

CN Acetic acid, [[4-(1-decynyl)-1-naphthalenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-61-3 CAPLUS

CN Acetic acid, 2-oxo-2-[[[4-(trifluoromethyl)phenyl]methyl][[4-(4-undecyl-2-thiazolyl)phenyl]methyl]amino]- (CA INDEX NAME)



RN 578025-62-4 CAPLUS


CN Acetic acid, [[4-(1-decynyl)phenyl]methyl][2-(2-fluorophenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-63-5 CAPLUS


CN Acetic acid, [[4-(1-dodecynyl)phenyl]methyl][2-(2-fluorophenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)

Print selected from 10-501,344.trn




RN 578025-64-6 CAPLUS

CN Acetic acid, [[4-(dodecyloxy)-1-naphthalenyl]methyl][2-(2-fluorophenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-65-7 CAPLUS

CN Acetic acid, [[2-(2-fluorophenyl)ethyl][[4-(octyloxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-66-8 CAPLUS

CN Acetic acid, [[4-(1-decynyl)phenyl]methyl][2-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-67-9 CAPLUS

CN Acetic acid, [[[4-(1-dodecynyl)phenyl]methyl][[2-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-68-0 CAPLUS

CN Acetic acid, [[[4-(dodecyloxy)-1-naphthalenyl]methyl][[2-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-69-1 CAPLUS


CN Acetic acid, [[[4-(octyloxy)phenyl]methyl][[2-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-70-4 CAPLUS


CN Acetic acid, [[[4-(1-decynyl)phenyl]methyl][2-(3,4-dichlorophenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)

Print selected from 10-501,344.trn




RN 578025-71-5 CAPLUS

CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(1-dodecynyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-72-6 CAPLUS

CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(dodecyloxy)-1-naphthalenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-73-7 CAPLUS

CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(octyloxy)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-74-8 CAPLUS

CN Acetic acid, 2-[[[4-[2-(4-hexylphenyl)ethynyl]phenyl]methyl][1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-75-9 CAPLUS

CN Acetic acid, 2-[[[4-(5-cyclohexyl-1-pentyn-1-yl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-76-0 CAPLUS

CN Acetic acid, 2-[[[3-[2-(4-hexylphenyl)ethynyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578025-77-1 CAPLUS

CN Acetic acid, [[4-(4-ethyl-3-hydroxy-1-octynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)



RN 578025-78-2 CAPLUS

CN Acetic acid, [[2-(1-decynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-79-3 CAPLUS

CN L-Lysine, mono[[[4-(1-decynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate] (9CI) (CA INDEX NAME)

CM 1

CRN 578024-74-5

CMF C27 H30 F3 N O3




CM 2

CRN 56-87-1

CMF C6 H14 N2 O2

Absolute stereochemistry.




RN 578025-80-6 CAPLUS

CN Acetic acid, [[[4-(1-decynyl)phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 578024-74-5


CMF C27 H30 F3 N O3



CM 2

CRN 77-86-1

CMF C4 H11 N O3




RN 578025-81-7 CAPLUS

CN L-Arginine, mono[[[4-(1-decynyl)phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate] (9CI) (CA INDEX NAME)

CM 1

CRN 578024-74-5

CMF C27 H30 F3 N O3




CM 2

CRN 74-79-3


CMF C6 H14 N4 O2

Absolute stereochemistry.



RN 578025-82-8 CAPLUS

CN Acetic acid, [[[4-(1-decynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, sodium salt (9CI) (CA INDEX NAME)



● Na


RN 578025-86-2 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl](phenylmethyl)amino]oxo-, compd. with 2-amino-2-(hydroxymethyl)-1,3-propanediol (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 578021-80-4

CMF C29 H40 N2 O4




CM 2

CRN 77-86-1

CMF C4 H11 N O3

Print selected from 10-501,344.trn




RN 578025-87-3 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-[(dodecylamino)carbonyl]phenyl]methyl](phenylmethyl)amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578021-80-4

CMF C29 H40 N2 O4




CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.




RN 578026-02-5 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578021-87-1

CMF C30 H39 F3 N2 O4




CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.




RN 578026-05-8 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][[3-(trifluoromethyl)phenyl]methyl]amino]oxoacetate (salt) (9CI)
(CA INDEX NAME)

CM 1

CRN 578021-88-2

CMF C30 H39 F3 N2 O4




CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.




RN 578026-12-7 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[[4-[(1-oxotridecyl)amino]phenyl)methyl][[4-(trifluoromethyl)phenyl)methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578021-90-6

CMF C30 H39 F3 N2 O4




CM 2

CRN 6284-40-8

CMF C7 H17 N O5

Absolute stereochemistry.



RN 578026-20-7 CAPLUS


CN D-Glucitol, 1-deoxy-1-(methylamino)-, oxo[[[4-[[[(9E)-1-oxo-9-tetradecenyl]amino]phenyl)methyl][[4-(trifluoromethyl)phenyl)methyl]amino]acetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578021-93-9

CMF C31 H39 F3 N2 O4

Double bond geometry as shown.




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578029-15-9 CAPLUS

CN Acetic acid, 2-[[1-(3-chlorophenyl)-1-methylethyl][4-[2-(4-hexylphenyl)ethynyl]phenyl]methyl]amino]-2-oxo- (CA INDEX NAME)




RN 578029-16-0 CAPLUS

CN D-Glucitol, 1-deoxy-1-(methylamino)-, [[1-(3-chlorophenyl)-1-methylethyl][4-[(4-hexylphenyl)ethynyl]phenyl]methyl]amino] oxoacetate (salt) (9CI) (CA INDEX NAME)

CM 1

CRN 578029-15-9

CMF C32 H34 Cl N O3




CM 2

CRN 6284-40-8


CMF C7 H17 N O5

Absolute stereochemistry.



RN 578029-47-7 CAPLUS

CN Benzeneacetic acid, α -[(carboxycarbonyl)[[4-[(dodecylamino)carbonyl]phenyl]methyl]amino] - (CA INDEX NAME)




IT 578022-19-2DP, [[4-[(Dodecylamino)carbonyl]benzyl][1-(1-naphthyl)ethyl]amino](oxo)acetic acid, resin-bound 578022-20-5DP, [Benzyl[3-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetic acid, resin-bound 578025-83-9P, 4-[[Benzyl(ethoxyoxalyl)amino]methyl]benzoic acid benzyl ester 578025-84-0P, 4-[[Benzyl(ethoxyoxalyl)amino]methyl]benzoic acid 578025-85-1P, Ethyl [benzyl[4-[(dodecylamino)carbonyl]benzyl]amino](oxo)acetate 578025-89-5P, Benzyl 4-[[[ethoxy(oxo)acetyl][4-(trifluoromethyl)benzyl]amino]methyl]benzoate 578025-90-8P, 4-[[[Ethoxy(oxo)acetyl][4-(trifluoromethyl)benzyl]amino]methyl]benzoic acid 578025-91-9P, Ethyl oxo[[4-[(pentadecylamino)carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino]acetate 578025-92-0P, Ethyl [benzyl[4-[(pentadecylamino)carbonyl]benzyl]amino](oxo)acetate 578025-93-1P, Ethyl [benzyl[4-[(tridecylamino)carbonyl]benzyl]amino](oxo)acetate 578025-94-2P, Ethyl [benzyl[4-

[[dodecyl(methyl)amino]carbonyl]benzyl]amino] (oxo)acetate
578025-95-3P, Ethyl [[4-[[dodecyl(methyl)amino]carbonyl]benzyl][4-
(trifluoromethyl)benzyl]amino] (oxo)acetate 578026-01-4P, Ethyl
[[4-[(dodecylamino)carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)ac
etate 578026-04-7P, Ethyl [[4-[(dodecylamino)carbonyl]benzyl][3-
(trifluoromethyl)benzyl]amino] (oxo)acetate 578026-09-2P, Ethyl
[[4-[(tert-butoxycarbonyl)amino]benzyl][4-(trifluoromethyl)benzyl]amino] (o
xo)acetate 578026-10-5P, Ethyl [(4-aminobenzyl)[4-
(trifluoromethyl)benzyl]amino] (oxo)acetate 578026-11-6P, Ethyl
oxo[[4-(tridecanoylamino)benzyl][4-(trifluoromethyl)benzyl]amino]acetate
578026-14-9P, Ethyl [benzyl[4-[(tert-butoxycarbonyl)amino]benzyl]a
mino] (oxo)acetate 578026-15-0P, Ethyl [(4-
aminobenzyl)(benzyl)amino] (oxo)acetate 578026-16-1P, Ethyl
[benzyl[4-[[4-(hexyloxy)benzoyl]amino]benzyl]amino] (oxo)acetate
578026-17-2P, Ethyl oxo[[4-(trifluoromethyl)benzyl][4-(undec-10-
enoylamino)benzyl]amino]acetate 578026-18-3P, Ethyl
oxo[[4-((9E)-tetradec-9-enoylamino)benzyl][4-(trifluoromethyl)benzyl]amino
]acetate 578026-21-8P, Ethyl [benzyl[4-
(tridecanoylamino)benzyl]amino] (oxo)acetate 578026-22-9P, Ethyl
[[4-[(2-hydroxydodecyl)amino]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)
acetate 578026-28-5P, Ethyl oxo[[4-(trifluoromethyl)benzyl][4-(3-
undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetate 578026-39-8DP,
Ethyl [[4-[(dodecylamino)carbonyl]benzyl][1-(1-
naphthyl)ethyl]amino] (oxo)acetate, resin-bound 578026-44-5DP,
Ethyl [benzyl[3-[(dodecylamino)carbonyl]benzyl]amino] (oxo)acetate,
resin-bound 578026-59-2P, Methyl 2-[[[4-
[(dodecylamino)carbonyl]phenyl][2-ethoxy-2-(oxo)acetyl]amino]methyl]benzoa
te 578026-72-9P, Ethyl [(4-dibenzo[b,d]furan-4-yl)benzyl][4-
(trifluoromethyl)benzyl]amino] (oxo)acetate 578026-77-4P, Ethyl
[[4-[(dodecylamino)carbonyl]benzyl][1-[4-(trifluoromethyl)phenyl]ethyl]ami
no] (oxo)acetate 578026-79-6P, tert-Butyl 4'-[[[2-ethoxy-2-
(oxo)acetyl][4-(trifluoromethyl)benzyl]amino]methyl]-1,1'-biphenyl-4-
carboxylate 578026-80-9P, 4'-[[[2-Ethoxy-2-(oxo)acetyl][4-
(trifluoromethyl)benzyl]amino]methyl]-1,1'-biphenyl-4-carboxylic acid
578026-81-0P, Ethyl [[4'-[(octylamino)carbonyl]-1,1'-biphenyl-4-
yl]methyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate
578026-83-2P, Ethyl [(4-bromobenzyl)[4-
(trifluoromethyl)benzyl]amino] (oxo)acetate 578026-85-4P, Ethyl
oxo[[4-tetradec-1-ynylbenzyl][4-(trifluoromethyl)benzyl]amino]acetate
578026-86-5P, Ethyl [(4-dodec-1-ynylbenzyl)[4-
(trifluoromethyl)benzyl]amino] (oxo)acetate 578026-88-7P, Ethyl
[[4-[(dodecylamino)carbonyl]benzyl][4-(trifluoromethyl)phenyl]amino] (oxo)a
cetate 578026-90-1P, Ethyl [[4-[(dodecylamino)carbonyl]phenyl][4-
(trifluoromethyl)benzyl]amino] (oxo)acetate 578026-96-7P, Ethyl
oxo[[1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-
yl)benzyl]amino]acetate 578027-03-9P, Ethyl [[1-[4-
[(dodecylamino)carbonyl]phenyl]ethyl][4-(trifluoromethyl)benzyl]amino] (oxo)
)acetate 578027-04-0P, Ethyl [[4-[[4-
octylphenyl]amino]carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)ac
etate 578027-06-2P, Ethyl [(3-chlorobenzyl)[4-(3-undecyl-1,2,4-
oxadiazol-5-yl)benzyl]amino] (oxo)acetate 578027-09-5P, Ethyl
[[cyclopentyl[4-(trifluoromethyl)phenyl]methyl][4-
nitrobenzyl]amino] (oxo)acetate 578027-10-8P, Ethyl
[N-[(4-aminophenyl)methyl]-N-[(cyclopentyl)[4-
(trifluoromethyl)phenyl]methyl]amino] (oxo)acetate 578027-11-9P,
Ethyl [[cyclopentyl[4-(trifluoromethyl)phenyl]methyl][4-
(tridecanoylamino)benzyl]amino] (oxo)acetate 578027-17-5P, Ethyl
oxo[[4-(trifluoromethyl)benzyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)-1-
naphthyl]methyl]amino]acetate 578027-19-7P, Ethyl

[[cyclopentyl[4-(trifluoromethyl)phenyl]methyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetate 578027-23-3P
 578027-25-5P, Ethyl [[4-(octyloxy)benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate 578027-29-9P, Ethyl
 [[2-(3-chlorophenyl)ethyl][4-dec-1-ynylbenzyl]amino] (oxo)acetate 578027-30-2P, Ethyl [[2-(3-chlorophenyl)ethyl][4-((1Z)-dec-1-enyl)benzyl]amino] (oxo)acetate 578027-33-5P, Ethyl
 [[2-(3-chlorophenyl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetate 578027-36-8P, Ethyl
 oxo[[[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetate 578027-38-0P, Ethyl
 oxo[[4-(trifluoromethyl)phenyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetate 578027-43-7P, Ethyl oxo[[[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetate 578027-45-9P, Ethyl [(3-chlorobenzyl)(4-dec-1-ynylbenzyl)amino] (oxo)acetate 578027-47-1P, Ethyl
 [[2-(3-chlorophenyl)ethyl][4-oct-1-ynylbenzyl]amino] (oxo)acetate 578027-49-3P, tert-Butyl [(4-dec-1-ynylbenzyl)[4-(trifluoromethyl)phenyl]amino] (oxo)acetate 578027-51-7P, Ethyl
 [(4-dec-1-ynylbenzyl)[1-[4-(trifluoromethyl)phenyl]ethyl]amino] (oxo)acetate 578027-54-0P, Ethyl [[1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetate 578027-57-3P, Ethyl
 [[2-(3-chlorophenyl)ethyl][4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetate 578027-59-5P, Ethyl
 [[4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate 578027-61-9P, Ethyl [[4-(dodecyloxy)-1-naphthyl]methyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate 578027-63-1P, Ethyl [(4-bromobenzyl)(4-oct-1-ynylbenzyl)amino] (oxo)acetate 578027-67-5P, Ethyl
 [(4-dec-1-ynylbenzyl)[1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl]amino] (oxo)acetate 578027-68-6P, Ethyl oxo[[4-((9Z)-tetradec-9-enoylamino)benzyl][4-(trifluoromethyl)benzyl]amino]acetate 578027-69-7P, Ethyl [[4-(dec-1-ynyl)benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate 578027-76-6P, Ethyl
 oxo[[4-(trifluoromethyl)benzyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetate 578027-77-7P, Ethyl [(4-dodecylbenzyl)[4-(trifluoromethyl)benzyl]amino] (oxo)acetate 578027-78-8P, Ethyl
 [[4-[[[(2-butylbenzofuran-3-yl)methyl]amino]carbonyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate 578027-79-9P, Ethyl
 [[4-[[4-(benzyloxy)benzoyl]amino]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate 578027-81-3P, Ethyl [(3,5-dichlorobenzyl)(4-nitrobenzyl)amino] (oxo)acetate 578027-82-4P, Ethyl
 [(4-aminobenzyl)(3,5-dichlorobenzyl)amino] (oxo)acetate 578027-83-5P, Ethyl [(3,5-dichlorobenzyl)[4-(tridecanoylamino)benzyl]amino] (oxo)acetate 578027-84-6P, Ethyl
 [[4-[[4-(octylphenyl)ethynyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate 578027-91-5P, Ethyl oxo[[4-(trifluoromethyl)benzyl][4-(5-undecyl-1,2,4-oxadiazol-3-yl)benzyl]amino]acetate 578027-92-6P, Ethyl
 [[4-[[4-(heptyloxy)phenyl]ethynyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate 578027-93-7P, Ethyl
 [[4-[[4-(butylphenyl)ethynyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate 578027-96-0P, Ethyl [[4-[[4-(hexylphenyl)ethynyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate 578027-97-1P, Ethyl
 oxo[[4-[[4-(pentyloxy)phenyl]ethynyl]benzyl][4-(trifluoromethyl)benzyl]amino]acetate 578027-98-2P, Ethyl
 oxo[[4-[[4-(propylphenyl)ethynyl]benzyl][4-(trifluoromethyl)benzyl]amino]acetate 578028-01-0P, Ethyl [[2-(3-chlorophenyl)ethyl][4-dodec-1-ynylbenzyl]amino] (oxo)acetate 578028-02-1P, Ethyl


[(4-oct-1-ynylbenzyl)[4-(trifluoromethyl)benzyl]amino] (oxo)acetate
 578028-03-2P, Ethyl [[4-(11-hydroxyundec-1-ynyl)benzyl][4-
 (trifluoromethyl)benzyl]amino] (oxo)acetate 578028-04-3P, Methyl
 11-[4-[[[ethoxy(oxo)acetyl][4-(trifluoromethyl)benzyl]amino]methyl]phenyl]
 undec-10-ynoate 578028-05-4P, Ethyl [[4-[[4-
 (benzyloxy)phenyl]ethynyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)ace
 tate 578028-06-5P, Ethyl [[4-[2-(4-hexylphenyl)ethyl]benzyl][4-
 (trifluoromethyl)benzyl]amino] (oxo)acetate 578028-08-7P, Ethyl
 [(4-dodec-1-ynylbenzyl)[4-(trifluoromethyl)phenyl]amino] (oxo)acetate
 578028-13-4P, Ethyl oxo[[4-(trifluoromethyl)benzyl][4-[2-(3-
 undecyl-1,2,4-oxadiazol-5-yl)ethyl]benzyl]amino]acetate
 578028-18-9P, Ethyl [[4-[2-(3-octyl-1,2,4-oxadiazol-5-
 yl)ethyl]benzyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate
 578028-19-0P, Ethyl [[4-[(4-octylbenzoyl)amino]benzyl][4-
 (trifluoromethyl)benzyl]amino] (oxo)acetate 578028-28-1P, Ethyl
 [[(3-bromobenzofuran-5-yl)methyl][4-(trifluoromethyl)benzyl]amino] (oxo)ace
 tate 578028-29-2P, Ethyl [[(3-dec-1-ynyl-1-benzofuran-5-
 yl)methyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate
 578028-30-5P, Ethyl [[(3-dodec-1-ynyl-1-benzofuran-5-yl)methyl][4-
 (trifluoromethyl)benzyl]amino] (oxo)acetate 578028-31-6P, Ethyl
 oxo[[[3-[(4-propylphenyl)ethynyl]-1-benzofuran-5-yl)methyl][4-
 (trifluoromethyl)benzyl]amino]acetate 578028-33-8P, Ethyl
 [(4-bromobenzyl)(4-fluorobenzyl)amino] (oxo)acetate 578028-34-9P,
 Ethyl [(4-dodec-1-ynylbenzyl)(4-fluorobenzyl)amino] (oxo)acetate
 578028-35-0P, Ethyl [bis(4-oct-1-ynylbenzyl)amino] (oxo)acetate
 578028-40-7P, Ethyl [(3-dodec-1-ynylbenzyl)[4-
 (trifluoromethyl)benzyl]amino] (oxo)acetate 578028-42-9P, Ethyl
 [[2-(2-fluorophenyl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-
 yl)benzyl]amino] (oxo)acetate 578028-45-2P, Ethyl
 [[2-(2-fluorophenyl)ethyl][3-(3-undecyl-1,2,4-oxadiazol-5-
 yl)benzyl]amino] (oxo)acetate 578028-47-4P, Ethyl
 [[2-(2-fluorophenyl)ethyl][4-(3-octyl-1,2,4-oxadiazol-5-
 yl)benzyl]amino] (oxo)acetate 578028-49-6P, Ethyl
 [[2-(3,4-dichlorophenyl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-
 yl)benzyl]amino] (oxo)acetate 578028-51-0P, Ethyl
 [[2-(3,4-dichlorophenyl)ethyl][3-(3-undecyl-1,2,4-oxadiazol-5-
 yl)benzyl]amino] (oxo)acetate 578028-53-2P, Ethyl
 [[2-(3,4-dichlorophenyl)ethyl][4-(3-octyl-1,2,4-oxadiazol-5-
 yl)benzyl]amino] (oxo)acetate 578028-55-4P, Ethyl
 [[2-(1,1'-biphenyl-4-yl)ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-
 yl)benzyl]amino] (oxo)acetate 578028-57-6P, Ethyl
 [[2-(1,1'-biphenyl-4-yl)ethyl][3-(3-undecyl-1,2,4-oxadiazol-5-
 yl)benzyl]amino] (oxo)acetate 578028-59-8P, Ethyl
 [[2-(1,1'-biphenyl-4-yl)ethyl][4-(3-octyl-1,2,4-oxadiazol-5-
 yl)benzyl]amino] (oxo)acetate 578028-61-2P, Ethyl
 oxo[(5,6,7,8-tetrahydronaphthalen-1-yl)[4-(3-undecyl-1,2,4-oxadiazol-5-
 yl)benzyl]amino]acetate 578028-63-4P, Ethyl oxo[(5,6,7,8-
 tetrahydronaphthalen-1-yl)[3-(3-undecyl-1,2,4-oxadiazol-5-
 yl)benzyl]amino]acetate 578028-65-6P, Ethyl oxo[(5,6,7,8-
 tetrahydronaphthalen-1-yl)[4-(3-octyl-1,2,4-oxadiazol-5-
 yl)benzyl]amino]acetate 578028-68-9P, Ethyl [(1,1'-biphenyl-3-
 ylmethyl)[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetate
 578028-70-3P, Ethyl [(1,1'-biphenyl-3-ylmethyl)[3-(3-undecyl-1,2,4-
 oxadiazol-5-yl)benzyl]amino] (oxo)acetate 578028-71-4P, Ethyl
 [(1,1'-biphenyl-3-ylmethyl)[4-(3-octyl-1,2,4-oxadiazol-5-
 yl)benzyl]amino] (oxo)acetate 578028-79-2P, Ethyl
 oxo[[2-(trifluoromethyl)benzyl][4-(3-undecyl-1,2,4-oxadiazol-5-
 yl)benzyl]amino]acetate 578028-81-6P, Ethyl oxo[[2-
 (trifluoromethyl)benzyl][3-(3-undecyl-1,2,4-oxadiazol-5-

yl)benzyl]amino]acetate 578028-83-8P, Ethyl oxo[[2-(trifluoromethyl)benzyl][4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetate 578028-85-0P, Ethyl oxo[[3-(trifluoromethyl)benzyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetate 578028-87-2P, Ethyl oxo[[3-(trifluoromethyl)benzyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetate 578028-89-4P, Ethyl oxo[[3-(trifluoromethyl)benzyl][4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetate 578028-91-8P, Ethyl [(2-methoxybenzyl)[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetate 578028-93-0P, Ethyl [(2-methoxybenzyl)[3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetate 578028-95-2P, Ethyl [(2-methoxybenzyl)[4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetate 578028-98-5P, Ethyl oxo[[4-[(trifluoromethyl)sulfonyl]benzyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetate 578029-00-2P, Ethyl oxo[[4-[(trifluoromethyl)sulfonyl]benzyl][3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetate 578029-02-4P, Ethyl oxo[[4-[(trifluoromethyl)sulfonyl]benzyl][4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino]acetate 578029-04-6P, Ethyl [(1,3-benzodioxol-5-yl)[4-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetate 578029-06-8P, Ethyl [(1,3-benzodioxol-5-yl)[3-(3-undecyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetate 578029-08-0P, Ethyl [(1,3-benzodioxol-5-yl)[4-(3-octyl-1,2,4-oxadiazol-5-yl)benzyl]amino] (oxo)acetate 578029-12-6P, Ethyl [[(4-bromo-1-naphthyl)methyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate 578029-13-7P, Ethyl [[(4-dodec-1-ynyl-1-naphthyl)methyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate 578029-14-8P, Ethyl [[(4-dec-1-ynyl-1-naphthyl)methyl][4-(trifluoromethyl)benzyl]amino] (oxo)acetate 578029-18-2P, Ethyl [[1-(3-chlorophenyl)-1-methylethyl][4-(4-hexylphenyl)ethynyl]benzyl]amino] (oxo)acetate 578029-21-7P, Ethyl oxo[[4-(trifluoromethyl)benzyl][4-(4-undecyl-1,3-thiazol-2-yl)benzyl]amino]acetate 578029-23-9P, Ethyl [(4-dec-1-ynylbenzyl)[2-(2-fluorophenyl)ethyl]amino] (oxo)acetate 578029-25-1P, Ethyl [(4-dodec-1-ynylbenzyl)[2-(2-fluorophenyl)ethyl]amino] (oxo)acetate 578029-27-3P, Ethyl [[4-(dodecyloxy)-1-naphthyl]methyl][2-(2-fluorophenyl)ethyl]amino] (oxo)acetate 578029-29-5P, Ethyl [[2-(2-fluorophenyl)ethyl][4-(octyloxy)benzyl]amino] (oxo)acetate 578029-31-9P, Ethyl [(4-dec-1-ynylbenzyl)[2-(trifluoromethyl)benzyl]amino] (oxo)acetate 578029-33-1P, Ethyl [(4-dodec-1-ynylbenzyl)[2-(trifluoromethyl)benzyl]amino] (oxo)acetate 578029-35-3P, Ethyl [[4-(dodecyloxy)-1-naphthyl]methyl][2-(trifluoromethyl)benzyl]amino] (oxo)acetate 578029-37-5P, Ethyl [[4-(octyloxy)benzyl][2-(trifluoromethyl)benzyl]amino] (oxo)acetate 578029-39-7P, Ethyl [(4-dec-1-ynylbenzyl)[2-(3,4-dichlorophenyl)ethyl]amino] (oxo)acetate 578029-41-1P, Ethyl [[2-(3,4-dichlorophenyl)ethyl][4-dodec-1-ynylbenzyl]amino] (oxo)acetate 578029-43-3P, Ethyl [N-[2-(3,4-dichlorophenyl)ethyl]-N-[[4-(dodecyloxy)-1-naphthalenyl]methyl]amino] (oxo)acetate 578029-45-5P, Ethyl [[2-(3,4-dichlorophenyl)ethyl][4-(octyloxy)benzyl]amino] (oxo)acetate
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of [(arylmethyl)amino] (oxo)acetic acids as PTP inhibitors for antidiabetics)
 RN 578022-19-2 CAPLUS
 CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][1-(1-naphthalenyl)ethyl]amino]oxo- (9CI) (CA INDEX NAME)




RN 578022-20-5 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl] (phenylmethyl) amino]oxo- (9CI) (CA INDEX NAME)




RN 578025-83-9 CAPLUS

CN Benzoic acid, 4-[[[(ethoxyoxoacetyl) (phenylmethyl) amino]methyl] -, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 578025-84-0 CAPLUS

CN Benzoic acid, 4-[[[(ethoxyoxoacetyl) (phenylmethyl) amino]methyl] - (9CI) (CA INDEX NAME)




RN 578025-85-1 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl] (phenylmethyl)amin o]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578025-89-5 CAPLUS

CN Benzoic acid, 4-[[[(ethoxyoxoacetyl)[[4-(trifluoromethyl)phenyl]methyl]amin o]methyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)




RN 578025-90-8 CAPLUS

CN Benzoic acid, 4-[[[(ethoxyoxoacetyl)[[4-(trifluoromethyl)phenyl]methyl]amin o]methyl]- (9CI) (CA INDEX NAME)




RN 578025-91-9 CAPLUS

CN Acetic acid, oxo[[[4-[(pentadecylamino)carbonyl]phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578025-92-0 CAPLUS

CN Acetic acid, oxo[[[4-[(pentadecylamino)carbonyl]phenyl]methyl](phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578025-93-1 CAPLUS

CN Acetic acid, oxo[(phenylmethyl)[[4-[(tridecylamino)carbonyl]phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578025-94-2 CAPLUS

CN Acetic acid, [[4-[(dodecylmethylamino)carbonyl]phenyl]methyl](phenylmethyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578025-95-3 CAPLUS

CN Acetic acid, [[[4-[(dodecylmethylamino)carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-01-4 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-04-7 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][[3-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-09-2 CAPLUS

CN Acetic acid, [[[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-10-5 CAPLUS

CN Acetic acid, [[(4-aminophenyl)methyl][[4-(trifluoromethyl)phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-11-6 CAPLUS

CN Acetic acid, oxo[[[4-[(1-oxotridecyl)amino]phenyl)methyl][[4-(trifluoromethyl)phenyl)methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-14-9 CAPLUS

CN Acetic acid, [[4-[[[(1,1-dimethylethoxy)carbonyl]amino]phenyl)methyl](phenylmethyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-15-0 CAPLUS

CN Acetic acid, [[(4-aminophenyl)methyl](phenylmethyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-16-1 CAPLUS

CN Acetic acid, [[[4-[[4-(hexyloxy)benzoyl]amino]phenyl]methyl] (phenylmethyl) amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578026-17-2 CAPLUS


CN Acetic acid, oxo[[[4-[(1-oxo-10-undecenyl)amino]phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 578026-18-3 CAPLUS


CN Acetic acid, oxo[[[4-[(9E)-1-oxo-9-tetradecenyl]amino]phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 578026-21-8 CAPLUS

CN Acetic acid, oxo[[[4-[(1-oxotridecyl)amino]phenyl]methyl] (phenylmethyl) amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-22-9 CAPLUS

CN Acetic acid, [[4-[(2-hydroxydodecyl)amino]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-28-5 CAPLUS

CN Acetic acid, oxo[[[4-(trifluoromethyl)phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-39-8 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][1-(1-naphthalenyl)ethyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-44-5 CAPLUS

CN Acetic acid, [[[3-[(dodecylamino)carbonyl]phenyl]methyl] (phenylmethyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-59-2 CAPLUS

CN Benzoic acid, 2-[[[4-[(dodecylamino)carbonyl]phenyl] (ethoxyoxoacetyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 578026-72-9 CAPLUS

CN Acetic acid, [[[4-(4-dibenzofuranyl)phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-77-4 CAPLUS

CN Acetic acid, [[[4-[(dodecylamino)carbonyl]phenyl]methyl][1-[4-(trifluoromethyl)phenyl]ethyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578026-79-6 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid, 4'--[[[(ethoxyoxoacetyl)[[4-(trifluoromethyl)phenyl]methyl]amino]methyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 578026-80-9 CAPLUS


CN [1,1'-Biphenyl]-4-carboxylic acid, 4'--[[[(ethoxyoxoacetyl)[[4-

(trifluoromethyl)phenyl)methyl]amino]methyl] - (9CI) (CA INDEX NAME)




RN 578026-81-0 CAPLUS

CN Acetic acid, [[4'-(octylamino)carbonyl][1,1'-biphenyl]-4-yl]methyl [[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-83-2 CAPLUS

CN Acetic acid, [[4-(4-bromophenyl)methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-85-4 CAPLUS

CN Acetic acid, oxo[[4-(1-tetradecynyl)phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-86-5 CAPLUS

CN Acetic acid, [[4-(1-dodecynyl)phenyl]methyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-88-7 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl]methyl][4-(trifluoromethyl)phenyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-90-1 CAPLUS

CN Acetic acid, [[4-[(dodecylamino)carbonyl]phenyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578026-96-7 CAPLUS

CN Acetic acid, oxo[[1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-03-9 CAPLUS

CN Acetic acid, [[1-[4-[(dodecylamino)carbonyl]phenyl]ethyl][4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-04-0 CAPLUS

CN Acetic acid, [[4-[[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-06-2 CAPLUS

CN Acetic acid, [[(3-chlorophenyl)methyl] [[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-09-5 CAPLUS

CN Acetic acid, [[cyclopentyl[4-(trifluoromethyl)phenyl]methyl] [[4-nitrophenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-10-8 CAPLUS

CN Acetic acid, [[(4-aminophenyl)methyl][cyclopentyl[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578027-11-9 CAPLUS


CN Acetic acid, [[cyclopentyl[4-(trifluoromethyl)phenyl]methyl][[4-[(1-oxotridecyl)amino]phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578027-17-5 CAPLUS


CN Acetic acid, oxo[[[4-(trifluoromethyl)phenyl]methyl][[4-(3-undecyl-1,2,4-

oxadiazol-5-yl)-1-naphthalenyl)methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-19-7 CAPLUS

CN Acetic acid, [[cyclopentyl[4-(trifluoromethyl)phenyl)methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-23-3 CAPLUS

CN Acetic acid, [[4-(4-dibenzofuranyl)phenyl][[4-(trifluoromethyl)phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-25-5 CAPLUS

CN Acetic acid, [[4-(octyloxy)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578027-29-9 CAPLUS


CN Acetic acid, [[2-(3-chlorophenyl)ethyl][[4-(1-decynyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578027-30-2 CAPLUS


CN Acetic acid, [[2-(3-chlorophenyl)ethyl][[4-(1Z)-1-decynyl]phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 578027-33-5 CAPLUS


CN Acetic acid, [[2-(3-chlorophenyl)ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578027-36-8 CAPLUS


CN Acetic acid, oxo[[[(1R)-1-[4-(trifluoromethyl)phenyl]ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 578027-38-0 CAPLUS


CN Acetic acid, oxo[[[4-(trifluoromethyl)phenyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 578027-43-7 CAPLUS


CN Acetic acid, oxo[[[(1S)-1-[4-(trifluoromethyl)phenyl]ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 578027-45-9 CAPLUS

CN Acetic acid, [[[(3-chlorophenyl)methyl][[4-(1-decynyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-47-1 CAPLUS

CN Acetic acid, [[2-(3-chlorophenyl)ethyl][[4-(1-octynyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-49-3 CAPLUS

CN Acetic acid, [[[4-(1-decynyl)phenyl]methyl][4-(trifluoromethyl)phenyl]amino]oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 578027-51-7 CAPLUS

CN Acetic acid, [[[4-(1-decynyl)phenyl]methyl][1-[4-(trifluoromethyl)phenyl]ethyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578027-54-0 CAPLUS


CN Acetic acid, [[1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl][4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578027-57-3 CAPLUS


CN Acetic acid, [[2-(3-chlorophenyl)ethyl][4-(3-octyl-1,2,4-oxadiazol-5-

yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-59-5 CAPLUS

CN Acetic acid, [[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578027-61-9 CAPLUS


CN Acetic acid, [[[4-(dodecyloxy)-1-naphthalenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



Print selected from 10-501,344.trn


RN 578027-63-1 CAPLUS

CN Acetic acid, [[[4-bromophenyl)methyl][[4-(1-octynyl)phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578027-67-5 CAPLUS


CN Acetic acid, [[[4-(1-decynyl)phenyl)methyl][1-methyl-1-[4-(trifluoromethyl)phenyl]ethyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578027-68-6 CAPLUS

CN Acetic acid, oxo[[[4-[[[4-(9Z)-1-oxo-9-tetradecenyl]amino]phenyl)methyl][[4-(trifluoromethyl)phenyl)methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 578027-69-7 CAPLUS


CN Acetic acid, [[[4-(1-decynyl)phenyl)methyl][[4-(trifluoromethyl)phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)

NAME)




RN 578027-76-6 CAPLUS

CN Acetic acid, oxo[[[4-(trifluoromethyl)phenyl]methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-77-7 CAPLUS

CN Acetic acid, [[(4-dodecylphenyl)methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-78-8 CAPLUS

CN Acetic acid, [[(4-[[[(2-butyl-3-benzofuranyl)methyl]amino]carbonyl]phenyl)methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-79-9 CAPLUS

CN Acetic acid, oxo[[[4-[[[4-(phenylmethoxy)benzoyl]amino]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-81-3 CAPLUS

CN Acetic acid, [[(3,5-dichlorophenyl)methyl][(4-nitrophenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-82-4 CAPLUS

CN Acetic acid, [[(4-aminophenyl)methyl][(3,5-dichlorophenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578027-83-5 CAPLUS


CN Acetic acid, [[(3,5-dichlorophenyl)methyl][(4-[(1-oxotridecyl)amino]phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578027-84-6 CAPLUS


CN Acetic acid, [[(4-octylphenyl)ethynyl]phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)

NAME)




RN 578027-91-5 CAPLUS

CN Acetic acid, oxo[[[4-(trifluoromethyl)phenyl)methyl][[4-(5-undecyl-1,2,4-oxadiazol-3-yl)phenyl)methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-92-6 CAPLUS

CN Acetic acid, [[[4-[[4-(heptyloxy)phenyl]ethynyl]phenyl)methyl][[4-(trifluoromethyl)phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-93-7 CAPLUS

CN Acetic acid, [[[4-[(4-butylphenyl)ethynyl]phenyl)methyl][[4-(trifluoromethyl)phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-96-0 CAPLUS

CN Acetic acid, [[4-[(4-hexylphenyl)ethynyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-97-1 CAPLUS

CN Acetic acid, oxo[[[4-[(4-(pentyloxy)phenyl)ethynyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578027-98-2 CAPLUS

CN Acetic acid, oxo[[[4-[(4-(propylphenyl)ethynyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-01-0 CAPLUS


CN Acetic acid, [[2-(3-chlorophenyl)ethyl][[4-(1-dodecynyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-02-1 CAPLUS
 CN Acetic acid, [[[4-(1-octynyl)phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-03-2 CAPLUS
 CN Acetic acid, [[[4-(11-hydroxy-1-undecynyl)phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578028-04-3 CAPLUS
 CN 10-Undecynoic acid, 11-[4-[[[(ethoxyoxoacetyl) [[4-(trifluoromethyl)phenyl]methyl]amino]methyl]phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 578028-05-4 CAPLUS
 CN Acetic acid, oxo[[[4-[[4-(phenylmethoxy)phenyl]ethynyl]phenyl]methyl] [[4-(trifluoromethyl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-06-5 CAPLUS

CN Acetic acid, [[[4-[2-(4-hexylphenyl)ethyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-08-7 CAPLUS

CN Acetic acid, [[[4-(1-dodecynyl)phenyl]methyl][4-(trifluoromethyl)phenyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578028-13-4 CAPLUS


CN Acetic acid, oxo[[[4-(trifluoromethyl)phenyl]methyl][[4-[2-(3-undecyl-1,2,4-oxadiazol-5-yl)ethyl]phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 578028-18-9 CAPLUS


CN Acetic acid, [[[4-[2-(3-octyl-1,2,4-oxadiazol-5-yl)ethyl]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)

NAME)




RN 578028-19-0 CAPLUS

CN Acetic acid, [[[4-[(4-octylbenzoyl)amino]phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-28-1 CAPLUS

CN Acetic acid, [[[3-bromo-5-benzofuranyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-29-2 CAPLUS

CN Acetic acid, [[[3-(1-decynyl)-5-benzofuranyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-30-5 CAPLUS

CN Acetic acid, [[[3-(1-dodecynyl)-5-benzofuranyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-31-6 CAPLUS

CN Acetic acid, oxo[[[3-[(4-propylphenyl)ethynyl]-5-benzofuranyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-33-8 CAPLUS

CN Acetic acid, [[[4-bromophenyl]methyl][[4-fluorophenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-34-9 CAPLUS

CN Acetic acid, [[[4-(1-dodecynyl)phenyl]methyl][[4-fluorophenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-35-0 CAPLUS

CN Acetic acid, [bis[[4-(1-octynyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-40-7 CAPLUS

CN Acetic acid, [[3-(1-dodecynyl)phenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-42-9 CAPLUS

CN Acetic acid, [[2-(2-fluorophenyl)ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-45-2 CAPLUS

CN Acetic acid, [[2-(2-fluorophenyl)ethyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-47-4 CAPLUS

CN Acetic acid, [[2-(2-fluorophenyl)ethyl][[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-49-6 CAPLUS

CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-51-0 CAPLUS

CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-53-2 CAPLUS

CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-55-4 CAPLUS

CN Acetic acid, [(2-[1,1'-biphenyl]-4-ylethyl)[[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-57-6 CAPLUS

CN Acetic acid, [(2-[1,1'-biphenyl]-4-ylethyl)[[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-59-8 CAPLUS

CN Acetic acid, [(2-[1,1'-biphenyl]-4-ylethyl)[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-61-2 CAPLUS

CN Acetic acid, oxo[(5,6,7,8-tetrahydro-1-naphthalenyl)[[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-63-4 CAPLUS

CN Acetic acid, oxo[(5,6,7,8-tetrahydro-1-naphthalenyl)[[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-65-6 CAPLUS

CN Acetic acid, [[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl] (5,6,7,8-tetrahydro-1-naphthalenyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-68-9 CAPLUS

CN Acetic acid, [[[1,1'-biphenyl]-3-ylmethyl] [[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-70-3 CAPLUS

CN Acetic acid, [[[1,1'-biphenyl]-3-ylmethyl] [[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-71-4 CAPLUS

CN Acetic acid, [[([1,1'-biphenyl]-3-ylmethyl)[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-79-2 CAPLUS

CN Acetic acid, oxo[[[2-(trifluoromethyl)phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-81-6 CAPLUS

CN Acetic acid, oxo[[[2-(trifluoromethyl)phenyl]methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-83-8 CAPLUS

CN Acetic acid, [[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl][[2-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-85-0 CAPLUS

CN Acetic acid, oxo[[[3-(trifluoromethyl)phenyl]methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-87-2 CAPLUS

CN Acetic acid, oxo[[[3-(trifluoromethyl)phenyl]methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-89-4 CAPLUS

CN Acetic acid, [[[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl][[3-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-91-8 CAPLUS

CN Acetic acid, [[[2-methoxyphenyl)methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-93-0 CAPLUS

CN Acetic acid, [[[2-methoxyphenyl)methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-95-2 CAPLUS

CN Acetic acid, [[[2-methoxyphenyl)methyl][[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578028-98-5 CAPLUS

CN Acetic acid, oxo[[[4-[(trifluoromethyl)sulfonyl]phenyl)methyl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl)methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-00-2 CAPLUS

CN Acetic acid, oxo[[[4-[(trifluoromethyl)sulfonyl]phenyl]methyl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-02-4 CAPLUS

CN Acetic acid, [[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl][[4-[(trifluoromethyl)sulfonyl]phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-04-6 CAPLUS

CN Acetic acid, [1,3-benzodioxol-5-yl][[4-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-06-8 CAPLUS

CN Acetic acid, [1,3-benzodioxol-5-yl][[3-(3-undecyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-08-0 CAPLUS

CN Acetic acid, [1,3-benzodioxol-5-yl][[4-(3-octyl-1,2,4-oxadiazol-5-yl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-12-6 CAPLUS

CN Acetic acid, [[[4-bromo-1-naphthalenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578029-13-7 CAPLUS


CN Acetic acid, [[[4-(1-dodecynyl)-1-naphthalenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



Me- (CH₂)₉-C≡C


RN 578029-14-8 CAPLUS

CN Acetic acid, [[[4-(1-decynyl)-1-naphthalenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-18-2 CAPLUS

CN Acetic acid, [[1-(3-chlorophenyl)-1-methylethyl][[4-[(4-hexylphenyl)ethynyl]phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-21-7 CAPLUS

CN Acetic acid, oxo[[[4-(trifluoromethyl)phenyl]methyl][[4-(4-undecyl-2-thiazolyl)phenyl]methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-23-9 CAPLUS

CN Acetic acid, [[1-(3-chlorophenyl)-1-methylethyl][[4-[(4-undecyl-2-thiazolyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-25-1 CAPLUS

CN Acetic acid, [[4-(1-dodecynyl)phenyl]methyl][2-(2-fluorophenyl)ethyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-27-3 CAPLUS

CN Acetic acid, [[4-(dodecyloxy)-1-naphthalenyl]methyl][2-(2-fluorophenyl)ethyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-29-5 CAPLUS

CN Acetic acid, [[2-(2-fluorophenyl)ethyl][4-(octyloxy)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-31-9 CAPLUS

CN Acetic acid, [[[4-(1-decynyl)phenyl]methyl][[2-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-33-1 CAPLUS

CN Acetic acid, [[[4-(1-dodecynyl)phenyl]methyl][[2-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-35-3 CAPLUS

CN Acetic acid, [[[4-(dodecyloxy)-1-naphthalenyl]methyl][[2-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-37-5 CAPLUS

CN Acetic acid, [[[4-(octyloxy)phenyl]methyl][2-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-39-7 CAPLUS

CN Acetic acid, [[[4-(1-decynyl)phenyl]methyl][2-(3,4-dichlorophenyl)ethyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 578029-41-1 CAPLUS

CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(1-dodecynyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 578029-43-3 CAPLUS


CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(dodecyloxy)-1-naphthalenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



Me- (CH₂)₁₁-O

RN 578029-45-5 CAPLUS

CN Acetic acid, [[2-(3,4-dichlorophenyl)ethyl][[4-(octyloxy)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




IT 578029-46-6, Ethyl [(2-bromobenzyl)[4-(trifluoromethyl)benzyl]amino] (oxo)acetate

RL: RCT (Reactant); RACT (Reactant or reagent)

(starting material; preparation of [(arylmethyl)amino] (oxo)acetic acids as PTP inhibitors for antidiabetics)



RN 578029-46-6 CAPLUS

CN Acetic acid, [[[2-bromophenyl]methyl][[4-(trifluoromethyl)phenyl]methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:336125 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 139:85287
 TITLE: A Short Synthesis and Biological Evaluation of Potent and Nontoxic Antimalarial Bridged Bicyclic β -Sulfonyl-Endoperoxides
 AUTHOR(S): Bachi, Mario D.; Korshin, Edward E.; Hoos, Roland; Szpilman, Alex M.; Ploypradith, Poonsakdi; Xie, Suji; Shapiro, Theresa A.; Posner, Gary H.
 CORPORATE SOURCE: Department of Organic Chemistry, Weizmann Institute of Science, Rehovot, 76100, Israel
 SOURCE: Journal of Medicinal Chemistry (2003), 46(12), 2516-2533
 CODEN: JMCMAR; ISSN: 0022-2623
 PUBLISHER: American Chemical Society
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 139:85287
 GI



AB The syntheses and in vitro antimalarial screening of 50 bridged, bicyclic endoperoxides I ($n = 0 - 2$; $R_1 = H, HO, MeCO_2, EtO_2CCO_2, PhCH_2O$, etc.; $R_2 = Ph, 4-FC_6H_4, MeO_2CCH_2$) and II ($n = 0, 2$; $R_1 = HO, MeCO_2$; $R_2 = Ph$; $R_3 = H, HO, PhCO_2$) are reported. In contrast to antimalarial trioxanes of the artemisinin family, but like yingzhaosu A and arteflene, the peroxide function of I and II is contained in a 2,3-dioxabicyclo[3.3.1]nonane system. Peroxides I and II ($n = 0$; $R_1 = OH$) are readily available through a multicomponent, sequential, free-radical reaction involving thiol-monoterpenes co-oxygenation. These sulfides are converted into the corresponding β -sulfinyl and β -sulfonyl peroxides by controlled S-oxidation and manipulation of the tert-hydroxyl group through acylation, alkylation, or dehydration followed by selective hydrogenation. Ten enantiopure β -sulfonyl peroxides I and II ($n = 2$) exhibit in vitro antimalarial activity comparable to that of artemisinin ($IC_{50} = 6-24$ nM against *Plasmodium falciparum* NF54). In vivo testing of a few selected peroxides against *Plasmodium berghei* N indicates that the antimalarial efficacies of β -sulfonyl peroxides I ($n = 2$; $R_1 = MeCO_2, PhCH_2O, 4-MeOC_6H_4CH_2O$; $R_2 = Ph$) are comparable to those of some of the best antimalarial drugs and are higher than artemisinin against chloroquine-resistant *Plasmodium yoelii* ssp. NS. In view of the nontoxicity of I ($n = 2$; $R_1 = MeCO_2, PhCH_2O$; $R_2 = Ph$) in mice, at high

dosing, these compds. are regarded as promising antimalarial drug candidates.

IT 208646-68-8P 208646-69-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of bridged bicyclic β -sulfonyl-endoperoxides as nontoxic antimalarial agents)

RN 208646-68-8 CAPLUS

CN Acetic acid, [bis(phenylmethyl)amino]oxo-, (1R,4R,5R,8R)-4,8-dimethyl-4-[(phenylsulfonyl)methyl]-2,3-dioxabicyclo[3.3.1]non-8-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208646-69-9 CAPLUS

CN Acetic acid, [bis(phenylmethyl)amino]oxo-, (1R,4S,5R,8R)-4,8-dimethyl-4-[(phenylsulfonyl)methyl]-2,3-dioxabicyclo[3.3.1]non-8-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 221293-39-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of bridged bicyclic β -sulfonyl-endoperoxides as nontoxic antimalarial agents)

RN 221293-39-6 CAPLUS


CN Acetic acid, [bis(phenylmethyl)amino]oxo-, (1R,5R,8R)-4,8-dimethyl-4-[(phenylthio)methyl]-2,3-dioxabicyclo[3.3.1]non-8-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 99 THERE ARE 99 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:689741 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 138:153101
 TITLE: Preparation of oxime oxalate amides and their use in free-radical mediated syntheses of lactams
 AUTHOR(S): Scanlan, Eoin M.; Walton, John C.
 CORPORATE SOURCE: School of Chemistry, University of St. Andrews, Fife, KY16 9ST, UK
 SOURCE: Chemical Communications (Cambridge, United Kingdom) (2002), (18), 2086-2087
 CODEN: CHCOFS; ISSN: 1359-7345
 PUBLISHER: Royal Society of Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 138:153101
 AB Photosensitized decomposition of oxime oxalate amides is a useful new route to carbamoyl radicals that may cyclize to afford β - or γ -lactams.
 IT 496864-32-5P
 RL: CPS (Chemical process); PEP (Physical, engineering or chemical process); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); PROC (Process); RACT (Reactant or reagent)
 (photochem. N-O bond cleavage/radical cyclization; preparation of oxime oxalate amides and photochem. N-O bond cleavage/decarboxylation to unsatd. aminoacyl radicals that cyclize to β - or γ -lactams)
 RN 496864-32-5 CAPLUS
 CN Acetamide, 2-oxo-N-(phenylmethyl)-2-[[[(phenylmethylene)amino]oxy]-N-(3-phenyl-2-propenyl)- (9CI) (CA INDEX NAME)





REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:502825 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 137:63237
 TITLE: Preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compounds as antidiabetic and antiobesity agents
 INVENTOR(S): Cheng, Peter T.; Devasthale, Pratik; Jeon, Yoon; Chen,

Sean; Zhang, Hao
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: U.S., 190 pp., Cont.-in-part of U.S. Ser. No. 664,598.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6414002	B1	20020702	US 2001-812960	20010320 <--
EP 1589006	A1	20051026	EP 2005-10760	20000919 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
US 2003069275	A1	20030410	US 2002-80965	20020222 <--
US 6919358	B2	20050719		
US 2003087935	A1	20030508	US 2002-81075	20020222 <--
US 6727271	B2	20040427		
US 2003096846	A1	20030522	US 2002-80981	20020222 <--
US 6653314	B2	20031125		
US 2004171644	A1	20040902	US 2003-655876	20030905 <--
US 7084162	B2	20060801		
US 2004147560	A1	20040729	US 2003-737210	20031216 <--
US 7053106	B2	20060530		
US 2005119311	A1	20050602	US 2004-964395	20041013 <--
US 7241780	B2	20070710		
US 2007015797	A1	20070118	US 2005-155965	20050822 <--
PRIORITY APPLN. INFO.:				
			US 1999-155400P	P 19990922 <--
			US 2000-664598	A2 20000918 <--
			EP 2000-965172	A3 20000919 <--
			US 2001-812960	A3 20010320 <--
			US 2002-80965	A3 20020222 <--
			US 2002-80981	A3 20020222 <--
			US 2002-81075	A3 20020222 <--
			US 2003-655876	A3 20030905 <--

OTHER SOURCE(S): MARPAT 137:63237
 GI



AB Title compds. I [wherein Q = C, N; A = O, S; B = (CH₂)_x; Z = O, bond; X = CH, N; R₁ = H, alkyl; R₂ = H, alkyl, alkoxy, halo, amino; R₃ = H, alkyl, aralkyl, aryloxy, carbonyl, alkoxy, carbonyl, aryl, carbonyl, aryl, heteroaryl, hydroxyalkyl, aryloxyarylalkyl, etc.; R_{2a}, R_{2b}, R_{2c} = H, alkyl, alkoxy, halo, amino; Y = CO₂R₄, 1-tetrazolyl, PO(OR_{4a})R₅; R₄ = H, alkyl, prodrug or ester; R_{4a} = H, prodrug ester; R₅ = alkyl, aryl; x = 1-4; m, n = 1, 2] were prepared as modulators of blood glucose levels, triglyceride levels, insulin levels, and non-esterified fatty acid levels (no data). For example, 4-hydroxybenzaldehyde, 5-methyl-2-phenyloxazole-4-ethanol, Ph₃P, and DEAD were stirred in THF at 0°-room temperature to give 4-(5-methyl-2-phenyloxazole-4-ethyl)benzaldehyde (65%). Addition of N-benzylglycine Et ester and NaBH(OAc)₃ in 1,2-dichloroethane afforded the benzylamine derivative (55%), which was stirred with aqueous NaOH in MeOH for


14 h to give the title compound II (71%). I are useful for the treatment of diabetes, especially Type II diabetes, as well as hyperglycemia, hyperinsulinemia, hyperlipidemia, obesity, atherosclerosis, and related diseases (no data).

IT 331740-97-7P, Acetic acid, (2,2-dimethylpropoxy) [[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl] [(4-phenoxyphenyl)methyl]amino]-, (2R)-
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

RN 331740-97-7 CAPLUS

CN Acetic acid, (2,2-dimethylpropoxy) [[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl] [(4-phenoxyphenyl)methyl]amino]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:221217 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 136:247349
 TITLE: Preparation of amino(oxo)acetic acid derivatives as protein tyrosine phosphatase inhibitors
 INVENTOR(S): Liu, Gang; Li, Yihong; Janowick, David A.; Pei, Zhonghua

PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 28 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002035136	A1	20020321	US 2001-934765	20010822 <--
US 6627767	B2	20030930		
PRIORITY APPLN. INFO.:			US 2000-228656P	P 20000829 <--
OTHER SOURCE(S):	MARPAT	136:247349		

GI




AB The title compds. I [A = NH, O, S, N:CH, CH:CH; B = N, CH; d = 0-2; L1 = bond, O; L2 = CHR6, CH2CHR6; R1 = H, carboxy protecting group; R2 = H, aminoalkyl, alkyl, cycloalkyl, etc.; R3 = H, alkoxy, alkoxyalkenyl, carboxy, etc.; R4 = H, alkoxy, aryl, heteroaryl, etc.], protein tyrosine kinase PTP1B inhibitors, were prepared. E.g., N-benzyl-2-hydroxy-N-((4,1'-binaphth-1-yl)methyl)amino(oxo)acetic acid was prepared I may be used for treatment of type II diabetes or obesity.

IT 402935-24-4P 402935-27-7P 402935-28-8P
 402935-29-9P 402935-32-4P 402935-33-5P
 402935-35-7P 402935-38-0P 402935-41-5P
 402935-42-6P 402935-43-7P 402935-45-9P
 402935-46-0P 402935-48-2P 402935-49-3P
 402935-52-8P 402935-54-0P 402935-55-1P
 402935-56-2P 402935-57-3P 402935-60-8P
 402935-61-9P 402935-62-0P 402935-63-1P
 402935-65-3P 402935-66-4P 402935-67-5P
 402935-68-6P 402935-83-5P 402935-84-6P
 402935-85-7P 402935-86-8P 402935-87-9P
 402935-88-0P 402935-91-5P 402935-92-6P
 402935-94-8P 402935-95-9P 404578-71-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of amino(oxo)acetic acid derivs. as protein tyrosine phosphatase inhibitors)

RN 402935-24-4 CAPLUS
 CN Acetic acid, [[2-(4-bromophenyl)-2-cyclohexylethyl](phenylmethyl)amino]oxo-
 (9CI) (CA INDEX NAME)




RN 402935-27-7 CAPLUS

CN Acetic acid, [[[2,3-dichloro-4-(1-naphthalenyl)phenyl]methyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-28-8 CAPLUS

CN Acetic acid, [[[1,1'-binaphthalen]-4-ylmethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-29-9 CAPLUS


CN Acetic acid, [[[2-chloro-4-(1-naphthalenyl)phenyl]methyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-32-4 CAPLUS
 CN Acetic acid, oxo[(phenylmethyl)[[4-(2-quinolinylmethoxy)phenyl]methyl]amino] - (9CI) (CA INDEX NAME)



RN 402935-33-5 CAPLUS
 CN Acetic acid, oxo[(2-phenylethyl)[[4-(2-quinolinylmethoxy)phenyl]methyl]amino] - (9CI) (CA INDEX NAME)




RN 402935-35-7 CAPLUS
 CN Acetic acid, [[[2-methoxy-4-(1-naphthalenyl)phenyl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-38-0 CAPLUS

CN Acetic acid, [[2-cyclohexyl-2-[4-(1-naphthalenyl)phenyl]ethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-41-5 CAPLUS

CN Acetic acid, [[[2-(carboxymethoxy)-4-(1-naphthalenyl)phenyl]methyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-42-6 CAPLUS


CN Acetic acid, [[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-4-(1-naphthalenyl)phenyl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 402935-43-7 CAPLUS
CN Benzoic acid, 3-[[[2-[[[(carboxycarbonyl)(phenylmethyl)amino]methyl]-5-(1-naphthalenyl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 402935-45-9 CAPLUS
CN Acetic acid, [[[4-(1-naphthalenyl)-2-[2-oxo-2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]ethoxy]phenyl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-46-0 CAPLUS

CN 2-Furancarboxylic acid, 5-[[2-[[[(carboxycarbonyl)(phenylmethyl)amino]methyl]-5-(1-naphthalenyl)phenoxy]methyl]- (CA INDEX NAME)




RN 402935-48-2 CAPLUS

CN Acetic acid, [[[2-methoxy-4-(1-naphthalenyl)phenyl]methyl] (2-phenylethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-49-3 CAPLUS


CN Acetic acid, [[[2,3-dichloro-4-(1-naphthalenyl)phenyl]methyl] (2-phenylethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 402935-52-8 CAPLUS
 CN Acetic acid, [[[5-(1-naphthalenyl)[1,1'-biphenyl]-2-yl)methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 402935-54-0 CAPLUS
 CN Acetic acid, [[[4'-(phenylmethyl)-5-(1-naphthalenyl)[1,1'-biphenyl]-2-yl)methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-55-1 CAPLUS
 CN 2-Propenoic acid, 3-[2-[[[(carboxycarbonyl)(phenylmethyl)amino]methyl]-5-(1-

Print selected from 10-501,344.trn

naphthalenyl)phenyl]-, 1-(1,1-dimethylethyl) ester, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 402935-56-2 CAPLUS

CN 2-Propenoic acid, 3-[2-[[[(carboxycarbonyl)(phenylmethyl)amino]methyl]-5-(1-naphthalenyl)phenyl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 402935-57-3 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-[[[(carboxycarbonyl)(phenylmethyl)amino]-1-cyclohexylethyl]phenyl]-, 1-(1,1-dimethylethyl) ester, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 402935-60-8 CAPLUS

CN Acetic acid, [[[4-(1-naphthalenyl)-2-[(1E)-3-oxo-3-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-1-propenyl]phenyl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 402935-61-9 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-[(carboxycarbonyl)(phenylmethyl)amino]-1-cyclohexylethyl]phenyl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 402935-62-0 CAPLUS


CN Acetic acid, [[2-cyclohexyl-2-[4-[(1E)-3-[(2'-hydroxy[1,1':3',1''-terphenyl]-5'-yl)amino]-3-oxo-1-propenyl]phenyl]ethyl] (phenylmethyl)amino] oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 402935-63-1 CAPLUS


CN Acetic acid, [[2-cyclohexyl-2-[4-[3-[(2'-hydroxy[1,1':3',1''-terphenyl]-5'-yl)amino]-3-oxopropyl]phenyl]ethyl] (phenylmethyl)amino] oxo- (9CI) (CA INDEX NAME)




RN 402935-65-3 CAPLUS
 CN Acetic acid, [[2-cyclohexyl-2-[1,1':3',1''-terphenyl]-4-ylethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 402935-66-4 CAPLUS
 CN Acetic acid, [[2-cyclohexyl-2-[4-(2-dibenzofuranyl)phenyl]ethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-67-5 CAPLUS
 CN Acetic acid, [[2-cyclohexyl-2-[4-(8-quinolinyl)phenyl]ethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 402935-68-6 CAPLUS


CN Acetic acid, [[2-cyclohexyl-2-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]ethyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 402935-83-5 CAPLUS

CN Acetic acid, [[2-[4-[(1E)-3-([1,1'-biphenyl]-4-ylamino)-3-oxo-1-propenyl]phenyl]-2-cyclohexylethyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 402935-84-6 CAPLUS

CN Acetic acid, [[2-[4-[(1E)-3-[[3,5-bis(1,1-dimethylethyl)phenyl]amino]-3-oxo-1-propenyl]phenyl]-2-cyclohexylethyl](phenylmethyl)amino]oxo- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 402935-85-7 CAPLUS

CN Acetic acid, [[2-cyclohexyl-2-[4-[(1E)-3-oxo-3-[(4-phenoxyphenyl)amino]-1-propenyl]phenyl]ethyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 402935-86-8 CAPLUS

CN Acetic acid, [[2-cyclohexyl-2-[4-[(1E)-3-[4-(2,3-dimethylphenyl)-1-piperazinyl]-3-oxo-1-propenyl]phenyl]ethyl](phenylmethyl)amino]oxo- (9CI)

(CA INDEX NAME)


Double bond geometry as shown.



RN 402935-87-9 CAPLUS


CN Acetic acid, [[2-cyclohexyl-2-[4-[(1E)-3-[4-(diphenylmethyl)-1-piperazinyl]-3-oxo-1-propenyl]phenyl]ethyl] (phenylmethyl)amino]oxo- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 402935-88-0 CAPLUS


CN Acetic acid, [[(1,1'-binaphthalen)-4-ylmethyl] (2-phenylethyl)amino]oxo- (9CI)
(CA INDEX NAME)



RN 402935-91-5 CAPLUS
 CN Acetic acid, [[[4-(decyloxy)-1-naphthalenyl]methyl](2-phenylethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-92-6 CAPLUS
 CN Acetic acid, [[[4-(octadecyloxy)-1-naphthalenyl]methyl](2-phenylethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-94-8 CAPLUS
 CN Acetic acid, [[[4-(butoxy)-1-naphthalenyl]methyl](2-phenylethyl)amino]oxo-

(9CI) (CA INDEX NAME)



RN 402935-95-9 CAPLUS


CN Acetic acid, oxo[(2-phenylethyl)[[4-(tetradecyloxy)-1-naphthalenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 404578-71-8 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[2-[(carboxycarbonyl)(phenylmethyl)amino]methyl]-5-(1-naphthalenyl)phenoxy]acetyl]amino]methyl]-, 1-methyl ester, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.





IT 402936-05-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of amino(oxo)acetic acid derivs. as protein tyrosine
 phosphatase inhibitors)
 RN 402936-05-4 CAPLUS
 CN Acetic acid, [[[2,3-dichloro-4-(1-naphthalenyl)phenyl]methyl] (phenylmethyl
)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:171839 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 136:232060
 TITLE: Preparation of amino(oxo)acetic acid protein tyrosine
 phosphatase inhibitors
 INVENTOR(S): Liu, Gang; Li, Yihong; Janowick, David A.; Pei,
 Zhonghua
 PATENT ASSIGNEE(S): Abbott Laboratories, USA
 SOURCE: PCT Int. Appl., 61 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002018321	A2	20020307	WO 2001-US26133	20010821 <--
WO 2002018321	A3	20030410		
W: CA, JP, MX				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
PRIORITY APPLN. INFO.:			US 2000-650923	A 20000829 <--
OTHER SOURCE(S):			MARPAT 136:232060	
GI				




AB Title compds. I [A = N(H), O, S, N=C(H), C(H)=C(H), etc.; B = N, C(H); with the proviso that when A is N=C(H) or C(H)=C(H), B is C(H); p = 0-2; L¹ = bond, O; L² = CHR₆, CH₂CHR₆; R¹ = H, carboxy protecting group; R² = H, aminoalkyl, cycloalkyl(alkyl), cycloalkenyl(alkyl), (hetero)aryl, heterocycle, etc.; R³ = H, alkoxy, alkoxyalk(en)yl, alkoxyalkoxy, alkoxycarbonyl, alkoxycarbonylalkyl, alkoxycarbonylalkenyl, alkoxycarbonylalkoxy, aryl, arylalkyl, arylalkenyl, arylalkoxy, carboxamido, carboxamidoalkyl, etc.; R⁴ = H, alkoxy, loweralkoxy, alkoxycarbonylalkyl, alkoxycarbonylalkenyl, aryl, arylalkyl, arylalkoxy, arylthioxyalkyl, carboxamidoalkenyl, carboxamidoalkyl, carboxyalkyl, carboxylalkenyl, heteroaryl, etc.; with the proviso that at when R⁴ = H, at least one of R³ is other than H; R⁶ = H, aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, etc.] were prepared Over 70 synthetic examples were provided. For instance, 4-bromophenylacetonitrile was alkylated with cyclohexyl bromide (DMF/benzene, NaH, 0°C) to give (4-bromophenyl)(cyclohexyl)acetonitrile which was subsequently reduced to the amine (PhMe, DIBAL-H → BH₃•THF), the amine acylated with Et oxalyl chloride (CH₂Cl₂, 0°C) and saponified to give II. Example compds. were found to inhibit protein tyrosine phosphatase PTP1B with inhibitory potencies in a range of about 3 μM to about 100

μM. I are used for the treatment of type II diabetes and obesity.
 IT 402935-24-4P, [Benzyl[2-(4-bromophenyl)-2-cyclohexylethyl]amino](oxo)acetic acid 402935-27-7P,
 [Benzyl[2,3-dichloro-4-(1-naphthyl)benzyl]amino](oxo)acetic acid
 402935-28-8P 402935-29-9P 402935-32-4P,
 [Benzyl[4-(2-quinolinylmethoxy)benzyl]amino](oxo)acetic acid
 402935-33-5P, Oxo[(2-phenylethyl)[4-(2-quinolinylmethoxy)benzyl]amino]acetic acid 402935-35-7P,
 [Benzyl[2-methoxy-4-(1-naphthyl)benzyl]amino](oxo)acetic acid
 402935-38-0P, [Benzyl[2-cyclohexyl-2-[4-(1-naphthyl)phenyl]ethyl]amino](oxo)acetic acid 402935-41-5P,
 [Benzyl[2-(carboxymethoxy)-4-(1-naphthyl)benzyl]amino](oxo)acetic acid
 402935-42-6P, [Benzyl[2-(2-tert-butoxy-2-oxoethoxy)-4-(1-naphthyl)benzyl]amino](oxo)acetic acid 402935-43-7P,
 3-[[[2-[[Benzyl(carboxycarbonyl)amino]methyl]-5-(1-naphthyl)phenoxy]acetyl]amino]benzoic acid 402935-44-8P,
 [Benzyl[2-[2-[[4-(methoxycarbonyl)cyclohexyl]methyl]amino]-2-oxoethoxy]-4-(1-naphthyl)benzyl]amino](oxo)acetic acid 402935-45-9P,
 [Benzyl[4-(1-naphthyl)-2-[2-oxo-2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]ethoxy]benzyl]amino](oxo)acetic acid
 402935-46-0P, 5-[[2-[[Benzyl(carboxycarbonyl)amino]methyl]-5-(1-naphthyl)phenoxy]methyl]-2-furoic acid 402935-48-2P,
 [[2-Methoxy-4-(1-naphthyl)benzyl](2-phenylethyl)amino](oxo)acetic acid
 402935-49-3P, [[2,3-Dichloro-4-(1-naphthyl)benzyl](2-phenylethyl)amino](oxo)acetic acid 402935-52-8P
 402935-54-0P 402935-55-1P, [Benzyl[2-((1E)-3-tert-butoxy-3-oxo-1-propenyl)-4-(1-naphthyl)benzyl]amino](oxo)acetic acid
 402935-56-2P, (2E)-3-[2-[[Benzyl(carboxycarbonyl)amino]methyl]-5-(1-naphthyl)phenyl]-2-propenoic acid 402935-57-3P,
 [Benzyl[2-[4-((1E)-3-tert-butoxy-3-oxo-1-propenyl)phenyl]-2-cyclohexylethyl]amino](oxo)acetic acid 402935-60-8P
 402935-61-9P, (2E)-3-[4-[2-[[Benzyl(carboxycarbonyl)amino]-1-cyclohexylethyl]phenyl]-2-propenoic acid 402935-62-0P,
 [Benzyl[2-cyclohexyl-2-[4-((1E)-3-(4-hydroxy-3,5-diphenylanilino)-3-oxo-1-propenyl)phenyl]ethyl]amino](oxo)acetic acid 402935-63-1P,
 [Benzyl[2-cyclohexyl-2-[4-[3-(4-hydroxy-3,5-diphenylanilino)-3-oxopropyl]phenyl]ethyl]amino](oxo)acetic acid 402935-65-3P,
 [Benzyl[2-cyclohexyl-2-(3'-phenyl[1,1'-biphenyl]-4-yl)ethyl]amino](oxo)acetic acid 402935-66-4P,
 [Benzyl[2-cyclohexyl-2-(4-(dibenzofuran-2-yl)phenyl)ethyl]amino](oxo)acetic acid 402935-67-5P, [Benzyl[2-cyclohexyl-2-[4-(8-quinolinyl)phenyl]ethyl]amino](oxo)acetic acid 402935-68-6P,
 [Benzyl[2-cyclohexyl-2-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]ethyl]amino](oxo)acetic acid 402935-83-5P
 402935-84-6P, [Benzyl[2-cyclohexyl-2-[4-((1E)-3-(3,5-di-tert-butylanilino)-3-oxo-1-propenyl)phenyl]ethyl]amino](oxo)acetic acid
 402935-85-7P, [Benzyl[2-cyclohexyl-2-[4-((1E)-3-oxo-3-(4-phenoxyanilino)-1-propenyl)phenyl]ethyl]amino](oxo)acetic acid
 402935-86-8P, [Benzyl[2-cyclohexyl-2-[4-((1E)-3-[4-(2,3-dimethylphenyl)-1-piperazinyl]-3-oxo-1-propenyl)phenyl]ethyl]amino](oxo)acetic acid 402935-87-9P, [[2-[4-((1E)-3-(4-Benzhydryl-1-piperazinyl)-3-oxo-1-propenyl)phenyl]-2-cyclohexylethyl](benzyl)amino](oxo)acetic acid 402935-88-0P, Oxo[(2-phenylethyl)[(4,1'-binaphth-1-yl)methyl]amino]acetic acid 402935-91-5P, [[4-(Decyloxy)-1-naphthyl]methyl](2-phenylethyl)amino](oxo)acetic acid 402935-92-6P
 , [[4-(Octadecyloxy)-1-naphthyl]methyl](2-phenylethyl)amino](oxo)acetic acid 402935-94-8P, [[4-Butoxy-1-naphthyl]methyl](2-phenylethyl)amino](oxo)acetic acid 402935-95-9P,
 Oxo[(2-phenylethyl)[4-(tetradecyloxy)-1-naphthyl]methyl]amino]acetic acid

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; preparation of amino(oxo)acetic acid protein tyrosine phosphatase inhibitors)


RN 402935-24-4 CAPLUS

CN Acetic acid, [[2-(4-bromophenyl)-2-cyclohexylethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-27-7 CAPLUS

CN Acetic acid, [[[2,3-dichloro-4-(1-naphthalenyl)phenyl]methyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-28-8 CAPLUS

CN Acetic acid, [([1,1'-binaphthalen]-4-ylmethyl) (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-29-9 CAPLUS

CN Acetic acid, [[[2-chloro-4-(1-naphthalenyl)phenyl]methyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-32-4 CAPLUS

CN Acetic acid, oxo[(phenylmethyl)[[4-(2-quinolinylmethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 402935-33-5 CAPLUS

CN Acetic acid, oxo[(2-phenylethyl)[[4-(2-quinolinylmethoxy)phenyl]methyl]amino]- (9CI) (CA INDEX NAME)




RN 402935-35-7 CAPLUS


CN Acetic acid, [[[2-methoxy-4-(1-naphthalenyl)phenyl]methyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 402935-38-0 CAPLUS
 CN Acetic acid, [[2-cyclohexyl-2-[4-(1-naphthalenyl)phenyl]ethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-41-5 CAPLUS
 CN Acetic acid, [[[2-(carboxymethoxy)-4-(1-naphthalenyl)phenyl]methyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-42-6 CAPLUS

CN Acetic acid, [[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-4-(1-naphthalenyl)phenyl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-43-7 CAPLUS

CN Benzoic acid, 3-[[[2-[[[(carboxycarbonyl)(phenylmethyl)amino]methyl]-5-(1-naphthalenyl)phenoxy]acetyl]amino]- (9CI) (CA INDEX NAME)




RN 402935-44-8 CAPLUS

CN Cyclohexanecarboxylic acid, 4-[[[2-[[[(carboxycarbonyl)(phenylmethyl)amino]methyl]-5-(1-naphthalenyl)phenoxy]acetyl]amino]methyl]-, 1-methyl ester (9CI) (CA INDEX NAME)




RN 402935-45-9 CAPLUS

CN Acetic acid, [[[4-(1-naphthalenyl)-2-[2-oxo-2-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]ethoxy]phenyl]methyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-46-0 CAPLUS

CN 2-Furancarboxylic acid, 5-[[2-[[[(carboxycarbonyl) (phenylmethyl)amino]methyl]-5-(1-naphthalenyl)phenoxy]methyl]- (CA INDEX NAME)




RN 402935-48-2 CAPLUS

CN Acetic acid, [[[2-methoxy-4-(1-naphthalenyl)phenyl]methyl] (2-phenylethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-49-3 CAPLUS

CN Acetic acid, [[[2,3-dichloro-4-(1-naphthalenyl)phenyl]methyl](2-phenylethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 402935-52-8 CAPLUS


CN Acetic acid, [[[5-(1-naphthalenyl)[1,1'-biphenyl]-2-yl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)



Print selected from 10-501,344.trn

RN 402935-54-0 CAPLUS


CN Acetic acid, [[[4'-formyl-5-(1-naphthalenyl)[1,1'-biphenyl]-2-yl)methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 402935-55-1 CAPLUS

CN 2-Propenoic acid, 3-[2-[[[(carboxycarbonyl)(phenylmethyl)amino]methyl]-5-(1-naphthalenyl)phenyl]-, 1-(1,1-dimethylethyl) ester, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 402935-56-2 CAPLUS


CN 2-Propenoic acid, 3-[2-[[[(carboxycarbonyl)(phenylmethyl)amino]methyl]-5-(1-naphthalenyl)phenyl]-, (2E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 402935-57-3 CAPLUS
 CN 2-Propenoic acid, 3-[4-[2-[(carboxycarbonyl)(phenylmethyl)amino]-1-cyclohexylethyl]phenyl]-, 1-(1,1-dimethylethyl) ester, (2E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 402935-60-8 CAPLUS
 CN Acetic acid, [[[4-(1-naphthalenyl)-2-[(1E)-3-oxo-3-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-1-propenyl]phenyl]methyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 402935-61-9 CAPLUS

CN 2-Propenoic acid, 3-[4-[2-[(carboxycarbonyl)(phenylmethyl)amino]-1-cyclohexylethyl]phenyl]-, (2E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 402935-62-0 CAPLUS


CN Acetic acid, [[2-cyclohexyl-2-[4-[(1E)-3-[(2'-hydroxy[1,1':3',1''-terphenyl]-5'-yl)amino]-3-oxo-1-propenyl]phenyl]ethyl](phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 402935-63-1 CAPLUS

CN Acetic acid, [[2-cyclohexyl-2-[4-[3-[(2'-hydroxy[1,1':3',1''-terphenyl]-5'-yl)amino]-3-oxopropyl]phenyl]ethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-65-3 CAPLUS

CN Acetic acid, [[2-cyclohexyl-2-[1,1':3',1''-terphenyl]-4-ylethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-66-4 CAPLUS

CN Acetic acid, [[2-cyclohexyl-2-[4-(2-dibenzofuranyl)phenyl]ethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-67-5 CAPLUS

CN Acetic acid, [[2-cyclohexyl-2-[4-(8-quinoliny)phenyl]ethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 402935-68-6 CAPLUS

CN Acetic acid, [[2-cyclohexyl-2-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]ethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-83-5 CAPLUS

CN Acetic acid, [[2-[4-[(1E)-3-([1,1'-biphenyl]-4-ylamino)-3-oxo-1-

Print selected from 10-501,344.trn

propenyl]phenyl]-2-cyclohexylethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 402935-84-6 CAPLUS

CN Acetic acid, [[2-[4-[(1E)-3-[[3,5-bis(1,1-dimethylethyl)phenyl]amino]-3-oxo-1-propenyl]phenyl]-2-cyclohexylethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 402935-85-7 CAPLUS

CN Acetic acid, [[2-cyclohexyl-2-[4-[(1E)-3-oxo-3-[(4-phenoxyphenyl)amino]-1-propenyl]phenyl]ethyl] (phenylmethyl)amino]oxo- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 402935-86-8 CAPLUS

CN Acetic acid, [[2-cyclohexyl-2-[4-[(1E)-3-[4-(2,3-dimethylphenyl)-1-piperazinyl]-3-oxo-1-propenyl]phenyl]ethyl](phenylmethyl)amino]oxo- (9CI)
(CA INDEX NAME)


Double bond geometry as shown.



RN 402935-87-9 CAPLUS


CN Acetic acid, [[2-cyclohexyl-2-[4-[(1E)-3-[4-(diphenylmethyl)-1-piperazinyl]-3-oxo-1-propenyl]phenyl]ethyl](phenylmethyl)amino]oxo- (9CI)
(CA INDEX NAME)

Double bond geometry as shown.




RN 402935-88-0 CAPLUS

CN Acetic acid, [[(1,1'-binaphthalen)-4-ylmethyl] (2-phenylethyl) amino] oxo- (9CI) (CA INDEX NAME)



RN 402935-91-5 CAPLUS


CN Acetic acid, [[4-(decyloxy)-1-naphthalenyl]methyl] (2-phenylethyl) amino] oxo- (9CI) (CA INDEX NAME)



RN 402935-92-6 CAPLUS


Print selected from 10-501,344.trn

CN Acetic acid, [[[4-(octadecyloxy)-1-naphthalenyl]methyl](2-phenylethyl)amino]oxo- (9CI) (CA INDEX NAME)




RN 402935-94-8 CAPLUS

CN Acetic acid, [[[4-butoxy-1-naphthalenyl]methyl](2-phenylethyl)amino]oxo- (9CI) (CA INDEX NAME)



RN 402935-95-9 CAPLUS

CN Acetic acid, oxo[[[4-(tetradecyloxy)-1-naphthalenyl]methyl]amino]-(2-phenylethyl)- (9CI) (CA INDEX NAME)




IT 402936-05-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(intermediate; preparation of amino(oxo)acetic acid protein tyrosine
phosphatase inhibitors)

RN 402936-05-4 CAPLUS

CN Acetic acid, [[[2,3-dichloro-4-(1-naphthalenyl)phenyl]methyl] (phenylmethyl
)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




IT 402936-06-5, Ethyl [benzyl[2-cyclohexyl-2-[4-(1-naphthyl)phenyl]ethyl]amino] (oxo)acetate 402936-07-6
402936-08-7 402936-11-2 402936-12-3
402936-14-5

RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of amino(oxo)acetic acid protein tyrosine phosphatase
inhibitors)


RN 402936-06-5 CAPLUS

CN Acetic acid, [[2-cyclohexyl-2-[4-(1-naphthalenyl)phenyl]ethyl] (phenylmethyl)
amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 402936-07-6 CAPLUS

CN Acetic acid, [[[2-[2-(1,1-dimethylethoxy)-2-oxoethoxy]-4-(1-naphthalenyl)phenyl]methyl] (phenylmethyl)amino]oxo-, ethyl ester (9CI)
(CA INDEX NAME)



RN 402936-08-7 CAPLUS


CN Benzoic acid, 3-[[[2-[[[(ethoxyoxoacetyl)(phenylmethyl)amino]methyl]-5-(1-naphthalenyl)phenoxy]acetyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 402936-11-2 CAPLUS

CN 2-Propenoic acid, 3-[2-[[[(ethoxyoxoacetyl)(phenylmethyl)amino]methyl]-5-(1-naphthalenyl)phenyl]-, 1,1-dimethylethyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 402936-12-3 CAPLUS

CN 2-Propenoic acid, 3-[4-[1-cyclohexyl-2-[(ethoxyoxoacetyl)(phenylmethyl)amino]ethyl]phenyl]-, 1,1-dimethylethyl ester, (2E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 402936-14-5 CAPLUS

CN Acetic acid, [[[4-(1-naphthalenyl)-2-[(1E)-3-oxo-3-[[3-(2-oxo-1-pyrrolidinyl)propyl]amino]-1-propenyl]phenyl]methyl](phenylmethyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.





L5 ANSWER 8 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:228872 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 134:266299
 TITLE: Preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compounds as antidiabetic and antiobesity agents.
 INVENTOR(S): Cheng, Peter T. W.; Devasthale, Pratik; Jeon, Yoon T.; Chen, Sean; Zhang, Hao
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
 SOURCE: PCT Int. Appl., 362 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001021602	A1	20010329	WO 2000-US25710	20000919 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
TW 260321	B	20060821	TW 2000-89119155	20000918 <--
CA 2388452	A1	20010329	CA 2000-2388452	20000919 <--
CA 2388452	C	20070403		
EP 1218361	A1	20020703	EP 2000-965172	20000919 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
BR 2000014189	A	20020820	BR 2000-14189	20000919 <--
TR 200200732	T2	20021021	TR 2002-732	20000919 <--
JP 2003509503	T	20030311	JP 2001-524981	20000919 <--
HU 2002004416	A2	20030428	HU 2002-4416	20000919 <--
NZ 516820	A	20041126	NZ 2000-516820	20000919 <--

AU 782031	B2	20050630	AU 2000-75935	20000919 <--
EP 1589006	A1	20051026	EP 2005-10760	20000919 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
RU 2279427	C2	20060710	RU 2002-108928	20000919 <--
IN 2002DN00107	A	20070406	IN 2002-DN107	20020128 <--
ZA 2002000937	A	20030502	ZA 2002-937	20020201 <--
MX 2002PA01847	A	20021023	MX 2002-PA1847	20020221 <--
NO 2002001408	A	20020514	NO 2002-1408	20020321 <--
NO 322500	B1	20061016		
HK 1049337	A1	20070729	HK 2003-101528	20030228 <--
PRIORITY APPLN. INFO.:			US 1999-155400P	P 19990922 <--
			EP 2000-965172	A3 20000919 <--
			WO 2000-US25710	W 20000919 <--

OTHER SOURCE(S): MARPAT 134:266299
GI



AB Title compds. [I; Q = C, N; A = O, S; B = (CH₂)_x; Z = O, bond; X = CH, N; R₁ = H, alkyl; R₂ = H, alkyl, alkoxy, halo, amino; R₃ = H, alkyl, aralkyl, aryloxycarbonyl, alkoxy, carbonyl, aryl, heteroaryl, hydroxyalkyl, aryloxyarylalkyl, etc.; R_{2a}, R_{2b}, R_{2c} = H, alkyl, alkoxy, halo, amino; Y = CO₂R₄, 1-tetrazolyl, PO(OR_{4a})R₅; R₄ = H, alkyl, prodrug or ester; R_{4a} = H, prodrug ester; R₅ = alkyl, aryl; x = 1-4; m, n = 1, 2], were prepared as modulators of blood glucose levels, triglyceride levels, insulin levels, and non-esterified fatty acid levels (no data). Thus, 4-hydroxybenzaldehyde, 5-methyl-2-phenyloxazole-4-ethanol, Ph₃P, and DEAD were stirred in THF at 0°-room temperature to give 65% 4-(5-methyl-2-phenyloxazole-4-ethyl)benzaldehyde. This was stirred 12 h with N-benzylglycine Et ester and NaBH(OAc)₃ in 1,2-dichloroethane to give 55% benzylamine derivative, which was stirred 14 h with aqueous NaOH in MeOH to give 71% title compound (II).

IT 331740-97-7P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of oxazolyl- and thiazolylalkoxybenzylglycines and related compds. as antidiabetic and antiobesity agents)

Print selected from 10-501,344.trn

RN 331740-97-7 CAPLUS

CN Acetic acid, (2,2-dimethylpropoxy) [[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl] [(4-phenoxyphenyl)methyl]amino]-, (2R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:458501 CAPLUS <<LOGINID::20080103>>

DOCUMENT NUMBER: 133:237826

TITLE: 1,3-Disubstituted-2-carboxyquinolones: highly potent and selective endothelin A receptor antagonists

AUTHOR(S): Haesslein, Jean-Luc; Baholet, Isabelle; Fortin, Michel; Iltis, Alain; Khider, Jean; Periers, Anne Marie; Pierre, Christine; Vever, Jean-Paul

CORPORATE SOURCE: Medicinal Chemistry, Hoechst Marion Roussel, Romainville, 93235, Fr.

SOURCE: Bioorganic & Medicinal Chemistry Letters (2000), 10(13), 1487-1490

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The design, synthesis, and in vitro biol. activity of 2-carboxyquinolone antagonists selective for the endothelin A receptor are presented. Introduction of a 2nd acid group in position 3 of the quinolone ring increases dramatically the selectivity for ETA.


IT 292859-74-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of endothelin A receptor antagonist quinolonecarboxylates)

RN 292859-74-6 CAPLUS

CN Acetic acid, [(1,3-benzodioxol-5-ylmethyl) [2-[3-(4-methoxyphenyl)-1-oxopropyl]phenyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2000:277967 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 132:293781
 TITLE: Preparation process of 1,5-benzodiazepines as medicine
 INVENTOR(S): Oi, Satoru; Suzuki, Nobuhiro; Matsumoto, Takahiro
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 171 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000023428	A1	20000427	WO 1999-JP5754	19991019 <--
W: AE, AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, US, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2347938	A1	20000427	CA 1999-2347938	19991019 <--
AU 9961245	A1	20000508	AU 1999-61245	19991019 <--
JP 2000191648	A	20000711	JP 1999-297130	19991019 <--
EP 1123928	A1	20010816	EP 1999-947961	19991019 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2003149027	A1	20030807	US 2001-894105	20010628 <--
PRIORITY APPLN. INFO.: ,			JP 1998-298941	A 19981020 <--
			WO 1999-JP5754	W 19991019 <--
OTHER SOURCE(S): MARPAT 132:293781				
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. [I; wherein ring B represents an optionally substituted

cyclic hydrocarbon group; Z represents hydrogen or an optionally substituted cyclic group; R1 represents hydrogen, an optionally substituted hydrocarbon group, an optionally substituted heterocyclic group, or acyl; R2 represents optionally substituted amino; D represents a bond or a divalent group; E represents a bond, CO, CON(Ra), COO, N(Ra)CON(Rb), N(Ra)CON(Rb), N(Ra)CON(Rb), N(Ra)SO2, N(Ra), S, SO, SO2; Ra and Rb each independently represents hydrogen or an optionally substituted hydrocarbon group; L represents a bond or a divalent group; A represents hydrogen or a substituent; X and Y each represents hydrogen or an independent substituent; dotted bond indicates that R2 may be bonded to an atom on the ring B to form a ring] and salts are prepared (preparation given) from RaNHGZ and tested as medicine. Thus, the title compound II was prepared


IT 264916-10-1P 264916-11-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation process of 1,5-benzodiazepines as medicine)


RN 264916-10-1 CAPLUS

CN 2H-Isoindole-2-carboxylic acid, 5-[[2-[[[1,1'-biphenyl]-4-ylmethyl](ethoxyoxoacetyl)amino]phenyl]amino]-1,3-dihydro-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 264916-11-2 CAPLUS

CN 2H-Isoindole-2-carboxylic acid, 5-[[2-[[[1,1'-biphenyl]-4-ylmethyl](carboxycarbonyl)amino]phenyl]amino]-1,3-dihydro-, 2-(1,1-dimethylethyl) ester (CA INDEX NAME)



REFERENCE COUNT:


7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 11 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:798572 CAPLUS <<LOGINID::20080103>>


DOCUMENT NUMBER: 132:151793
TITLE: Synthesis of 8-chloro-4,5-dihydro-1H-benzo[e][1,4]diazepine-2,3-diones as potential NMDA receptor glycine site antagonists
AUTHOR(S): Hwang, Ki-Jun
CORPORATE SOURCE: Department of Chemistry, College of Natural Science, Chonbuk National University, Jeonju, 561-756, S. Korea
SOURCE: Korean Journal of Medicinal Chemistry (1999), 9(2), 79-82
CODEN: KJMCE7; ISSN: 1225-0058
PUBLISHER: Korean Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



AB Title compds. I (R = benzyl, 3-bromobenzyl, H) were prepared in several steps from 4-chloroanthranilic acid.
IT 257603-95-5P 257603-96-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of)
RN 257603-95-5 CAPLUS
CN Acetic acid, [[[2-amino-4-chlorophenyl)methyl](phenylmethyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 257603-96-6 CAPLUS
CN Acetic acid, [[[2-amino-4-chlorophenyl)methyl]][(3-bromophenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L5 ANSWER 12 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1999:194120 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 130:237573
 TITLE: Preparation of 2,3-dioxabicyclo[3.3.1]nonanes as antimalarials.
 INVENTOR(S): Bachi, Mario; Posner, Gary H.; Korshin, Edward
 PATENT ASSIGNEE(S): Yeda Research and Development Co. Ltd., Israel; Johns Hopkins University
 SOURCE: PCT Int. Appl., 59 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9912900	A2	19990318	WO 1998-IL440	19980910 <--
WO 9912900	A3	19990506		
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9890938	A	19990329	AU 1998-90938	19980910 <--
EP 1021403	A2	20000726	EP 1998-942990	19980910 <--
EP 1021403	B1	20050420		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 293597	T	20050515	AT 1998-942990	19980910 <--
US 6166065	A	20001226	US 2000-508428	20000511 <--
PRIORITY APPLN. INFO.:			IL 1997-121749	A 19970911 <--
			WO 1998-IL440	W 19980910 <--
OTHER SOURCE(S):			MARPAT 130:237573	
GI				




- AB Title compds. [I; X = H, OH, (alkoxy- or acyloxy-substituted) alkoxy, (alkoxy- or aryloxy-substituted) aralkoxy, acyloxy; M = H, OH, alkoxy, alkenyloxy, (acyl- or acyloxy-substituted) acyloxy, aralkoxy, aralkenyloxy, (alkoxy-, dialkylamino-, or arylalkylamino-substituted) oxalyloxy, (aryloxy-, dialkylamino-, or diaralkylamino-substituted) di(aralkyl)amino, carbonyloxy; XM = bond, O; L = H; LM = bond; either Z = RS(O)_n and Y = H, or Y = RS(O)_n and Z = H; R = (alkoxy- or alkoxycarbonyl-substituted), alkyl, cycloalkyl, (alkyl-, halo-, or CF₃-substituted) aryl, aralkyl; n = 0-2], were prepared Thus, (R)-(+)-limonene in heptane/benzene was treated with di-tert-Bu peroxalate and then simultaneously with O₂ and PhSH in benzene at room temperature CH₂Cl₂ was added, the mixture was cooled to 0-5°, and Ph₃P was added followed by stirring to room temperature to give 54.6% (1R,4R,5R,8R)- and (1R,4S,5R,8R)-4,8-dimethyl-4-phenylthiomethyl-2,3-dioxabicyclo[3.3.1]nonan-8-ol. The mixture was acetylated with AcCl/pyridine/DMAP in CH₂Cl₂ and the mixture of acetates was treated with MCPBA in EtOAc at 0° to room temperature to give (1R,4R,5R,8R)- and (1R,4S,5R,8R)-8-acetoxy-4,8-dimethyl-4-phenylsulfonylmethyl-2,3-dioxabicyclo[3.3.1]nonane. Both of the above compds. showed IC₅₀ = 17 nM against Plasmodium falciparum in vitro.
- IT 208646-68-8P 208646-69-9P 221293-39-6P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 2,3-dioxabicyclo[3.3.1]nonanes as antimalarials)
- RN 208646-68-8 CAPLUS
- CN Acetic acid, [bis(phenylmethyl)amino]oxo-, (1R,4R,5R,8R)-4,8-dimethyl-4-[(phenylsulfonyl)methyl]-2,3-dioxabicyclo[3.3.1]non-8-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- RN 208646-69-9 CAPLUS
- CN Acetic acid, [bis(phenylmethyl)amino]oxo-, (1R,4S,5R,8R)-4,8-dimethyl-4-[(phenylsulfonyl)methyl]-2,3-dioxabicyclo[3.3.1]non-8-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 221293-39-6 CAPLUS

CN Acetic acid, [bis(phenylmethyl)amino]oxo-, (1R,5R,8R)-4,8-dimethyl-4-[(phenylthio)methyl]-2,3-dioxabicyclo[3.3.1]non-8-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 13 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:310415 CAPLUS <<LOGINID::20080103>>

DOCUMENT NUMBER: 129:54332

TITLE: Synthesis and in vitro antimalarial activity of sulfone endoperoxides

AUTHOR(S): Bachi, Mario D.; Korshin, Edward E.; Ploypradith, Poonsakdi; Cumming, Jared N.; Xie, Suji; Shapiro, Theresa A.; Posner, Gary H.

CORPORATE SOURCE: Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, 76100, Israel

SOURCE: Bioorganic & Medicinal Chemistry Letters (1998), 8(8), 903-908


CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



I.


AB A series of 4,8-dimethyl-4-phenylsulfonylmethyl-2,3-dioxabicyclo[3.3.1]nonanes carrying a variety of substituents at C-8 [I; R = H, Ac, 4-MeOC₆H₄CH₂, EtOCOCO, (PhCH₂)₂NCOCO, AcCH₂CO; R₁, R₂ = H, PhSO₂] were prepared by a short and efficient method from R-(+)-limonene. Key reactions include thiol oxygen cooxidn., and alkylation and acylation of a sterically hindered tertiary alc. compatible with the endoperoxy functionality. Some of compds. which are structurally related to yingzhaosu A had in vitro antimalarial activity comparable to that of artemisinin and superior to that of arteflene.

IT 208646-68-8P 208646-69-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (preparation and antimalarial activity of (phenylsulfonyl)dioxabicyclononanes)

RN 208646-68-8 CAPLUS

CN Acetic acid, [bis(phenylmethyl)amino]oxo-, (1R,4R,5R,8R)-4,8-dimethyl-4-[(phenylsulfonyl)methyl]-2,3-dioxabicyclo[3.3.1]non-8-yl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 208646-69-9 CAPLUS

CN Acetic acid, [bis(phenylmethyl)amino]oxo-, (1R,4S,5R,8R)-4,8-dimethyl-4-[(phenylsulfonyl)methyl]-2,3-dioxabicyclo[3.3.1]non-8-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:748455 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 126:31277

TITLE: Quinoline derivatives useful as endothelin receptor antagonists, process for their preparation, the resultant intermediates, their use as medicaments, and pharmaceutical compositions containing them

INVENTOR(S): Hawsslein, Jean-Luc

PATENT ASSIGNEE(S): Roussel-UCLAF, Fr.; Haesslein, Jean-Luc

SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2




DOCUMENT TYPE: Patent

LANGUAGE: French

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9633190	A1	19961024	WO 1996-FR591	19960418 <--
W: JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
FR 2733233	A1	19961025	FR 1995-4722	19950420 <--
FR 2733233	B1	19970530		
PRIORITY APPLN. INFO.:			FR 1995-4722	A 19950420 <--
OTHER SOURCE(S):	MARPAT 126:31277			
GI				



AB The invention concerns compds. I and their isomers and addition salts [wherein A = H or CH₂B; B = alkyl, C₆H₃R₁R₂R₃, (un)substituted 3-pyridyl, cyclohexyl, or 2-furyl; Z₁, Z₂ = H, or together form fused carbo- or


heterocyclic (O, S, N, NH) ring; Z = O or S; X = CO₂H or derivs., tetrazolyl, CONHSO₂R₆; R₆ = (un)substituted alkyl, alkenyl or Ph; R = H, halo, OH, SH, CO₂H, alkyl, phenylthioalkyl, alkoxy, Ph, naphthyl, PhCH₂, PhCH₂CH₂, various heterocycles, and PhS, most of which may be substituted; R₁-R₅ = H, halo, OH, alkyl, alkoxy, cyano, NO₂, etc.; or R₂R₃ may likewise form the rings formed by Z₁ and Z₂, with the proviso that when A = H, then Z₁Z₂ form ring]. I are endothelin receptor antagonists, useful for treatment of vascular spasms, renal insufficiency, atherosclerosis, hypertension, asthma, osteoporosis, etc. For example, the intermediate II (preparation given) underwent a sequence of condensation with aniline, thermal cyclization to a dihydroquinolone, N-alkylation with piperonyl bromide, and hydrolysis with aqueous ethanolic KOH, to give title potassium salt III. In tests for inhibition of endothelin receptors A and B in vitro, III had IC₅₀ values of 10.6 nM and 606 nM, resp.

IT 184242-49-7P 184242-56-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of quinoline derivs. as endothelin receptor antagonists)


RN 184242-49-7 CAPLUS

CN Acetic acid, [[[6-chloro-1,3-benzodioxol-5-yl)methyl][2-[3-[2-(2-ethoxy-2-oxoethoxy)-4-methoxyphenyl]-1-oxopropyl]phenyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)





RN 184242-56-6 CAPLUS

CN Acetic acid, [(2-acetylphenyl)(1,3-benzodioxol-5-ylmethyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 1996:485770 CAPLUS <<LOGINID::20080103>>
DOCUMENT NUMBER: 125:142568
TITLE: Preparation of novel N-imidoyl-[p-
[(amidinonaphthylmethyl)amino]phenoxy]piperidine
derivatives and analogs as blood platelet aggregation
inhibitors
INVENTOR(S): Hirayama, Fukushi; Koshio, Hiroyuki; Matsumoto, Yuzo;
Kawasaki, Tomihisa; Kaku, Seiji; Yanagisawa, Isao
PATENT ASSIGNEE(S): Yamanouchi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 156 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9616940	A1	19960606	WO 1995-JP2458	19951201 <--
W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2206532	A1	19960606	CA 1995-2206532	19951201 <--
CA 2206532	C	20060711		
AU 9539942	A	19960619	AU 1995-39942	19951201 <--
AU 688628	B2	19980312		
EP 798295	A1	19971001	EP 1995-938625	19951201 <--
EP 798295	B1	20030226		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
CN 1167484	A	19971210	CN 1995-196546	19951201 <--
CN 1087736	B	20020717		
HU 77313	A2	19980330	HU 1997-2028	19951201 <--
JP 3004362	B2	20000131	JP 1996-518590	19951201 <--
RU 2154633	C2	20000820	RU 1997-108576	19951201 <--
PL 184824	B1	20021231	PL 1995-320486	19951201 <--
AT 233240	T	20030315	AT 1995-938625	19951201 <--
PT 798295	T	20030731	PT 1995-938625	19951201 <--
ES 2193202	T3	20031101	ES 1995-938625	19951201 <--
NO 9702482	A	19970801	NO 1997-2482	19970530 <--
NO 309566	B1	20010219		
US 5869501	A	19990209	US 1997-849391	19970530 <--
FI 9702326	A	19970602	FI 1997-2326	19970602 <--
FI 115051	B1	20050228		
PRIORITY APPLN. INFO.:			JP 1994-299963	A 19941202 <--
			JP 1995-105205	A 19950428 <--
			JP 1995-198816	A 19950803 <--
			WO 1995-JP2458	W 19951201 <--
OTHER SOURCE(S):			CASREACT 125:142568; MARPAT 125:142568	
GI				



AB The title compds. [I; R1 = H or A-W-R4; wherein A = C(:X), COCO, SO2; X = O or S; W = a single bond or NR5; R4 = OH, lower alkoxy, (un)substituted lower alkyl, cycloalkyl, aryl, or heteroaryl; R5 = H, carbamoyl, lower alkoxycarbonyl, mono- or dialkylaminocarbonyl, lower alkylsulfonyl, mono- or dialkylaminothiocarbonyl, (un)substituted lower alkyl or alkanoyl; R2 = lower alkyl; R3 = H, halo, carboxy, NH2, cyano, NO2, OH, lower alkoxy, lower alkyl, lower alkoxycarbonyl; B = lower alkylene or carbonyl; n = 0 or 1], which have an antiplatelet aggregation effect on the basis of the effect of inhibiting activated blood coagulation factor X and are useful as antithrombotic agents, etc., are prepared Thus, a cyanonaphthalene derivative (II; R1 = Ac, X = cyano, X1 = Boc) (preparation given, 128 mg) was dissolved in a mixture of CH2Cl2 and EtOH, cooled to -20°, saturated with HCl(g), stirred at 5° for 4 days, treated with a saturated methanolic NH3, and stirred at 5° for 6 days to give an amidinonaphthalene derivative II.2HCl (R1 = Ac, X = amidino, X1 = H) (92 mg), which (56 mg) was dissolved in EtOH, treated with 28 mg Et acetimidate dihydrochloride and 36 mg Et3N, and stirred at room temperature for 2 days to give the title compound II [R1 = Ac, X = amidino, X1 = C(:NH)Me]. II.2HCl [R1 = SO2NHCO2Et, X = amidino, X1 = C(:NH)Me] at 0.04 μM in vitro prolonged twice the activated blood coagulation factor X-induced aggregation time of human serum as compared to 0.59 μM for a reference compound


IT 179755-30-7P 179755-36-3P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-imidoyl-[p-[(aminonaphthylmethyl)amino]phenoxy]piperidine derivs. and analogs as antithrombotics and blood platelet aggregation inhibitors)


RN 179755-30-7 CAPLUS

CN Acetic acid, [[[7-(aminoiminomethyl)-2-naphthalenyl]methyl][4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]amino]oxo-, ethyl ester, dihydrochloride (9CI) (CA INDEX NAME)




● 2 HCl

RN 179755-36-3 CAPLUS
 CN Acetic acid, [[[7-(aminoiminomethyl)-2-naphthalenyl]methyl] [4-[[1-(1-iminoethyl)-4-piperidinyl]oxy]phenyl]amino]oxo-, dihydrochloride (9CI)
 (CA INDEX NAME)




● 2 HCl

IT 179755-95-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of N-imidoyl-[p-[(amidinonaphthylmethyl)amino]phenoxy]piperidine derivs. and analogs as antithrombotics and blood platelet aggregation inhibitors)
 RN 179755-95-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 4-[4-[[[7-cyano-2-naphthalenyl]methyl] (ethoxyoxoacetyl)amino]phenoxy]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 16 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1996:349682 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 125:10856
 TITLE: Preparation of (pyrrolyl)-5,6,7,8-tetrabenzo[f]quinoxaline-2,3-dione neurotransmitter antagonists
 INVENTOR(S): Lubisch, Wilfried; Vierling, Michael; Behl, Berthold; Hofmann, Hans-Peter
 PATENT ASSIGNEE(S): BASF A.-G., Germany
 SOURCE: Ger. Offen., 26 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4436852	A1	19960418	DE 1994-4436852	19941014 <--
CA 2201527	A1	19960425	CA 1995-2201527	19951002 <--
WO 9611922	A1	19960425	WO 1995-EP3902	19951002 <--
W: AU, BG, BR, BY, CA, CN, CZ, FI, HU, JP, KR, KZ, MX, NO, NZ, PL, RU, SG, SI, SK, UA, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9538034	A	19960506	AU 1995-38034	19951002 <--
EP 785932	A1	19970730	EP 1995-935894	19951002 <--
EP 785932	B1	19991229		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1160400	A	19970924	CN 1995-195650	19951002 <--
CN 1078208	B	20020123		
BR 9509337	A	19980127	BR 1995-9337	19951002 <--
JP 10507186	T	19980714	JP 1996-512892	19951002 <--
AT 188214	T	20000115	AT 1995-935894	19951002 <--
ZA 9508643	A	19970414	ZA 1995-8643	19951013 <--
IN 1995MA01321	A	20050225	IN 1995-MA1321	19951013 <--
US 5849744	A	19981215	US 1997-809697	19970327 <--
FI 9701528	A	19970411	FI 1997-1528	19970411 <--
NO 9701674	A	19970611	NO 1997-1674	19970411 <--
PRIORITY APPLN. INFO.:			DE 1994-4436852	A 19941014 <--
			WO 1995-EP3902	W 19951002 <--
OTHER SOURCE(S):			CASREACT 125:10856; MARPAT 125:10856	
GI				



AB The title compds. [I; R1 = H, C1-6 aliphatic residue; (un)substituted CO2H, (un)substituted CONH2, etc.; R2 = H, C1-4 alkyl, Ph; R3 = H, (CH2)mR7; m = 0-4; R7 = H, alkyl, Ph, phenylsulfonyl, NO2, CN, etc.], useful as antiepileptics (no data), anxiolytics (no data), antidepressants (no data), and as AMPA and glycine-binding-site-NMPA receptor antagonists, are prepared. Thus, 9-amino-1-hydroxy-5,6,7,8-tetrahydrobenzo[f]quinoxaline-2,3-(1H,4H)-dione (sic) was reacted with 2,5-dimethoxytetrahydrofuran (sic), producing quinoxalinedione II (sic), m.p. >250°, which demonstrated a Ki of <10 µM in the binding of 3H-AMPA to rat-derived cerebral membranes.


IT 177493-99-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of (pyrrolyl)-5,6,7,8-tetrahydrobenzo[f]quinoxaline-2,3-dione neurotransmitter antagonists)

RN 177493-99-1 CAPLUS

CN Acetic acid, oxo[(phenylmethyl)(5,6,7,8-tetrahydro-2,4-dinitro-1-naphthalenyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 17 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1995:264648 CAPLUS <<LOGINID::20080103>>

DOCUMENT NUMBER: 122:56055


TITLE: Preparation of [1,2,4]triazolo[4,3-a]quinoxaline excitatory neurotransmitter antagonists

INVENTOR(S): Jacobsen, Poul; Nielsen, Flemming Elmelund; Jeppesen,

PATENT ASSIGNEE(S): Lone
 SOURCE: Novo Nordisk A/S, Den.
 PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9421639	A1	19940929	WO 1994-DK77	19940225 <--
W: AU, BG, BY, CA, CN, CZ, FI, HU, JP, KP, KR, KZ, LV, NO, NZ, PL, RO, RU, SK, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2158545	A1	19940929	CA 1994-2158545	19940225 <--
AU 9462018	A	19941011	AU 1994-62018	19940225 <--
AU 685783	B2	19980129		
EP 691969	A1	19960117	EP 1994-908979	19940225 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1122601	A	19960515	CN 1994-191979	19940225 <--
CN 1041930	B	19990203		
HU 73419	A2	19960729	HU 1995-2726	19940225 <--
JP 08507536	T	19960813	JP 1994-520538	19940225 <--
IL 108800	A	19980222	IL 1994-108800	19940301 <--
ZA 9401926	A	19950918	ZA 1994-1926	19940318 <--
US 5559106	A	19960924	US 1994-350744	19941207 <--
FI 9504386	A	19950918	FI 1995-4386	19950918 <--
NO 9503673	A	19951117	NO 1995-3673	19950918 <--
PRIORITY APPLN. INFO.:			DK 1993-310	A 19930319 <--
			WO 1994-DK77	W 19940225 <--
			US 1994-202524	B1 19940228 <--

OTHER SOURCE(S): MARPAT 122:56055
 GI



AB The title compds. [I; R1 = COX1, POX1X2, (un)substituted alkyl; X1, X2 = HO, C1-6 alkoxy; R6-R9 = H, alkyl, halogen, NH2, NO2, CN, CF3, etc.; R6R7 and R8R9 may form fused rings], useful as excitatory neurotransmitter antagonists, are prepared and I-containing formulations presented. Thus, 1-phosphonomethyl-7-trifluoromethyl[1,2,4]triazolo[4,3-a]quinoxalin-4(5H)-one, m.p. >290° (decomposition), was prepared and demonstrated a IC50 for 3H-AMPA binding to rat brain cerebral cortical membrane homogenate of 0.26 M.


IT 159891-83-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of [1,2,4]triazolo[4,3-a]quinoxaline excitatory
 neurotransmitter antagonists)
 RN 159891-83-5 CAPLUS
 CN Acetic acid, [(4-bromo-2-nitro-1-naphthalenyl) [(2,4-
 dimethoxyphenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 18 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1994:508834 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 121:108834
 TITLE: Quinoxalinedione derivatives as EAA (excitatory amino
 acid) antagonists
 INVENTOR(S): Bigge, Christopher Franklin; Malone, Thomas Charles;
 Waetjen, Frank
 PATENT ASSIGNEE(S): Warner-Lambert Co., USA
 SOURCE: PCT Int. Appl., 121 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9409000	A1	19940428	WO 1993-US9667	19931008 <--
W: AU, CA, CZ, FI, HU, JP, KR, NO, NZ, RU, SK				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9351715	A	19940509	AU 1993-51715	19931008 <--
AU 680632	B2	19970807		
EP 664807	A1	19950802	EP 1993-922849	19931008 <--
EP 664807	B1	19970910		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 08502483	T	19960319	JP 1993-510172	19931008 <--
AT 157977	T	19970915	AT 1993-922849	19931008 <--
ES 2109516	T3	19980116	ES 1993-922849	19931008 <--

MX 9306325	A	20000630	MX 1993-6325	19931011 <--
US 2003114422	A1	20030619	US 1995-443507	19950518 <--
US 6703391	B2	20040309		
PRIORITY APPLN. INFO.:			US 1992-960157	A 19921013 <--
			US 1993-34332	A 19930322 <--
			US 1993-124770	A 19930924 <--
			WO 1993-US9667	W 19931008 <--
			US 1995-375059	B3 19950119 <--
OTHER SOURCE(S):			MARPAT 121:108834	
GI				



AB Title compds. and pharmaceutically acceptable salts thereof are disclosed, i.e. I [R = H, OH; R1 = H, alkyl, arylalkyl, (CH₂)_nOH or (CH₂)_nNR₇R₈; R5, R6 = H, halo, NO₂, CN, CF₃, SO₂NR₇R₈, PO₃R₉R₁₀, alkyl, alkenyl, alkynyl, (CH₂)_nCONR₇R₈, (CH₂)_nCO₂R₁₀, NHCOR₁₁; R7, R8 = H, alkyl; or R₇R₈ forms a ring of 3-7 atoms; R9, R10, R11 = H, alkyl; n = 0-4; A = NR₁₂CHR₁₃CHR₁₄, CHR₁₃CHR₁₄NR₁₂, CHR₁₃NR₁₂CHR₁₄, CHR₁₄CH₂NR₁₂CHR₁₃, CHR₁₃NR₁₂CH₂CHR₁₄, CH₂CH₂CHR₁₃NR₁₂, NR₁₂CHR₁₃CH₂CH₂, CH₂CH₂NR₁₂CH₂CH₂, CH₂CH₂CH₂NR₁₂CH₂, CH₂NR₁₂CH₂CH₂CH₂, CH₂CH₂CH₂CH₂NR₁₂, NR₁₂CH₂CH₂CH₂CH₂; R12 = H, CH₂CH₂OH, alkyl; R13, R14 = H, CN, CONH₂, CH₂NH₂, CH₂OH, alkyl, arylalkyl, alkenyl, CO₂R₁₅; R15 = H, alkyl]. The compds. are useful in the treatment of mammalian disorders responsive to blockade of glutamic and aspartic acid receptors. Processes for preparing the compds. and novel intermediates are also disclosed. For example, 5-nitroisoquinoline underwent quaternization with EtI, hydrogenation of 1 ring and the nitro group, and N-acetylation (17% overall), bromination (53%), nitration (71%), deacetylation (82%), and hydrogenation of the 2nd nitro group (98%) to give isoquinolinediamine derivative II. Cyclocondensation of II with oxalic acid in refluxing aqueous

HCl gave 59% title compound III. The IC₅₀ of III for inhibition of [3H]-AMPA binding to rat cortical membranes was 2.4 μM. A total of 119 synthetic examples cover preparation of various I and precursors. Receptor binding data (AMPA, kainic acid, and glycine receptors) are given for selected I.


IT 156694-87-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and reaction of, in preparation of quinoxalinediones as
excitatory


amino acid antagonists)

RN 156694-87-0 CAPLUS

CN Acetic acid, oxo[(phenylmethyl)(1,2,3,4-tetrahydro-6-nitro-5-
quinolinyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 19 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:8563 CAPLUS <<LOGINID::20080103>>
DOCUMENT NUMBER: 120:8563
TITLE: Synthesis and antimicrobial activity of some new
indolo[2,1-b]quinazolin-6(12H)ones
AUTHOR(S): Baiocchi, Leandro; Giannangeli, Marilena; Rossi,
Vilma; Ambrogi, Valeria; Grandolini, Giuliano;
Perioli, Luana
CORPORATE SOURCE: Ist. Ric. Francesco Angelini, Pomezia, Italy
SOURCE: Farmaco (1993), 48(4), 487-501
CODEN: FRMCE8; ISSN: 0014-827X
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 120:8563
GI




AB New indolo[2,1-b]quinazolin-6(12H)ones I (R = halo, alkoxy, etc.; R1 =
halo, hydrogen; R2 = hydrogen, alkyl) were prepared and tested as
antimicrobial agents. I are tryptanthrin derivs.

IT 151383-63-0P 151383-64-1P 151383-65-2P
151383-66-3P 151383-67-4P 151383-68-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for tryptanthrin derivative (antimicrobial agent))


RN 151383-63-0 CAPLUS

CN Acetic acid, [[(2-nitrophenyl)methyl]phenylamino]oxo-, ethyl ester (9CI)
(CA INDEX NAME)




RN 151383-64-1 CAPLUS

CN Acetic acid, [(4-methoxyphenyl)[(2-nitrophenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 151383-65-2 CAPLUS

CN Acetic acid, [(4-chlorophenyl)[(2-nitrophenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 151383-66-3 CAPLUS


CN Acetic acid, [(2-methylphenyl)[(2-nitrophenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 151383-67-4 CAPLUS
 CN Benzeneacetic acid, 4-[(ethoxyoxoacetyl) [(2-nitrophenyl)methyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 151383-68-5 CAPLUS
 CN Acetic acid, [[[5-chloro-2-nitrophenyl)methyl]phenylamino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 20 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1990:216962 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 112:216962
 TITLE: Preparation of oxadiazolyylimidazoquinoxalinone derivatives as central nervous system agents
 INVENTOR(S): Hansen, Holger Claus; Watjen, Frank
 PATENT ASSIGNEE(S): Aktieselskabet Ferrosan, Den.
 SOURCE: Eur. Pat. Appl., 14 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

EP 344943	A1	19891206	EP 1989-304982	19890517 <--
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5075304	A	19911224	US 1989-353793	19890518 <--
ZA 8903872	A	19900228	ZA 1989-3872	19890523 <--
DK 8902582	A	19891202	DK 1989-2582	19890526 <--
DK 161022	B	19910521		
DK 161022	C	19911028		
AU 8935174	A	19891207	AU 1989-35174	19890526 <--
AU 627181	B2	19920820		
CA 1315786	C	19930406	CA 1989-601114	19890530 <--
NO 8902204	A	19891204	NO 1989-2204	19890531 <--
NO 173185	B	19930802		
NO 173185	C	19931110		
FI 8902684	A	19891202	FI 1989-2684	19890601 <--
FI 92203	B	19940630		
FI 92203	C	19941010		
JP 02025486	A	19900126	JP 1989-137578	19890601 <--
PRIORITY APPLN. INFO.:			DK 1988-2971	A 19880601 <--
			DK 1988-6259	A 19881110 <--
OTHER SOURCE(S):	MARPAT 112:216962			
GI				



AB The title compds. (I; R3 = Q, Q1, CO2R4; R4 = C3-7 cycloalkyl; R5 = Me substituted with alkoxy, carbonyl, heteroaryl, morpholino C3-7 cycloalkyl, C1-6 alkenyl, arylacyl, alkylacyl, alkoxyalkyl, alkoxy, phthalimidoiphenyl, aryl, or aralkyl, all of which are substituted with halo, C1-6 alkyl, NH2, N3, or C1-6 alkoxy; R6 = H, C1-6 alkyl, CF3), which have strong affinity for benzodiazepine receptors and are useful in psychopharmaceutical preps. such as anticonvulsants, anxiolytics, and hypnotics and in improving cognitive function, are prepared by cyclocondensation of quinoxaline derivs. (II; Y = leaving group) with CNCH2R3 or I (R3 = CO2H) with R4C(:NOH)NH2. Thus, treatment of 4-benzyl-1,2,3,4-tetrahydro-2,3-dioxoquinoxaline (preparation given) with Me3COK in DMF under ice-cooling followed by (EtO)2P(O)Cl at room temperature and then a preformed cold (-40°) solution of Me3COK and 5-cyclopropyl-3-isocyanomethyl-1,2,4-oxadiazole in DMF gave I (R3 = Q1, R4 = cyclopropyl, R5 = PhCH2, R6 = H) (III). I (R3 = Q1, R4 = cyclopropyl, R5


= Me, R6 = CF3) and III in vivo inhibited 3H-flunitrazepan-binding to the brain benzodiazepine receptors in mice with an ED50 of 0.09 and 1.2 mg/kg body weight, resp. A total of 34 I were prepared

IT 126991-26-2P 126991-27-3P 126991-29-5P
126991-31-9P 126991-32-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as intermediate for oxadiazolyimidazoquinoline central nervous system agent)


RN 126991-26-2 CAPLUS

CN Acetic acid, [[[2-methoxyphenyl)methyl] (2-nitrophenyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 126991-27-3 CAPLUS

CN Acetic acid, [[[4-methoxyphenyl)methyl] (2-nitrophenyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 126991-29-5 CAPLUS

CN Acetic acid, [[[2-chlorophenyl)methyl] (2-nitrophenyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 126991-31-9 CAPLUS


CN Acetic acid, [(2-nitrophenyl) (phenylmethyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 126991-32-0 CAPLUS
 CN Acetic acid, [(2-chloro-6-nitrophenyl) [(2-chlorophenyl)methyl]amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 21 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1990:55371 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 112:55371
 TITLE: A facile synthesis of 1,2,3,4-tetrahydroisoquinolines through cyclization of O,N-acetals. II. Syntheses of isoquinolinequinone antibiotics
 AUTHOR(S): Saito, Naoki; Kawakami, Nanko; Yamada, Eri; Kubo, Akinori
 CORPORATE SOURCE: Meiji Coll. Pharm., Tokyo, 154, Japan
 SOURCE: Chemical & Pharmaceutical Bulletin (1989), 37(6), 1493-9
 CODEN: CPBTAL; ISSN: 0009-2363
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 112:55371
 GI



I



II

AB A mild and efficient method for the synthesis of 1,2,3,4-

tetrahydroisoquinolines I (R = H, CO₂Et, CO₂Bu) and II involves a modified Pictet-Spengler reaction involving Lewis acid-mediated cyclization of the O,N-acetals. The synthetic utility of this reaction is demonstrated with a preparation of renierone and mimocin from I (R = CO₂Bu).


IT 124867-30-7P 124867-32-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and cyclization of)


RN 124867-30-7 CAPLUS

CN Acetic acid, ethoxy[(phenylmethyl)[2-(2,4,5-trimethoxy-3-methylphenyl)ethyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)



RN 124867-32-9 CAPLUS

CN Acetic acid, butoxy[(phenylmethyl)[2-(2,4,5-trimethoxy-3-methylphenyl)ethyl]amino]-, butyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 22 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1983:83183 CAPLUS <<LOGINID::20080103>>

DOCUMENT NUMBER: 98:83183

ORIGINAL REFERENCE NO.: 98:12549a,12552a

TITLE: A bendazac metabolite

AUTHOR(S): Giannangeli, M.; Interdonato, N.; Baiocchi, L.

CORPORATE SOURCE: Ist. Ric. F. Angelini, Rome, Italy


SOURCE: Bollettino Chimico Farmaceutico (1982), 121(9), 465-74

CODEN: BCFAAI; ISSN: 0006-6648

DOCUMENT TYPE: Journal

LANGUAGE: Italian

GI




AB Extraction and chromatog. of the urine of patients treated orally with bendazac lysine salt (I) [82576-52-1] showed the presence of a metabolite which was identified by NMR, IR, and UV spectroscopy as the corresponding hydroxylated compound, 5-hydroxy-1-benzylindazole-3-oxyaceic acid (II) [84745-02-8]. Unmetabolized bendazac was also present. II was identified by comparison with an authentic sample, which was synthesized from N-benzyl-5-benzyloxyisatin [84745-03-9]. The synthetic data and the characterization of the intermediate products are reported.

IT 84754-16-5P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation and cyclization of)

RN 84754-16-5 CAPLUS

CN Acetic acid, oxo[[4-(phenylmethoxy)phenyl](phenylmethyl)amino]-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 23 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1982:217213 CAPLUS <<LOGINID::20080103>>

DOCUMENT NUMBER: 96:217213

ORIGINAL REFERENCE NO.: 96:35877a,35880a

TITLE: Competitive pathways in chlorine dioxide oxidation of amines: amide formation from acyclic amines

AUTHOR(S): Burrows, Elizabeth P.; Rosenblatt, David H.

CORPORATE SOURCE: Army Med. Bioeng. Res. Dev. Lab., Fort Detrick, MD, USA


SOURCE: Report (1981), USAMBRDL-TR-8109; Order No. AD-A107242, 12 pp. Avail.: NTIS
 From: Gov. Rep. Announce. Index (U. S.) 1982, 82(6), 1147

DOCUMENT TYPE: Report


LANGUAGE: English

AB Treatment of dibenzylamine or Et N,N-dibenzylglycinate with ClO2 gave, in addition to the expected products of oxidative dealkylation, substantial amts. of amides. With the second reaction and preformed ClO2 at pH 4-7, Et N,N-dibenzylloxamate was the predominant isomer; with ClO2 generated in situ at pH 2.5-3, Et N-benzoyl-N-benzylglycinate was predominant. In the latter case the combined yield of amides was sufficiently high (80%) to be

of synthetic utility.
IT 80326-96-1P
RL: PREP (Preparation)
(from reaction of Et N,N-dibenzylglycinate with chlorine dioxide)
RN 80326-96-1 CAPLUS
CN Acetic acid, [bis(phenylmethyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 24 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1982:85183 CAPLUS <<LOGINID::20080103>>
DOCUMENT NUMBER: 96:85183
ORIGINAL REFERENCE NO.: 96:13975a,13978a
TITLE: Conversion of acyclic amines to amides by chlorine dioxide
AUTHOR(S): Burrows, Elizabeth P.; Rosenblatt, David H.
CORPORATE SOURCE: U. S. Army Med. Bioeng. Res. Dev. Lab., Frederick, MD, 21701, USA
SOURCE: Journal of Organic Chemistry (1982), 47(5), 892-3
CODEN: JOCEAH; ISSN: 0022-3263
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Treatment of (PhCH₂)₂NH and (PhCH₂)₂NCH₂CO₂Et (I) with ClO₂ gave, in addition to the expected products of oxidative dealkylation, substantial amts. of amides. With I and preformed ClO₂ at pH 4-7, (PhCH₂)₂NCOCO₂Et was the principal isomer; however, with ClO₂ generated in situ at pH 2.5-3, BzN(CH₂Ph)CH₂CO₂Et predominated. In the latter case the combined yield of amides was sufficiently high (80%) to be of synthetic utility.
IT 80326-96-1P
RL: FORM (Formation, nonpreparative); PREP (Preparation)
(formation of, in reaction of Et dibenzylglycinate with chlorine dioxide)
RN 80326-96-1 CAPLUS
CN Acetic acid, [bis(phenylmethyl)amino]oxo-, ethyl ester (9CI) (CA INDEX NAME)




L5 ANSWER 25 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1980:568596 CAPLUS <<LOGINID::20080103>>
DOCUMENT NUMBER: 93:168596

ORIGINAL REFERENCE NO.: 93:26871a,26874a
 TITLE: Fungicidal N-oxalyl derivatives of
 N-phenylaminoacid(s) (esters)
 INVENTOR(S): Lunkenheimer, Winfried; Brandes, Wilhelm
 PATENT ASSIGNEE(S): Bayer A.-G., Fed. Rep. Ger.
 SOURCE: Ger. Offen., 42 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2836158	A1	19800228	DE 1978-2836158	19780818 <--
US 4248886	A	19810203	US 1979-62400	19790731 <--
EP 9569	A1	19800416	EP 1979-102817	19790806 <--
EP 9569	B1	19820428		
R: AT, BE, CH, DE, FR, GB, IT, NL, SE				
AT 912	T	19820515	AT 1979-102817	19790806 <--
AU 7949884	A	19800221	AU 1979-49884	19790814 <--
DD 145492	A5	19801217	DD 1979-214991	19790815 <--
IL 58050	A	19830331	IL 1979-58050	19790815 <--
JP 55031079	A	19800305	JP 1979-103632	19790816 <--
CA 1146954	A1	19830524	CA 1979-333876	19790816 <--
DK 7903444	A	19800219	DK 1979-3444	19790817 <--
ES 483448	A1	19800416	ES 1979-483448	19790817 <--
BR 7905305	A	19800513	BR 1979-5305	19790817 <--
ZA 7904349	A	19800924	ZA 1979-4349	19790817 <--
PRIORITY APPLN. INFO.:			DE 1978-2836158	A 19780818 <--
			EP 1979-102817	A 19790806 <--

GI



AB The title compds. I [R1 = H, alkyl, halo; R2 and R3 = H, alkyl; R4 = N, alkyl, (un)substituted Ph; R5 and R6 = H, alkyl, cyanoalkyl, alkenyl, alkynyl, haloalkyl, cycloalkyl, cycloalkylalkyl, alkoxyalkyl, alkoxyalkoxyalkyl, alkoxyalkoxyalkyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, dialkylaminoalkyl, (un)substituted aryl or aralkyl; R6 = epoxyalkyl, ZN+R7R8R9.A+ or ZN(O)R7R8 (Z = alkylene, alkylidene, R7, R8, and R9 = alkyl; A+ = inorg. or organic acid anion); X = O, S] were prepared as fungicides. Thus, MeO2CCOC1 in DMF was added dropwise over 15 min to N-(2,6-xyllyl)alanine Me ester in toluene, and the resulting solution was stirred for 1.5 h at room temperature to give II.

Several I exhibited fungicidal activity in the protection of tomato plant.


IT 74863-50-6P

RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)


RN 74863-50-6 CAPLUS

CN Benzeneacetic acid, α -[(2,6-dimethylphenyl)(methoxyoxoacetyl)amino] -
 , methyl ester (9CI) (CA INDEX NAME)




L5 ANSWER 26 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1980:128752 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 92:128752
 ORIGINAL REFERENCE NO.: 92:20991a,20994a
 TITLE: 3-Isoquinolone derivatives
 INVENTOR(S): Mishima, Hiroshi; Fukumi, Hiroshi
 PATENT ASSIGNEE(S): Sankyo Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 54132583	A	19791015	JP 1978-39970	19780405 <--
PRIORITY APPLN. INFO.: GI			JP 1978-39970	A 19780405 <--




I





II

AB 3-Isoquinolone derivs. (I; R, R1 = H, alkyl, alkoxy, halo; R2 = H, alkyl, aralkyl) were prepared by cyclization of benzylacetamide derivs. (II; R3 = alkyl). Thus, concentrated H2SO4 was added to 1 g II (R = H, R1 = 2-Cl, R2 = R3 = Et) with cooling and the mixture stirred 4 h at room temperature to give 0.63 g I (R = H, R1 = 8-Cl, R2 = Et). Similarly prepared were 8 addnl. I.
 IT 68057-16-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and cyclization of)
RN 68057-16-9 CAPLUS
CN Acetamide, 2,2-diethoxy-N,N-bis(phenylmethyl)- (CA INDEX NAME)



L5 ANSWER 27 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1978:579829 CAPLUS <<LOGINID::20080103>>
DOCUMENT NUMBER: 89:179829
ORIGINAL REFERENCE NO.: 89:27927a,27930a
TITLE: Synthesis of 3-isoquinolones
AUTHOR(S): Fukumi, Hiroshi; Kurihara, Hideshi
CORPORATE SOURCE: Cent. Res. Lab., Sankyo Co., Ltd., Tokyo, Japan
SOURCE: Heterocycles (1978), 9(9), 1197-206
CODEN: HTCYAM; ISSN: 0385-5414
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 89:179829
GI



AB Isoquinolinols I (R = H, 6-Me, 8-Cl) were obtained in 32-60% yield by H₂SO₄ cyclization of RC₆H₄CH₂NHCOCH(OEt)₂, prepared in 41-76% yield by treating RC₆H₄CH₂NH₂ with ClCOCH(OEt)₂. The isoquinolones II (R = H, 6-Me, 7-OMe, R₁ = Me; R = H, 8-Cl, R₁ = Et; R = H, R₁ = CH₂Ph) were obtained by alkylating RC₆H₄CH₂NHCOCH(OEt)₂ before cyclizing.
IT 68057-16-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation and cyclization of)
RN 68057-16-9 CAPLUS
CN Acetamide, 2,2-diethoxy-N,N-bis(phenylmethyl)- (CA INDEX NAME)



L5 ANSWER 28 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1978:444240 CAPLUS <<LOGINID::20080103>>

DOCUMENT NUMBER: 89:44240

ORIGINAL REFERENCE NO.: 89:6909a,6912a

TITLE: Cyclic esters of 3,4-dihydroxythiophene-1,1 dioxide and 3,4-dihydroxycyclopentadienone compounds

INVENTOR(S): Steglich, Wolfgang; Hollitzer, Oswald; Seewald, Alfred

PATENT ASSIGNEE(S): BASF A.-G., Fed. Rep. Ger.

SOURCE: Ger. Offen., 27 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German



FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2625539	A1	19771222	DE 1976-2625539	19760605 <--
DE 2625539	C2	19821104		
CA 1106388	A1	19810804	CA 1977-279418	19770530 <--
GB 1578963	A	19801112	GB 1977-23381	19770602 <--
CH 636877	A5	19830630	CH 1977-6801	19770602 <--
FR 2353555	A1	19771230	FR 1977-16987	19770603 <--
FR 2353555	B1	19821231		
CA 1110385	A2	19811006	CA 1980-359156	19800827 <--
PRIORITY APPLN. INFO.:			DE 1976-2625539	A 19760605 <--
			CA 1977-279418	A3 19770530 <--

OTHER SOURCE(S): MARPAT 89:44240

GI




AB The esters I (X = CO, CS, COCO; Z = SO₂, CO) were prepared as intermediates for active esters in peptide synthesis. Thus, thiophene II (R = H) was treated with COCl₂ in THF in an autoclave for 24 h at 80° to give I (X = CO, Z = SO₂) (III). III was treated with BOC-Phe-OH (BOC = Me₃CO₂C) and pyridine in CH₂Cl₂ for 2 h to give active ester II (R = BOC-Phe) which was treated with H-Val-OMe to give 93% BOC-Phe-Val-OMe. The use of I as active esters in solid-phase peptide synthesis on polystyrene resins is presented.

IT 67106-17-6P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 67106-17-6 CAPLUS

CN Acetic acid, [bis(phenylmethyl)amino]oxo-, 4,5-dihydro-1,1-dioxido-4-oxo-2,5-diphenyl-3-thienyl ester (9CI) (CA INDEX NAME)




L5 ANSWER 29 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1977:120998 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 86:120998
 ORIGINAL REFERENCE NO.: 86:19099a,19102a
 TITLE: N-Benzyl-2,2-dimethoxyacetamides
 INVENTOR(S): Ghosez, Leon; Rossey, Guy; Didderen, Freddy
 PATENT ASSIGNEE(S): UCB S. A., Belg.
 SOURCE: Ger. Offen., 21 pp.
 CODEN: GWXXBX
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2623226	A1	19761216	DE 1976-2623226	19760524 <--
DE 2623226	C2	19860320		
SU 663299	A3	19790515	SU 1976-2356009	19760512 <--
DK 7602233	A	19761128	DK 1976-2233	19760520 <--
FI 7601421	A	19761128	FI 1976-1421	19760520 <--
NL 7605552	A	19761130	NL 1976-5552	19760524 <--
FR 2312489	A1	19761224	FR 1976-15720	19760524 <--
FR 2312489	B1	19790504		
US 4041077	A	19770809	US 1976-689148	19760524 <--
GB 1487104	A	19770928	GB 1975-23183	19760524 <--
BE 842181	A1	19761125	BE 1976-1007413	19760525 <--
JP 51143630	A	19761210	JP 1976-61049	19760526 <--
JP 61014146	B	19860417		
CA 1060045	A1	19790807	CA 1976-253407	19760526 <--
HU 173288	B	19790428	HU 1976-UE73	19760527 <--
PRIORITY APPLN. INFO.:			GB 1975-23183	A 19750527 <--
			GB 1975-23184	A 19750527 <--
AB	RR1C6H3CHR2NR3COCH(OMe)2 (I; R = R1 = H, Cl, Me, OMe, etc.; R2 = H, alkyl, Ph, PhCH2, etc.; R3 = H, Me, PhCH2) were prepared by reaction of an amine with (MeO)2CHCOCl or (MeO)2CHCO2Me (II). Thus, PhCH2NH2 reacted with II for 24 h to give 61% PhCH2NHCOCH(OMe)2, which was cyclized to 3(2H)-isoquinolone.			
IT	62373-74-4P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (preparation and cyclization of, to isoquinolone)			
RN	62373-74-4 CAPLUS			
CN	Acetamide, 2,2-dimethoxy-N,N-bis(phenylmethyl)- (CA INDEX NAME)			



L5 ANSWER 30 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1974:520538 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 81:120538
 ORIGINAL REFERENCE NO.: 81:19058h,19059a
 TITLE: Syntheses of imidazo[1,5-a]- and pyrazino[1,2-b]benzimidazoles
 AUTHOR(S): Schubert, H.; Lettau, H.; Fischer, J.
 CORPORATE SOURCE: Sekt. Chem., Martin Luther Univ., Halle, Ger. Dem. Rep.
 SOURCE: Tetrahedron (1974), 30(10), 1231-6
 CODEN: TETRAB; ISSN: 0040-4020
 DOCUMENT TYPE: Journal
 LANGUAGE: German
 OTHER SOURCE(S): CASREACT 81:120538
 GI For diagram(s), see printed CA Issue.
 AB 2-(α -Chlorobenzyl)benzimidazolium chloride with R₁NH₂ gave the 2-(α -aminobenzyl)benzimidazoles I (R₁ = H, cyclohexyl, CH₂Ph, alkyl, aryl). The benzhydryl analogs (II) were prepared similarly. 1,2-Dihydro-3H-imidazo [1,5-a] benzimidazoles (III), 1-oxo-1,2-dihydro-3H-imidazo [1,5-a] benzimidazoles, 3-oxo-1,2,3,4-tetrahydropyrazino [1,2-a] benzimidazoles (IV), and 3,4-dioxo-1,2,3,4-tetrahydropyrazino [1,2-a] benzimidazoles were prepared by reaction of I and II with CH₂O, COCl₂, ClCHR₂COCl, and (COCl)₂, resp. II (R₁ = H) with HC(OEt)₃ gave 3,3-diphenyl-3H-imidazo[1,5-a] benzimidazole.
 IT 54463-01-3P
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)
 RN 54463-01-3 CAPLUS
 CN Acetic acid, [(1H-benzimidazol-2-ylphenylmethyl) (4-methylphenyl) amino] oxo-, methyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 31 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1969:68045 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 70:68045
 ORIGINAL REFERENCE NO.: 70:12709a,12712a
 TITLE: Heterocycles. XLIV. Comparative facility of closure of 5- and 6-membered heterocycles in acidochromic

AUTHOR(S): condensation of arylides of diarylglycolic acids
 Petyunin, P. A.; Sukhomlinov, A. K.; Panferova, N. G.
 CORPORATE SOURCE: Khar'kov. Farm. Inst., Kharkov, USSR
 SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1968
), (6), 1033-7

CODEN: KGSSAQ; ISSN: 0132-6244

DOCUMENT TYPE: Journal

LANGUAGE: Russian


AB Acidic condensation of $\text{PhCH}_2\text{NPhCOC}_2\text{OH}$ (I), which could lead to either 5- or 6-membered ring closure, led exclusively to 5-membered ring closure to give 1-benzyl-3,3-(di-R-substituted)-2-oxindoles (II). Thus, 28.5 g. EtO_2CCOCl and 76.7 g. PhNHCH_2Ph in 100 cc. Et_2O heated 30 min. on a water bath and worked up gave 41.3 g. $\text{PhCH}_2\text{NPhCOCO}_2\text{Et}$, m. 55-6° (C_6H_6). This (2.83 g.) in 20 cc. Et_2O was added to Ph-MgBr (prepared from 6.28 g. PhBr and 0.97 g. Mg , in 20 cc. Et_2O), and the mixture heated on a water bath 1 hr. and worked up to give 3.4 g. I ($\text{R} = \text{Ph}$), m. 88-9° (EtOH). Similarly were prepared 93.1% I ($\text{R} = \text{p-MeC}_6\text{H}_4$), m. 126-7° (AcOH), and 90.5% I ($\text{R} = \text{o-MeOC}_6\text{H}_4$), m. 112-13° (EtOH). Concentrated H_2SO_4 (5 cc.) was added to a solution of 0.5 g. I ($\text{R} = \text{Ph}$) in 5 cc. AcOH , and the mixture poured into 20 cc. H_2O to give 0.48 g. II ($\text{R} = \text{Ph}$), m. 163° (EtOH). Similarly were prepared 98.3% II ($\text{R} = \text{p-MeC}_6\text{H}_4$), m. 154° (EtOH), and 96.2% II ($\text{R} = \text{o-MeO-C}_6\text{H}_4$), m. 191° (EtOH). A solution of 1.4 g. 3,3-diphenyl-2-oxindole in 4 cc. xylene was added to EtONa (prepared from 0.11 g. Na and 3 cc. EtOH), EtOH distilled off, a solution of 1 g. PhCH_2Cl in 2 cc. xylene added, and the mixture heated 5 hrs. to give 1.45 g. II ($\text{R} = \text{Ph}$). II ($\text{R} = \text{p-MeOC}_6\text{H}_4$) was prepared with 85% HCO_2H instead of H_2SO_4 ; yield 76.4%, m. 163-4° (EtOH). $\text{Ph}_2\text{C}(\text{OH})\text{CONMePh}$ (III), m. 106-7°, was prepared from PhNHMe and $\text{Ph}_2\text{CClCOCl}$ with subsequent hydrolysis, in 75.3% yield. Similarly, Ph_2CHCOCl and PhNHMe in $\text{C}_5\text{H}_5\text{N}$ gave $\text{Ph}_2\text{CHCONMePh}$, m. 102° (EtOH). Acidic condensation of III gave 93% 1-methyl-3,3-diphenyl-2-oxindole (IV), m. 176-7° (EtOH). A mixture of 4.28 g. PhNHMe , 5.3 g. $\text{Ph}_2\text{CClCOCl}$, and 50 cc. Et_2O was evaporated, dissolved in MeOH with heating, and kept 24 hrs. to give 90% IV. Considerable differences in ir and uv spectra of 5-, 6-, and 7-membered lactams can be used for their identification. Uv and ir spectra are given.

IT 22050-87-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (preparation of)

RN 22050-87-9 CAPLUS

CN Oxanilic acid, N-benzyl-, ethyl ester (8CI) (CA INDEX NAME)



L5 ANSWER 32 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1967:482033 CAPLUS <<LOGINID::20080103>>

DOCUMENT NUMBER: 67:82033

ORIGINAL REFERENCE NO.: 67:15455a,15458a

TITLE: New synthesis of N-substituted isatins

AUTHOR(S): Baiocchi, Leandro

CORPORATE SOURCE: Lab. Ric. A.C.R. Angelini Francesco, Rome, Italy

SOURCE: Annali di Chimica (Rome, Italy) (1967),
 57(5), 492-8

CODEN: ANCRAI; ISSN: 0003-4592

DOCUMENT TYPE: Journal

LANGUAGE: Italian

GI For diagram(s), see printed CA Issue.


AB Oxamic acid esters of the general formula p-R1C6H4NRCOCO2Et (I) are prepared and treated with PCl5 to give II. Thus, 15.3 g. ClCOCO2Et is slowly added to 10.7 g. PhNHMe and 7.9 g. pyridine in 50 ml. C6H6 and the mixture is heated 20 min. to give 80% MePhNCOCO2Et (III), b0.5 127-8°. Similarly prepared are 95% p-MeOC6H4NMeCOCO2Et (IV), b0.5 150°, and the following I (R, R1, b.p./mm., m.p., and % yield given): PhCH2, MeO, 193°/0.3, -, -; Ph, H, -, 87°, 80; PhCH2, CO2Et, 200°/0.5, -, -; PhCH2, NO2, -, 57-8°, 90. IV in CCl4 is treated with PCl5 and the mixture agitated to give 45% N-methyl-5-methoxyisatin, m. 174°. Similarly prepared are the following II (R, R1, m.p., and % yield given): PhCH2, MeO, 115-17°, 60; Ph, H, 138°, 60; PhCH2, CH2CO2H, 150°, 75. I (R = PhCH2, R1 = NO2) (3 g.) in CCl4 is treated with 2.1 g. PCl5, the CCl4 and POCl3 are removed, and the mixture is heated 1 hr. at 100° and treated with 30 ml. 2N HCl to give N,N'-dibenzyl-N,N'-bis(p-nitrophenyl)oxamide, m. 198-200°. III (20.7 g.) in 50 ml. CCl4 is treated with 20.8 g. PCl5 to give 22 g. 3-chloro-3-ethoxy-N-methylindolin-2-one (V), b1 130°. V is treated with 2N HCl to give N-methylisatin. V (20 g.) in 50 ml. C6H6 is treated with 2.3 g. Na in 50 ml. EtOH and the mixture is heated 45 min. to give 3,3-diethoxy-N-methylindolin-2-one, m. 104-5°.

IT 16077-06-8P 16077-07-9P 16077-08-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)


RN 16077-06-8 CAPLUS

CN Oxanilic acid, N-benzyl-4'-methoxy-, ethyl ester (8CI) (CA INDEX NAME)




RN 16077-07-9 CAPLUS

CN Oxanilic acid, N-benzyl-4'-(carboxymethyl)-, diethyl ester (8CI) (CA INDEX NAME)



RN 16077-08-0 CAPLUS

CN Oxanilic acid, N-benzyl-4'-nitro-, ethyl ester (8CI) (CA INDEX NAME)




L5 ANSWER 33 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1956:20042 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 50:20042
 ORIGINAL REFERENCE NO.: 50:4125d-i,4126a-b
 TITLE: 2,3-Pyrrolidinediones. IV. Further studies on
 tautomerism
 AUTHOR(S): Vaughan, Wyman R.; McCane, Donald I.
 CORPORATE SOURCE: Univ. of Michigan, Ann Arbor
 SOURCE: Journal of Organic Chemistry (1955), 20,
 143-54
 CODEN: JOCEAH; ISSN: 0022-3263

DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 50:20042

AB cf. C.A. 48, 3340i. Addnl. evidence has been presented that
 1,5-diaryl-2,3-pyrrolidinediones are tautomeric with α -arylimino-
 β -arylidene propionic acids and that it is the latter which undergo
 thermal decarboxylation. Refluxing 14.4 g. 1,4-diphenylazetidinone
 overnight in 125 cc. MeOH saturated with HCl, evaporating the mixture in
 vacuo, and
 treating the residue with H₂O and a little NaHCO₃ give 86.5% Me
 β -phenyl- β -phenylaminopropionate, needles, m. 105-6°,
 which (5.1 g.) is treated in 50 cc. dry (CH₂Cl)₂ containing 15 cc. C₅H₅N 3
 hrs. at 20° with 3 cc. MeO₂CCOCl, the mixture is diluted with 50 cc.
 Et₂O, and the residue of the washed (H₂O, 5% HCl-H₂O) and dried Et₂O solution
 evaporated, giving 95% Me β -phenyl- β -(N-methoxalyl-N-phenylamino)-
 propionate (I), m. 75.5-6°. Adding MeONa (from 0.07 g. Na) in 20
 cc. absolute MeOH to 0.9 g. I, keeping the mixture 4 hrs., neutralizing it with
 the calculated amount of AcOH in 50 cc. H₂O, and extracting with Et₂O give 0.5
 g.
 4-carbomethoxy-1,5-diphenyl-2,3-pyrrolidinedione (II), m. 196-9°
 (decomposition); it gives a deep red color with FeCl₃. Adding 2 g. Me
 methoxalylacetate to 50 cc. Et₂O containing 2 g. PhCH:NPh and evaporating the
 filtered solution give II. Refluxing a sample of the Et ester of II in PhNO₂
 gives 1 mole CO₂ and 1,5-diphenyl-2,3-pyrrolidinedione (III). Heating
 22.5 g. CuCl₄N with 37 g. AcBr 2 hrs. at 70-80° gives 54.3%
 MeCOC₁₄N, b. 87-91°, which (9 g.) is treated at 0° with 12.5
 cc. concentrated HCl, and the mixture diluted with 40 cc. H₂O and heated 2
 hrs. at
 70°, giving 38% MeCOC₁₄O₂H (IV), b₁₈ 40-60°. Adding 1 g. IV
 to 5 cc. 10% NaOH, then adding at 0° 1.2 g. BzH and, dropwise (10
 min.), 3 cc. 10% NaOH, and stirring the mixture 50 min. with the temperature
 kept
 below 12° give 0.9 g. PhCH:CHCOC₁₄O₂Na which, dissolved in 20 cc.
 ice H₂O, is decomposed with 25 drops concentrated HCl in 10 cc. ice-H₂O, giving
 47% PhCH:CHCOC₁₄O₂H (V), m. 68-9°. Adding 0.36 g. PhNH₂ in 5 cc.
 absolute EtOH dropwise to 0.67 g. V in 15 cc. absolute EtOH, stirring the
 mixture

0.5 hr. at 20°, diluting it with 25 cc. EtOH, and refluxing it 1 hr. give 80% III-2-C14 (VI), m. 158-60° (decomposition). o-C6H4(CO)2N15H is converted into PhN15H2 which, with PhCH:CHCOCO2H, gives III-1-N15 (VII). Refluxing 2.51 g. VII in 25 cc. absolute EtOH 0.5 hr. with 1.1 g. PhNHNH2 in 10 cc. absolute EtOH and 4 drops AcOH, keeping the mixture 12 hrs. at 20%, refluxing it another hr., and diluting the cooled solution with 70 cc. H2O give 79% inactive 1-anilino-5-phenyl-2,3-pyrrolidinedione (VIII), m. 154-5° (decomposition); the mother liquor is extracted with C6H6 and HCl is passed into the extract, giving PhN15H2.HCl (IX). Treating III with PhNHN15H2 (X) (prepared from PhNH2 and KN15O3) gives 75% active VIII, m. 154.5-6° (decomposition). For the collecting of N for mass spectrometric analysis 0.39 g. PhNH2.HCl, 6 g. 50% H3PO2, and 10 cc. H2O are treated at 5° with 0.21 g. NaNO2 in 10 cc. H2O. The decarboxylation of VI is carried out by heating 0.251 g. in 20 cc. o-C6H4Cl2 1 hr. at 180° (bath temperature), absorbing the CO2 in 1N NaOH by means of a CO2-free N stream, and precipitating it as BaCO3. This gives BaCl4O3 with 94.9% of the starting C14, indicating that VI is thermally decarboxylated to cinnamylideneaniline and C14O2 by initial rearrangement to the isomeric 3-arylidene-2-aryliminopropionic acids. In the reaction of III with X active VIII is formed by an exchange between tautomeric arylimino acid and X.

IT 855398-32-2P, Oxanilic acid, N-[α-(carboxymethyl)benzyl]-, dimethyl ester
 RL: PREP (Preparation)
 (preparation of)
 RN 855398-32-2 CAPLUS
 CN Oxanilic acid, N-[α-(carboxymethyl)benzyl]-, dimethyl ester (5CI)
 (CA INDEX NAME)




L5 ANSWER 34 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1949:46441 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 43:46441
 ORIGINAL REFERENCE NO.: 43:8380b-f
 TITLE: Ring closure of N-alkoxalyl-β-anilinopropionic acids
 AUTHOR(S): Southwick, Philip L.; Seivard, Louis L.
 SOURCE: Journal of the American Chemical Society (1949), 71, 2532-8
 CODEN: JACSAT; ISSN: 0002-7863
 DOCUMENT TYPE: Journal
 LANGUAGE: Unavailable
 OTHER SOURCE(S): CASREACT 43:46441
 AB KO2CCO2Me and SOCl2 (1 mol. each) give 63% MeO2CCOCl (I); EtO2CCOCl (II) results in 59% yield. PhNH2 (3 mols.) in 75 ml. AcOH, treated (1 hr.) with 3 mols. CH2:CHCO2Me, gives 57% PhNHCH2CH2CO2Me; KOH in MeOH gives 65% of the acid (III). PhNHCHPhCH2CO2H and twice its weight of I, heated 0.5 hr. on the steam bath, give 85% N-methoxalyl-β-anilino-β-phenylpropionic acid (IV), m. 127-8° (m.ps. corrected) (Me ester, m. 75-7°, 83%); N-ethoxalyl homolog (V), m. 111-13°, 78%.


N-Ethoxalyl- β -anilinopropionic acid (VI), m. 91-2°, 58%;
 N-ethoxalyl- β -amino- β -phenylpropionic acid (VII), m.
 116-18°, 43%. IV and an equal weight of I or II in 2 ml. CHCl₃ per g.
 IV (dioxane can be used as the solvent), treated with C₅H₅N equal to the
 weight of the acid, kept 30 min. at room temperature, diluted with 5 vols.

CHCl₃, shaken 2 hrs. with an equal volume of H₂O, and the CHCl₃ layer extracted with
 excess 5% NaHCO₃ and precipitated with 5% HCl, give 26% 1,5-diphenyl-2-keto-3-
 methoxy-3-pyrroline-4-carboxylic acid (VIII), m. 196-8°; Me ester,
 m. 128.5-30°; Et ester, m. 83-5°. V yields 32% of the 3-EtO
 analog (IX), m. 214-15°; Me ester (X), m. 91-2°; 3 g. V in 7
 cc. Ac₂O and 7 g. C₅H₅N, heated 3 hrs. on the steam bath, gives 10% IX; no
 reaction occurs with Ac₂O or C₅H₅N alone. VI yields 15%
 1-phenyl-2-keto-3-ethoxy- Δ 3-pyrroline-4-carboxylic acid (XI), m.
 189-91°; Me ester (XII), m. 75.5-7°. III and II in the
 presence of C₅H₅N give XI; in the absence of C₅H₅N, the product is VI.
 PhCH:NPh and MeO₂CCOCH₂CO₂Et give 66% Me 1,5-diphenyl-2,3-pyrrolidinedione-
 4-carboxylate (XIII), m. 201-3°; MeCHN₂ gives the Et ester.
 PhNHCH₂CH₂CO₂Me (7.2 g.) and 4.8 g. (CO₂Me)₂ in 50 ml. ether, treated (15
 min.) with 2.5 g. MeONa in 50 ml. ether and refluxed 2 hrs., give 38% Me
 1-phenyl-2,3-pyrrolidinedione-4-carboxylate, m. 185-7°; MeCHN₂
 gives XII. The Et ester corresponding to XIII and CH₂N₂ give the Et ester
 of VIII. A mechanism is proposed for the ring closure reaction which
 relates it to the Perkin reaction and to the Claisen condensation.

IT 5650-98-6, Oxanilic acid, N-[α -(carboxymethyl)benzyl]-
 (monoalkyl esters)
 RN 5650-98-6 CAPLUS
 CN Oxanilic acid, N-[α -(carboxymethyl)benzyl]- (8CI) (CA INDEX NAME)



IT 329702-08-1P, Hydrocinnamic acid, β -N-ethoxalylanilino-
 RL: PREP (Preparation)
 (preparation of)
 RN 329702-08-1 CAPLUS
 CN Benzenepropanoic acid, β -[(ethoxyoxoacetyl)phenylamino]- (9CI) (CA
 INDEX NAME)



L5 ANSWER 35 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1935:1069 CAPLUS <<LOGINID::20080103>>
 DOCUMENT NUMBER: 29:1069
 ORIGINAL REFERENCE NO.: 29:124a-h

TITLE: Compounds of bivalent carbon. VIII. Some derivatives of diethoxyacetic acid and their adaptation to carbon monoxide acetal cleavage

AUTHOR(S): Scheibler, Helmuth; Beiser, Willy; Cobler, Heinz; Schmidt, Anton

SOURCE: Berichte der Deutschen Chemischen Gesellschaft [Abteilung] B: Abhandlungen (1934), 67B, 1507-14

CODEN: BDCBAD; ISSN: 0365-9488

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

OTHER SOURCE(S): CASREACT 29:1069


AB cf. C. A. 28, 2326.3. In the reaction between $(\text{EtO})_2\text{CHCO}_2\text{Et}$ and NaOEt or Et_2NMgBr the $\text{C}(\text{OEt})_2$ formed by the cleavage of the C chain readily reacts with the EtOH which is split off simultaneously, forming pentaethoxyethane and heptaethoxypropane. Since the sec. NHet_2 , is indifferent toward $\text{C}(\text{OEt})_2$, attempts were made to prepare dialkylamides of $(\text{EtO})_2\text{CHCO}_2\text{H}$ for use instead of $(\text{EtO})_2\text{CHCO}_2\text{Et}$ for the $\text{C}(\text{OEt})_2$ cleavage. These dialkylamides cannot be prepared under the usual conditions but $(\text{EtO})_2\text{CHCONMe}_2$ (I) was finally obtained by heating the components in a sealed tube at 100° in the presence of CaCl_2 to bind the EtOH set free, and $(\text{EtO})_2\text{CHCON}(\text{CH}_2\text{Ph})_2$ (II) was obtained from $(\text{EtO})_2\text{CHCO}_2\text{Et}$ and $(\text{PhCH}_2)_2\text{NMgBr}$ in boiling C_6H_6 . When I and II were treated with Me_2NMgBr and $(\text{PhCH}_2)_2\text{NMgBr}$, resp., and, after removal of the ether (both that used as solvent and the ether of constitution), the products were subjected to dry distillation in vacuo, the product obtained from Me_2NMgBr yielded a compound m. 134° containing no trace of EtO (Zeisel) and giving NH_3 instead of NHMe_2 on hydrolysis. Analysis indicated that it was $\text{OHCCONH}_2 \cdot 3\text{H}_2\text{O}$, and from the low-boiling products of the reaction (condensed in liquid air) was isolated Et_2O after removal of the NHMe_2 with $\text{C}_6\text{H}_4(\text{CO})_2\text{O}$ in the presence of quinoline. In the experiment with II there was obtained no low-boiling distillate; the product was $\text{N}(\text{CH}_2\text{Ph})_3$. formed according to the scheme $(\text{EtO})_2\text{CHC}(\text{OMgBr})[\text{N}(\text{CH}_2\text{Ph})_2]_2 \rightarrow \text{N}(\text{CH}_2\text{Ph})_3 + (\text{EtO})_2\text{CHC}(\text{OMgBr})\text{:NCH}_2\text{Ph}$. These dialkylamides are therefore not adapted to the $\text{C}(\text{OEt})_2$ cleavage. As $(\text{EtO})_2\text{CHCO}_2\text{Et}$ can be used for this purpose but the EtOH formed simultaneously gives rise to secondary reactions, attempts were made to prepare the Ph instead of the Et ester. $(\text{EtO})_2\text{CHCOCl}$ cannot be made because 1 of the 2 EtO groups in $(\text{EtO})_2\text{CHCO}_2\text{H}$ immediately reacts with PCl_5 or SOCl_2 . The Ph ester can be obtained by treating the acid in the presence of excess of pyridine first with SOCl_2 and then with PhOH , but the ester so prepared is difficultly purified. Favorable results were obtained only when ClSO_2Ph was used with the acid in ether in the presence of pyridine, the resulting $(\text{EtO})_2\text{CHCOOSO}_2\text{Ph}$ decomposing on heating in ether into SO_2 and $(\text{EtO})_2\text{CHCO}_2\text{Ph}$. As the ester is very sensitive to acids it was freed from admixed pyridine with MeI . With Et_2NMgBr the ester gave $(\text{EtO})_2\text{CHCONEt}_2$ but the chief product was a non-distillable mass which decomposed at higher temps. and was perhaps formed by combination of PhOH with a polymerization product of $\text{C}(\text{OEt})_2$. Furthermore, in the part of the product consisting chiefly of NHet_2 , monomeric $\text{C}(\text{OEt})_2$ was detected and determined by means of HgCl_2 after it had been hydrolyzed to HCO_2H with dilute alkali. Diethoxyacetdimethylamide (I), b12 105° ; yield, 50.5%. Dibenzylamide (II), light yellow, b1 $168-70^\circ$ (yield, 26%). Ph diethoxyacetate, b13 $150-2^\circ$; yield, 61.1%. Diethoxyacetnitrile, obtained in 30% yield from the amide in quinoline slowly treated at 90° with P_2O_6 , b12 $55-6^\circ$.

IT 68057-16-9P, Glyoxylamide, N,N-dibenzyl-, diethyl acetal
RL: PREP (Preparation)

(preparation of)

RN 68057-16-9 CAPLUS

CN Acetamide, 2,2-diethoxy-N,N-bis(phenylmethyl)- (CA INDEX NAME)



L5 ANSWER 36 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1914:18469 CAPLUS <<LOGINID::20080103>>

DOCUMENT NUMBER: 8:18469

ORIGINAL REFERENCE NO.: 8:2680a-e

TITLE: Some derivatives of as-dipropyl- and -diamyloxamic acids

AUTHOR(S): Atkinson, Harford M.

CORPORATE SOURCE: Limerick

SOURCE: Journal of the Chemical Society, Transactions (1914), 105, 1290-6

CODEN: JCHTA3; ISSN: 0368-1645

DOCUMENT TYPE: Journal

LANGUAGE: Unavailable

AB This is a continuation of Wallach and Lehmann's work (Ann., 237, 245) on piperidyloxamic acid and is a part of a study of the constitution of the oxaline bases. Ethyl dibenzyloxamate, prepared by heating 1 mol. (PhCH₂)₂NH and (CO₂Et)₂ 2 days, b₁₀ 176-8°; yield, 10%. as-Dibenzyloxamide, H₂NCOCON(CH₂Ph)₂, by treating the ester with concentrate NH₃, needles, m. 86-7°. Ethyl dipropyloxamate, by heating 50 g. Pr₂NH and 73.2 g. (CO₂Et)₂ 4 hrs. at 100°, viscid oil, b₁₂ 146-8°. as-Dipropyloxamide, m. 96-7°. as-Dipropyloxamonitrile, NCCONPr₂, by distilling with P₂O₆, oily, b₁₄, 120°; yield, 65%. as-Dipropylthio-oxamide (A), by saturating the nitrile in absolute alc. with


NH₃

and then with H₂S, long, white needles from CHCl₃ and light petroleum, or large 4-sided prisms from Et₂O and alc., m. 129-30°; yield, 65%. Piperidylthioglyoxylamide, H₂NCSCONC₅H₁₀, rhombic tables, m. 66-7°. as-Diethylthio-oxamide, small, transparent, yellow, rhombic tables, m. 126-7°. as-Dimethyloxamonitrile, b. 202-3°. as-Dimethylthio-oxamide, m. 120-1°. Dipropyloxamic acid, prepared by Wallach's method (Ann., 214, 270), m. 73-4°. Chloride, b₁₄ 112-6°; yield, 80%. With dry NH₃ gas this gave (A). Tetrapropyloxamide, (CONPr₂)₂, from the chloride and Pr₂NH, m. 38-95°, b₁₁ 185-95°. Dipropylcarbamy chloride (B), ClCONPr₂, by heating the chloride under a reflux, b₂₈ 118-20° (yield, 45%), slowly decomposed by cold H₂O. CO(NPr₂)₂ (Chancel, Bulletin

society

chim., [3] 11, 395) was prepared from (B) and 2 mols. Pr₂NH. Piperidine-1-carboxyldipropylamide, C₅H₁₀NCONPr₂, viscid liquid, b₁₀ 173°. Dipropyldiamylcarbamide, b₁₂ 185°. Dipropylformanamide, by heating the acid above its m. p., b₁₇ 102°, b. 208°; yield, 82%. Chloroplatinate, red, m. 108°. Ethyl diamyloxamate, b₁₀ 166-7°; yield, 50%. as-Diamyloxamide, needles, m. 182°. as-Diamyloxamic acid, could not be crystallized. The crude product, heated for a short time, gave diamylformamide, b₁₄ 135°. Chloroplatinate, yellowish red, m. 140-1°. Diamylcarbamy chloride, from the crude acid and PCl₅, viscid oil, b₁₄ 147-9°.


Phenyldiamylcarbamide, PbNHCONAm_2 , small, glistening scales, m.
204°. $\text{N(Am)}_2\text{CON(Am)}_2$ (Custer, Ber., 12,1332), b. 182-3°.
IT 80326-96-1P, Oxamic acid, dibenzyl-, ethyl ester
RL: PREP (Preparation)
(preparation of)
RN 80326-96-1 CAPLUS
CN Acetic acid, [bis(phenylmethyl)amino]oxo-, ethyl ester (9CI) (CA INDEX
NAME)



L5 ANSWER 37 OF 37 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1907:1663 CAPLUS <<LOGINID::20080103>>
DOCUMENT NUMBER: 1:1663
ORIGINAL REFERENCE NO.: 1:416g-i,417a-i
TITLE: Resolution of N, N'-Diarylmethylenediamines
AUTHOR(S): Bischoff, C. A.; Frohlich, E.
CORPORATE SOURCE: Synthetic Lab., Polytechnicum, Riga
SOURCE: Berichte der Deutschen Chemischen Gesellschaft (1907), 39, 3964-81
CODEN: BDCGAS; ISSN: 0365-9496
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable
GI For diagram(s), see printed CA Issue.
AB Some years ago the author found that the methylene bases, RNHCH_2NHR , unlike the corresponding ethylene derivatives, do not yield closed chain compounds with diphenyl oxalate (Ber., 35, 3440) but hydroxybenzylamine derivatives, $\text{HOC}_3\text{H}_4\text{CH}_2\text{NHR}$, and oxalylarylamides, RNHCOCONHR . In certain cases, however, especially with p-tolyl derivatives, the secondary base is converted into an equimolecular mixture of primary, H_2NR , and tertiary base, RN NR , which latter, with phenols, yield the above hydroxybenzylamine compounds. Phenol and the secondary methylene bases give phenol salts of primary bases, PhONH_2R and a mixture of the components. The methylene usually enters the phenol ring in the ortho position, but in the case of orthomethoxybenzene and paraethoxybenzene the methylene enters at the para position. In the above cases $\text{R} = \text{C}_6\text{H}_6$, o- $\text{C}_4\text{H}_4\text{CH}_6$, o- $\text{C}_4\text{H}_4\text{CH}_3$, o- $\text{C}_4\text{H}_4\text{OCH}_3$, p- $\text{C}_3\text{H}_4\text{OCH}_3$, p- $\text{C}_6\text{H}_4\text{OC}_2\text{H}_5$. N,N'-Diphenylmethylenediamine, $\text{PhNH.CH}_2\text{NHPh}$. This base gives, with phenol, a hydroxybensylaniline, microscopic prisms, m. 156° and also the ortho isomeride, m. 113°. which is likewise formed from phenol and "anhydroformaldehyde aniline." Resorcinol yields a 1,3-dihydroxybenzylaniline, $(\text{HO})_2\text{C}_4\text{H}_3\text{CH}_2\text{NHPh}$, crystalline powder consisting of small rods. It could not be benzoylated. Diphenyl oxalate gives oxanilide and o-hydroxybenzylaniline. Sodium phenolate resolves the base into aniline. The base does not react with acetone, alcoholic potassium hydroxide, ethyl acetate, or benzaldehyde. Ethyl oxalate, ethyl malonate and ethyl succinate, on the other hand, yield the anilides of the respective acids and a mixture of tertiary "anhydro" bases. N,N'-Diorthotolylmethylenediamine. Prepared from o-toluidine hydrochloride and formaldehyde by an improved method. Yield, 50%. Aniline, under the same conditions, gives only mixtures of

"anhydroformaniline." With phenol the above base gives, in very small quantity, what is probably o-hydroxybenzyl-o-toluidine; transparent plates, m. 40°-50°. Diphenyl oxalate yields oxal-o-anilide, m. 210°. N,N'-Diparatolylmethylenediamine. With phenol o-hydroxybenzyl-p-toluidine is formed. Resorcinol yields m-dihydroxybenzyl-p-toluidine, (HO)2C6H3CH2NHC3H4Me, microscopic rods or plates, m. 165°. Diphenyl oxalate gives oxal-p-toluide and "anhydroformtoluidine," a mixture of tertiary bases, m. 127°-128° and 212°-223°, respectively. (vide Ber., 31, 3253). N,N'-Diorthoanisylmethylenediamine. The base b20 160°; distillation with phenol does not cause a reaction. At 180°-200° a hydroxybenzyl-o-onisidine, is formed, microscopic rods, m. 125°. It is probably the p-compound. The ortho isomer was also obtained by boiling the reacting substances in benzene. With diphenyl oxalate, oxalo-o-anisidide is formed, hexagonal plates, m. 246°. It was prepared for comparison from diphenyl oxalate and o-anisidine. p-Nitrophenol, pyrocatechol, resorcinol and hydroquinol could not be induced to act on this diamine and all attempts to prepare an "anhydro base" were fruitless. N,N'-Diparaanisylmethylenediamine. Phenol and p-anisidine combine, in ligroin solution, forming the phenolate, C18H16O2N, colorless prisms, m. 60°. With the methylene base phenol yields o-hydroxybenzylanisidine. Diphenyl oxalate forms oxanisidide and resorcinol gives 1,3-dihydroxy-p-anisidine, (HO)2C6H2CH2NHC3H4OMe, colorless thin plates, m. 149°; at 140° it becomes red. N,N'-Diparaphenetyl-methylenediamine, b12 174°; boiling in air resolves it into its constituents. No formation of tertiary base could be observed. Phenol and phenetidine yield the phenolate, long, lustrous needles, m. 52°. Phenol and the methylene base give a mixture of products, but in benzene solution a hydroxybenzyl-p-phenetidine is formed; small prisms, m. 106°. It becomes yellow in air and is probably the para compound. Diphenyl oxalate yields only oxalphenetidide. With resorcinol 1,3-dihydroxybenzylphenetidine, (HO)2C6H3CH2NHC4H4OEt, is formed; irregular, thin plates, m. 156°. In addition to the above methylene bases the action of a number of others on diphenyl oxalate has been studied. Methylaniline gives a mixture of dimethyloxanilide, PhNMeCOCOONMePh, colorless crystals, m. 86° and phenyl methyloxanilate, PhNMeCOCO2Ph, oii, b10 about 270°. The "methyloxanilide" of Norton and Livermore (Ber., 20, 2273), b. 249°-251°, cannot be a derivative of oxalic acid, but may, perhaps, be methylformanilide. Phenylhydrazine and diphenyl oxalate give oxalyldiphenylhydrazide, which has been previously prepared by E. Fischer from diethyl oxalate. Phenyl phenyloxanilate, Ph2NCOCO2Ph, from diphenyl oxalate and diphenylamine; prisms, m. 127°-128°. Phenyl benzyloxanilate, PhCH2NPhCOCO2Ph, from diphenyl oxalate and benzylaniline; colorless prisms, m. 93°-94°. Carbazole and diphenyl oxalate could not be induced to interact.

IT 859949-80-7P, Oxanilic acid, N-benzyl-, Ph ester
 RL: PREP (Preparation)
 (preparation of)
 RN 859949-80-7 CAPLUS
 CN Oxanilic acid, N-benzyl-, Ph ester (1CI) (CA INDEX NAME)



Print selected from 10-501,344.trn

=>